Factors affecting daytime function in the sleep apnoea/hypopnoea syndrome by Kingshott, Ruth N.
FACTORS AFFECTING DAYTIME FUNCTION IN THE SLEEP 
APNOEA/HYPOPNOEA SYNDROME 
Ruth N. Kingshott 
PhD 
Department of Medicine 
The University of Edinburgh 
1998 
ABSTRACT 
The sleep apnoea/hypopnoea syndrome (SAHS) is characterised by repetitive upper 
airway obstructions during sleep, which lead to recurrent hypoxaemia and brief 
arousals from sleep. SAHS patients suffer from excessive daytime sleepiness (EDS), 
cognitive impairments and decreased psychological well -being. Previous studies have 
examined relationships between the nocturnal events of SAHS and a limited number 
of daytime function measures, frequently in small, non -consecutive patient samples. 
Relationships found have been either weak or non -significant. This thesis examines the 
relationships between a wide range of nocturnal sleep and breathing variables and 
daytime function. Additionally, this thesis examines the use of subjective and objective 
measures of daytime sleepiness, to determine which tests provide the most useful 
information for SAHS patients. 
A pilot study found that neither the 103 patients' nor their partners' Epworth rating of 
sleepiness were strong predictors of SAHS severity. In 150 patients with a wide range 
of SAHS severity, relationships between nocturnal events and daytime function were 
examined using newer definitions of arousal and measures of sleep continuity. A 
broad battery of daytime tests were used including the maintenance of wakefulness 
test (MWT) and the short form (SF) -36. Unlike previous studies, all correlations were 
controlled for age and awake oxygen saturation, known to influence the variables 
measured. The current study also examined these correlations in an unselected patient 
sample with a range of disease severity. The study found a lack of strong relationships 
between conventional nocturnal sleep and breathing variables and daytime function. 
Few baseline variables significantly predicted CPAP use. 
Daytime function measures were compared within the 150 patients. The multiple sleep 
latency test (MSLT) and the MWT displayed a moderate, discordant relationship. 
Measures of cognitive function, psychological well -being and subjective sleepiness 
ii 
better related to the MWT than MSLT, suggesting that the MWT may be a more 
useful tool in assessing functional impairment in sleep apnoea. 
A randomised cross -over study, on 12 SANS patients, compared daytime sleepiness 
measured following a night's sleep at home (as performed in this thesis) versus a night 
in the sleep centre (standard protocol). Preliminary results indicated that daytime 
sleepiness, as measured by the MSLT and MWT, was not significantly different 
between the two study limbs. This suggests that the non -standard method of 
conducting the MSLT and MWT in this thesis does not explain the lack of 
correlational relationships between nocturnal measures and daytime sleepiness. 
The studies presented in this thesis demonstrate a lack of identified factors affecting 
daytime function in a group of unselected SANS patients. This may be due to inter - 
individual patient variability. Also, more sophisticated nocturnal SANS measures 
should be examined, as should more `real -life' daytime assessments, such as 
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Chapter 1 
Clinical Overview of the Sleep Apnoea/Hypopnoea Syndrome 
1.1 Introduction 
Since its original recognition only 30 years ago (Jung et al 1965, Gastaut et al 1966), 
the sleep apnoea/hypopnoea syndrome ( SAFTS), has been well researched. It is 
estimated to affect between 1 -2% of middle -aged women and 2 -4% of middle -aged 
men (Young et al 1993). Sleep apnoea is characterised by recurrent upper airway 
collapse (Remmers et al 1978) causing arousal from sleep (Phillipson & Sullivan 
1978, Sullivan & Issa 1980) and associated sleep fragmentation and hypoxaemia. 
Daytime consequences include excessive daytime sleepiness (Roth et al 1980), 
cognitive dysfunction (Greenberg et al 1987) and decreased psychological well -being 
(Kales et al 1985), the exact causes of which are unclear and are the main focus of 
this thesis. A detailed review of the sleep apnoea/hypopnoea syndrome follows. 
1.2 The Pathophysiolooy of SAHS 
1.2.1 The normal upper airway 
The pharynx, unlike the trachea, has no rigid support from cartilage. During 
wakefulness, inspiration creates a negative intraluminal pressure which tends to 
occlude the pharyngeal airway. This is opposed by an increase in the activity of the 
pharyngeal dilator muscles, in particular the genioglossus and palatoglossus muscles. 
Upper airway patency is maintained by a balance between these two opposing forces 
of collapse and dilation. When an individual goes to sleep, there is a decrease in 
muscle tone, including those dilator muscles situated in the upper airway. In normal 
individuals the airway lumen remains wide enough to compensate for this balance 
shift, but in SAHS patients, upper airway narrowing outweighs the dilation, resulting 
in upper airway collapse with clinical consequences. 
1 
1.2.2 The upper airway of an SANS patient 
Studies have used techniques such as acoustic reflection and Magnetic Resonance 
Imaging (MRI) to demonstrate that awake SAHS individuals have narrow upper 
airways (Bradley et al 1986, Shelton et al 1993), increased pharyngeal resistance 
(Suratt et al 1985) and increased pharyngeal compliance (Issa & Sullivan 1984, 
Brown et al 1985, Suratt et al 1985), compared to normals. A number of predisposing 
risk factors may contribute to these characteristic upper airway features in sleep 
apnoeics. 
Obesity 
Epidemiological studies (Young et al 1993, Bearpark et al 1995) have demonstrated 
that obesity is probably the most important risk factor associated with upper airway 
narrowing during sleep. Obesity is classified as a Body Mass Index (BMI), (the 
Quetelet index = weight /[height2]) of greater than 30 kg /m2 (Revicki & Israel 1986). 
Studies have found greater neck circumferences in sleep apnoeics compared to weight 
and age- matched non -apnoeic snorers and normals (Katz et al 1990, Hoffstein & 
Mateika 1992), and that neck circumference rather than general obesity demonstrates 
the best relationship with SAHS severity (Davies & Stradling 1990, Stradling & 
Crosby 1991a). Using MRI scanning, Homer et al (1989) found more fat deposited in 
the collapsible region of the pharynx in obese SANS patients compared to weight - 
matched controls. These studies hypothesise that a greater fat deposition in the SAHS 
upper airway decreases airway size, either by anatomically narrowing the airspace, or 
by indirectly decreasing muscle function, or a combination of both. However, 
Grunstein et al (1993) found that central obesity, as measured by waist circumference, 
was more closely related to SAHS severity than BMI or neck circumference. The 
authors suggested that abdominal and chest wall fat may reduce lung volume or lessen 
respiratory muscle activity causing ventilatory impairment by a different means. It is 
possible that both neck and abdominal fat are causative in the pathogenesis of SAHS, 




Men tend to deposit fat more centrally around the abdomen and the neck than 
women, and this is one of the possible reasons why men are twice as likely to suffer 
from SAHS (Young et al 1993). Studies examining the anatomical differences in 
normal men and women report that men have thicker necks (Martin et al 1997a), 
larger pharyngeal airways (Brooks & Strohl 1992), and longer soft palates 
(Guilleminault et al 1988a). Whittle et al (1997a) examined the distribution of fat in 
normal, non -obese males and females, who were age and BMI matched and found 
that the total volume of neck fat did not differ between the sexes, but the men had 
significantly larger anterior fat deposits at the level of the palate. These studies in 
normals suggest that upper airway sex differences may also be present in SANS 
patients. One possible explanation for these differences in men and women is the 
influence of sex hormones. Block et al (1980) found the prevalence of SAHS to 
increase after the menopause, suggesting progesterone has a protective role as a 
respiratory stimulant in premenopausal SAHS women. However, in this study, the 
possible confounding effect of age was not considered. In a similar study by Leech et 
al (1988), SAHS severity increased with age in both sexes, and it was concluded that 
the increase in disease severity was due to age as a risk factor and not sex hormones. 
Age 
Another interrelated SAHS risk factor is middle -age. White et al (1985) found airway 
resistance to increase with age in normal men, but not women. Men also tend to 
deposit more fat around the neck, and frequently do this during middle age. This may 
explain why middle age tends to be the most frequent time for SAHS to develop. 
Genetic predisposition 
Mathur and Douglas (1995) noted that with increasing recognition and referral rates, 
thin SANS patients exist, with 50% of SANS patient referrals having a BMI < 30 
kg/m2. In thin SANS patients it is possible that some anatomical abnormality is 
contributing to upper airway collapse, such as retroposition of the mandible or the 
maxillae (Riley et al 1983) narrowing the airway. 
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SANS is frequently clustered into family groups. One explanation (Strohl et al 1978), 
is that obesity is familial and strong links exist between SAHS and obesity. Mathur 
and Douglas (1995) removed the confounding effect of obesity, by only studying first 
degree relatives of SANS patients with a BMI < 30 kg /m2 . These relatives had 
significantly more nocturnal events measured by polysomnography, more symptoms, 
and smaller upper airways than weight, height, age and sex -matched controls. In 
addition, cephalometry identified these relatives as having significantly more backset 
mandibles and maxillae, and longer soft palates with wider uvulae (Mathur and 
Douglas 1995). A study by Redline et al (1995) found familial aggregation of SAHS 
symptoms which was not fully explained by BMI and neck circumference alone. In 
addition, Pillar and Lavie (1995) examined familial links in 105 offspring of 45 SAHS 
patients and found a higher prevalence of SANS offspring in their sample (47 %) than 
epidemiological studies would estimate (2 -4 %). These three studies suggest that 
genetic factors may be involved in predisposing an individual to SAHS. 
Anatomical factors 
Anatomical abnormalities can cause airway narrowing. These include tonsillar 
hypertrophy, large tongue size and upper airway mucosal oedema from continuous 
snoring. Also nasal obstructions, such as a deviated septum, polyps or a previously 
broken nose may increase airways resistance. In addition, posture has an effect on 
upper airway collapsibility, increasing when an individual is supine rather than erect 
(Cartwright 1984, Yildirim et al 1991). 
Factors affecting upper airway muscle activity 
SAHS risk factors are also known to act by decreasing the activity of the pharyngeal 
dilator muscles. Such factors include alcohol and sleep. Alcohol will decrease 
neuromuscular tone in upper airway dilator muscles and hence increase upper airway 
collapse (Issa & Sullivan 1984). The onset of sleep also decreases pharyngeal dilator 
muscle activity and the consequences of this in sleep apnoeics is discussed in Section 
1.2.4. 
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In summary, there are a variety of causative risk factors predisposing an individual to 
SAHS. Some patients will have multiple risk factors, whereas other patients have no 
known risk factor. Further understanding of the pathogenesis of SANS is required to 
be able to identify all individuals at risk from SAHS. 
1.2.3 The site of upper airway collapse 
The site of upper airway collapse varies between SANS individuals. Studies have 
found the most common sites to be retroglossal and retropalatal (Hudgel 1986, 
Chaban et al 1988). This variation in airway site is probably caused by the 
heterogeneous nature of the SAHS population and the variety of causative risk factors 
involved. A fuller understanding of the structure and pathophysiology of the SANS 
upper airway will help explain the sequence of nocturnal events that occur as a result 
of upper airway collapse. 
1.2.4 Sequence of nocturnal events in SANS 
During wakefulness SAHS patients' airways remain patent due to compensatory 
reflexes causing pharyngeal dilator muscles to overcome any airway limitation. This 
was described in a study by Mezzanotte et al (1992), where the genioglossal muscle in 
awake SAHS patients functioned at a higher percentage of maximum (41 %) than 
controls (13 %), thus compensating for a smaller airway lumen. With sleep onset there 
is a decrease in general skeletal muscle tone, which also affects the upper airway 
musculature (Figure 1.1). In SAHS patients with an already narrowed upper airway 
size when awake (Section 1.2.2), this sleep -related decrease in tone of upper airway 
dilator muscles may lead to partial (hypopnoea) or total (apnoea) collapse of the 
pharynx. Once a respiratory event begins, inadequate ventilation may lead to a fall in 
arterial oxygen levels (hypoxaemia) and a rise in carbon dioxide levels (hypercapnia). 
As the respiratory event continues, the changes in blood gas tensions can stimulate 
chemoreceptors leading to an increase in ventilatory effort. This increase in chest wall 
movement against an occluded airway causes the intra- airway pressure to become 
more negative and lung mechanoreceptors to be activated. Eventually the respiratory 
event is terminated, usually by a transient cortical electroencephalographic (EEG) 
arousal from sleep (Phillipson & Sullivan 1978). It is not fully understood which of 
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the events during the apnoea leads to its termination. The repetitive changes in blood 
gas tensions associated with SAHS may cause arousal from sleep and thus apnoea 
termination. Bowes et al (1981) denervated carotid bodies in sleeping dogs and found 
that on administering airway occlusion, the arousal response was decreased. The 
authors suggested that hypoxia activates carotid body chemoreceptors which induce 
arousal from sleep. Studies have proposed that hypercapnia also causes arousal from 
sleep. Berthon -Jones and Sullivan (1984) identified this in humans and proposed that 
hypercapnia acts via nasopharyngeal receptors and medullary chemoreceptors to 
promote arousal from sleep. More recently, Gleeson et al (1990) hypothesised that 
the arousal occurs as a result of the increased respiratory effort itself rather than 
changes in blood gases. In Gleeson's experiments a number of different stimuli were 
used to increase ventilatory effort (e.g. hypoxic and hypercapnic rebreathing and 
inspiratory flow resistive loading) in normal subjects. Results showed that each 
subject would arouse from sleep at the same level of inspiratory effort (oesophageal 
pressure) for that individual, regardless of the respiratory stimulus. These results 
were confirmed by Kimoff et al (1994) in SAHS patients. How the increase in 
respiratory effort promotes arousal is unknown but it is assumed to act via stimulation 
of the reticular activating system. These authors suggested that mechanoreceptors 
were important in causing arousal from sleep and that chemoreceptors may play an 
indirect role by increasing the level of ventilatory effort. 
Not all apnoeas and hypopnoeas terminate with a visible EEG arousal from sleep. In 
some cases only a sub -cortical blood pressure (BP) rise is seen. Davies et al (1993a) 
used auditory stimuli to arouse healthy normals and found that when an EEG arousal 
did not occur, they were able to consistently produce BP rises. A study by Rees et al 
(1995) in SAHS patients also found that not all obstructive apnoeic events terminated 
in a visible EEG arousal, but did have a postapnoeic BP rise. These blood pressure 
responses represent subcortical arousals, indicating autonomic activity, and are 
thought to be clinically significant. Martin et al (1997b), disturbed normal subjects 
with auditory tones producing subcortical BP arousals. Increases in objective 
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sleepiness and impaired mood were found in these individuals when compared to an 
undisturbed night's sleep. 
Once a patient has briefly aroused from sleep, there is an increase in upper airway 
muscle tone, airway patency returns, ventilation and blood gases normalise, the 
patient then falls back to sleep and the cycle can begin again (Figure 1.1). 
Figure 1.1; The Cyclical Nature of Events in the Sleep Apnoea/Hypopnoea 
Syndrome. 
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This repetitive cycle of sleeping, decreased ventilation, increased respiratory effort 
and subsequent arousal seen in sleep apnoea can cause sleep fragmentation and 
hypoxaemia with associated nocturnal and daytime consequences. 
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1.3 Clinical Features of SAHS 
The sleep apnoea/hypopnoea syndrome is made up of a collection of nocturnal and 
daytime features. Studies by Guilleminault et al (1978) and Whyte et al (1989) 
examined SAHS patients from their clinic populations to try and quantify clinical 
features of SANS. The main nocturnal feature of sleep apnoea is snoring, reported in 
97 - 100% of patients (Guilleminault et al 1978, Whyte et al 1989). This snoring 
tends to be loud and intermittent. Whyte et al (1989) reported that 35% of bed 
partners witnessed breathing pauses at night and that nocturnal choking was reported 
in 26% of SAHS patients. Another common nocturnal feature is restless sleep (36 %) 
(Whyte et al 1989), often caused by motor activity during arousal at apnoea 
termination. Guilleminault et al (1978) found abnormal motor activity during sleep in 
all 50 sleep apnoea patients studied, as reported by their bed partners, who most 
commonly described movements of the arms and legs when struggling to breathe. 
Other less common nocturnal symptoms reported by patients include nocturia (10 %) 
and occasional enuresis (5 %) and a decrease in sexual functioning (6 %) (Whyte et al 
1989). In the morning after a fragmented night's sleep, many patients (35 %) reported 
feeling unrefreshed on awakening. 
Excessive daytime sleepiness (EDS) is the most common daytime symptom associated 
with SAHS (Guilleminault et al 1976). Whyte et al (1989) defined daytime sleepiness 
as falling asleep at least once daily whilst not in bed and it was reported in 87% of 
patients surveyed. Patients also suffer from impaired cognitive function (Greenberg et 
al 1987, Cheshire et al 1992), often described by patients as a decrease in 
concentration and poor memory. Personality changes are also frequently reported by 
family members (48 %), and 16% of patients reported clinically significant levels of 
anxiety or depression (Guilleminault et al 1978). Patients also commonly describe a 
decrease in quality of life (Guilleminault et al 1976). This can be in terms of marital 
disharmony, low self esteem or lack of social interactions, for example. These daytime 
symptoms, their causes and consequences comprise the main theme of this thesis and 
are discussed further in Chapter 2. 
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1.4 Definition of the sleep apnoea/hypopnoea syndrome 
The term `Pickwickian Syndrome' was first described by Sir William Osler in 1918, 
outlining a particular type of patient who resembled `Joe the fat boy' from Dickens's 
Pickwick Papers, being obese and hypersomnolent. It was then not until 1956 that 
Burwell et al described additional symptoms associated with this syndrome such as 
periodic breathing with hypoventilation and associated cor pulmonale. In 1965/66 
both Jung and Gastaut's groups independently related these symptoms to breathing 
pauses during sleep. In 1966, Gastaut described three types of respiratory events in 
his case report. He described the majority (80 %) of events as obstructive apnoeas, 
defined as a cessation in airflow caused by upper airway obstruction. Central apnoeas 
were occasionally (15 %) seen, where there is no airflow or chest wall movement, 
possibly due to a disorder of the brainstem. Finally, complex apnoeas (mixed apnoeas) 
were reported, which start as central apnoeas and then become obstructive in nature, 
accounting for 5% of cases. 
In 1972 the syndrome was named the sleep- induced apnoea syndrome (Sadoul et al 
1972). Since this date the diagnostic criteria for clinically significant SANS has altered 
over the years. Early definitions included 30 apnoeic episodes, each lasting 10 seconds 
or more, in both REM (rapid eye movement) sleep and non -REM sleep during a 7 
hour period (Guilleminault et al 1976), or more than 5 breathing pauses per hour of 
sleep (Guilleminault et al 1978), or more than 10 apnoeas per hour of sleep (Lavie 
1983). These early definitions were quite arbitrary, but were needed in the first 
instance for comparisons with future definitions. 
It was originally thought that only apnoeas were of clinical relevance. However, 
Gould et al (1988) identified patients who had no apnoeas, but still had recurrent 
oxygen desaturations and the clinical symptoms of sleep apnoea. These patients were 
having hypopnoeas, which are respiratory events caused by upper airway narrowing, 
but not complete airway occlusion. Gould et al (1988) examined a range of 
hypopnoea definitions in a group of 50 sleep apnoea patients, to determine the best 
definition for what was obviously a clinically important arousal causing event. Results 
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found that a 50% reduction in thoracoabdominal amplitude for >10 seconds, rather 
than a 50% reduction in airflow, correlated most strongly with the number of arousals 
from sleep and 4% desaturations (two other measures of SAHS severity). Gould et 
al's (1988) definition of the sleep apnoea/hypopnoea syndrome (SAHS) required 15 
or more hypopnoeas per hour of sleep, (apnoeas defined as the ultimate hypopnoeas), 
in conjunction with 2 or more major clinical symptoms. This definition is one of many 
which differ depending on recording techniques and hypopnoea thresholds. Moser et 
al (1994) performed a survey on 100 accredited US sleep centres and found no 
consensus in hypopnoea definition. Some labs measure ventilation by airflow and 
others by thoracoabdominal movement, and the threshold levels of these measures are 
not well defined. The concurrent inclusion of oxygen desaturations in the criteria also 
varies. 
There is also variation as to what is a clinically relevant level of SAHS disease 
severity. Lugaresi et al (1983) described a continuum of sleep disordered breathing 
from mild snoring to severe SANS. At the mildest end of the range is simple snoring. 
Lugaresi et al (1978) suggested that snoring was clinically relevant, reporting 
fluctuations in blood pressure and alveolar hypoventilation associated with the 
snoring. Hoffstein et al (1995) found an association between snoring and arousal 
frequency. Both studies suggested that this milder end of the spectrum, snoring, is not 
just a social nuisance, but has pathophysiological implications. Studies have found 
decreased daytime alertness in snorers (Guilleminault et al 1991, Stradling et al 
1991b), again suggesting clinical consequences of snoring alone. Guilleminault et al 
(1993) have also focused on this previously neglected mild end of the spectrum. They 
described a group of individuals who were excessively sleepy in the daytime, but did 
not have apnoeas, hypopnoeas or sometimes even snoring. By monitoring 
oesophageal pressure, these individuals were identified as having periods of flow 
limitation and increased respiratory effort which caused transient EEG arousals from 
sleep, and hence a possible cause for their daytime sleepiness. This was named the 
upper airway resistance syndrome (UARS) (Guilleminault et al 1993). Mild forms of 
SAHS, often classified as <15 apnoeas + hypopnoeas per hour slept (the 
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apnoea/hypopnoea index - AHI), have also been demonstrated to be clinically 
significant. Engleman et al (1997a) recently found mild SAHS patients with an AHI 
between 5 and 15, and 2 or more associated SAHS symptoms, to benefit from 
continuous positive airway pressure (CPAP) therapy (Section 1.7.3). Mildly affected 
patients showed improvements in their SANS symptoms, depression ratings, and 
cognitive function (Engleman et al 1997a). 
Clearly there is still much debate as to what level of sleep- disordered breathing is 
clinically relevant, and what methods and definition thresholds should be used to 
quantify these respiratory irregularities . 
1.5 Epidemiology 
Estimating the prevalence of the sleep apnoea/hypopnoea syndrome in the general 
population is an extensive task. Firstly, what defines a representative sample of the 
general population? Secondly, what definition of SAHS should be used? 
One of the first epidemiological studies was carried out by Lavie (1983) who 
surveyed 1,502 Israeli male industrial workers. A screening questionnaire was used 
to identify a subsample of 300 males, of which 78 agreed to undergo 
polysomnography. This subsample comprised 17 insomniacs, 20 patients with 
excessive sleepiness and 41 control subjects. At the time of this early study only 
apnoeas had been identified, so the diagnostic criteria was chosen as >10 apnoeas 
/hour slept. Sleep apnoea was estimated to have a prevalence of 0.7% amongst males. 
Stradling and Crosby (199la) studied a more heterogeneous population recruited by 
age from a general practice. One thousand and one men aged 35 -65 years were 
approached, and 893 agreed to participate. This time, the screening included 
questionnaires and a physiological measurement, home oximetry. Those with >5 4% 
oxygen desaturations per hour were asked to attend for in lab polysomnography, and 
31/45 agreed. Three of this subgroup were diagnosed as having sleep apnoea. 
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Therefore a prevalence value for severe, symptomatic sleep apnoea, of 0.3% was 
estimated. 
Jennum and Sjol (1992) studied the prevalence of sleep apnoea in a representative 
sample of the Danish population aged 30 -60 years. Of 1,504 individuals, 748 had 
limited home monitoring with inductance plethysmography. Sleep apnoea was defined 
as a respiratory disturbance index (RDI) >_ 5 with associated hypersomnia, and a 
prevalence of 0.9% in females and 1.9% in males was found. Young et al's (1993) 
comprehensive study performed full polysomnography on 602 of 4,284 men and 
women, participating in the Wisconsin Sleep Cohort Study. All participants were 
employed and aged 30 -60 years old. Prevalence of SAFTS was estimated as 2% of 
middle aged women and 4% of middle aged men. A criteria of an AHI >_ 5 plus self 
reported hypersomnolence was used. Most recently, Bearpark et al (1995) studied 
294/486 Australian men recruited from a town health volunteer register. All had 
limited domiciliary recordings measuring snoring, heart rate, oximetry and position. 
The study found both snoring and sleep apnoea to be of high prevalence within the 
population. An SANS prevalence of 3.1% was found, when defined as a respiratory 
disturbance index (RDI) of >5 oxygen desaturations associated with heart rate 
changes and snoring sounds. Along with the study by Young et al (1993), these 
prevalences are higher than previously suggested. 
Only 2 studies (Jennum & Sjol 1992, Young et al 1993) examined at the prevalence of 
SAHS in both men and women, with figures suggesting a ratio of 2 men for every 
woman having sleep apnoea. Female SAHS patients are therefore underrepresented in 
sleep clinics, as it is estimated that only one patient in nine seen in the clinic is female 
(Young et al 1993). Young et al (1996) looked at the differences in referrals between 
men and women and found that both reported the same major symptoms of snoring 
and sleepiness, but that women also reported a higher prevalence of atypical 
symptoms. It was suggested that these additional symptoms may cause misdiagnosis 
of SAHS in women, being labelled as insomniacs, for example. Also it is thought that 
some general practitioners may only associate SAFTS with obese male Pickwickian 
stereotypes (Redline et al 1994). 
12 
It is difficult to compare the 5 major epidemiological studies described above, which 
use a variety of techniques and diagnostic thresholds. Davies and Stradling (1996) 
reanalysed their data on 1,001 Oxford men, in an attempt to make direct comparisons 
with other studies from abroad, taking into account their definitions and population 
sample. The prevalence of sleep apnoea in their sample when using >10 4% oxygen 
desaturations per hour was 1.1 %. When the desaturation definition was changed to 
>3% per hour, the prevalence rose to 2.7 %. Not all individuals with SAHS visibly 
desaturate with their respiratory events as was shown by Douglas et al (1992), where 
34 °. /0 of SAHS patients remained undiagnosed on oximetry alone. Stradling and 
Crosby's study (1991a) used oximetry alone and when this was corrected for a 20% 
`underreporting factor' in their reanalysis, prevalence rose to 3.6 %. Risk factors 
mentioned in 1.2.2, such as obesity, may differ between population samples. For 
example, the prevalence rate of obesity in the US and Australia is reported to be 14- 
16% compared to 8 -9% in English men (Bearpark et al 1995). Davies and Stradling 
(1996) found their SANS prevalence rose to 4.7% if adjusted for the higher level of 
obesity in America. 
This reanalysis by Davies and Stradling (1996) highlights what effect differences in 
methodological design, definitions and population sampling can have on the 
prevalence of a disorder such as the sleep apnoea/hypopnoea syndrome. 
1.6 Morbidity and Mortality 
Sleep apnoea is a recently recognised disorder, and consequently only limited data are 
available on its long term consequences. Untreated sleep apnoea is thought to be 
associated with an increased risk of cardiovascular morbidity including myocardial 
infarctions, ischaemic heart disease, and cardiac arrhythmia (Ferguson & Fleetham 
1995). There is debate as to whether a causative link exists between sleep apnoea and 
systemic hypertension, with risk factors such as obesity, age, alcohol and 
antihypertensive therapy, confounding any possible relationship (Levinson & Millman 
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1991). There may also be an increased risk of cerebrovascular morbidity and mortality 
related to the cyclical increase in intracranial pressure occurring at the end of an 
apnoea (Ferguson & Fleetham 1995). Another consequence concerned with increased 
morbidity and mortality is excessive daytime sleepiness. This symptom may be 
associated with the 2 -7 fold increase in vehicle accidents (George et al 1987, Findley 
et al 1988) and 3 fold increase in work accidents (Findley 1996) in SANS patients 
compared to controls. 
Studies have examined survival rates in sleep apnoeics, comparing follow up on 
different forms of SANS therapy. He et al (1988) performed a retrospective study on 
385/706 male sleep apnoeics. This study found a higher mortality rate in patients with 
an apnoea index >20 compared to those < -20. However, this study gave no causes of 
death. Partinen et al (1988) improved on this by documenting the cause of death. Of 
198 patients, 71 underwent tracheostomy (Section 1.7.2), and 127 elected for 
conservative treatment (weight loss). Survival curves for the two groups were 
compared and there were 14 deaths in 5 years in the conservative group and none in 
the tracheostomy group. In addition, the conservatively treated group had a higher 
cardiovascular mortality rate, suggesting that surgical treatment decreases vascular 
morbidity. Another retrospective study (Lavie et al 1995) in 1,620 SAHS men and 
women found a significantly higher mortality rate in the male subgroup aged 30 -50 
years, with myocardial infarction as the most common cause of death. The study 
found that age, BMI, hypertension and apnoea index (AI >10 /hour) were all significant 
predictors of general mortality. Only age and BMI were significant predictors of 
cardiopulmonary deaths alone. Lavie et al (1995) suggested that SAHS is a risk factor 
for cardiopulmonary deaths indirectly by acting as a risk factor for hypertension. 
The above studies are retrospective and therefore the individuals were not placed 
randomly into treatment groups. Ideally one needs to carry out a prospective matched 
controlled study, recruiting patients at an early age, when fewer cardiovascular 
problems have started and the time since first occurrence of SAHS is less. Patients 
would then be randomised into treated and untreated groups for long term follow -up. 
However, this would not be possible, as it is unethical to withhold treatment for an 
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extended period of time. Recently, a large American cohort study, the Sleep Heart 
and Health Study, has been set up (Quan et al 1997). This prospective study aims to 
investigate 6,600 subjects at baseline, for the presence of sleep disordered breathing 
(SDB) and SAHS, and then monitor at regular follow -up intervals for the incidence of 
cardiovascular events. The aim being to assess the role of SDB and SAHS as risk 
factors for cardiovascular disease. Such a large -scale study (Quan et al 1997), which 
will take into account confounding risk factors, is likely to provide useful answers 
concerning the long -term morbidity and mortality of SANS. 
1.7 Treatment 
Treatments for SAHS can be classified under three main headings: conservative, 
surgical and non -surgical. 
1.7.1 Conservative Treatments 
Conservative regimes include weight loss, avoidance of evening alcohol and sleeping 
in the supine position. Such therapies may help in a few cases (Browman et al 1984), 
particularly in SAHS patients who cannot tolerate the more obtrusive alternatives. 
However, benefits from such therapies tend to be short term. 
1.7.2 Surgical Treatments 
The original surgical treatment for sleep apnoea was to perform a tracheostomy, with 
the aim of bypassing the obstructed airway (Hill et al 1978). Follow -up studies have 
shown that this operation normalises sleep disordered breathing (Guilleminault et al 
1981) and improves long term survival (Partinen et al 1988). Tracheostomies have 
been superseded by other treatments requiring less postoperative care, being more 
acceptable to patients. 
The surgical procedure of uvulopalatopharyngoplasty (UPPP) was introduced in 
1981 (Fujita et al) to treat snoring. In this procedure the uvula and part of the soft 
palate are surgically removed. UPPP was also used to treat patients with SAHS, and 
in the early 80's was a common procedure. UPPP has since fallen out of favour and 
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the efficacy of this treatment for snoring and SAHS is debatable. It is well known that 
many simple snorers go on to develop sleep apnoea as they get older, and may 
therefore require CPAP therapy (Section 1.7.3). By removing pharyngeal and palatal 
tissues, some individuals cannot tolerate CPAP therapy. This is because a leak can 
develop between the soft palate and the tongue, and so positive air pressure from the 
CPAP machine may travel down the nose and then leak out through the mouth, 
instead of passing down the nasopharynx. Mortimore et al (1996) compared 
maximum CPAP pressure tolerance in 13 normals, 13 SAHS patients and 13 SAHS 
patients with a previous UPPP, all matched for age, sex and body mass. Both normals 
and SAHS patients could tolerate high pressures of 20cm of water, but SAES 
patients, with a previous UPPP, tolerated a significantly lower maximum pressure of 
14.5 cm of water. This study also found a poorer CPAP run time in UPPP SAES 
patients versus SAHS patients matched for age, body mass and AHI. Long -term 
follow -up has identified poor success rates for UPPP in SAHS patients (Larsson et al 
1991) and many snorers (Miljeteig et al 1994). Original UPPP studies may have 
appeared successful as only subjective improvements in snoring and sleepiness were 
reported ( Miljeteig et al 1994). In addition, He et al (1988) found UPPP treated 
individuals had a survival rate similar to untreated individuals. 
Surgical procedures can be used to successfully remove anatomical upper airway 
abnormalities such as large tonsils, nasal polyps, or to straighten a deviated septum. 
Occasionally, reconstructive surgery is performed to advance the mandible and the 
hyoid bone (Riley et al 1993), in retrognathic SAHS patients. Apart from these 
procedures, all surgical therapies of SAHS should be considered with utmost caution, 
as once the soft tissue is removed it is a non -reversible alteration of the upper airway. 
1.7.3 Non- surgical Treatments 
Various drug treatments have been tried over the years as possible SAHS therapies. 
Protriptyline, a tricyclic antidepressant, has been found, in some studies to reduce the 
frequency of apnoeas and hypopnoeas (Clark et al 1979, Conway et al 1982), but not 
in all studies (Whyte et al 1988). Protriptyline is thought to act by suppressing REM 
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sleep and therefore removing the longer respiratory events which tend to occur in this 
sleep stage. Patients have reported troublesome side effects with this tricyclic 
antidepressant (Whyte et al 1988). 
Drug therapies can also be used to treat the daytime consequences of SAHS, such as 
the daytime sleepiness and poor concentration. Modafinil is a new drug for the 
treatment of narcolepsy. Modafinil is a novel wake -promoting agent and its exact 
mechanism of action in the brain is unknown. Arnulf et al (1997) recently performed a 
randomised placebo controlled, double blind crossover study in sleep apnoeics, with 
Modafinil. Results found Modafinil to improve objective sleepiness and long -term 
memory, with no adverse effects on the night -time parameters. Therefore Modafinil 
may provide part of an adjunct therapy to be used with a nocturnal treatment. 
Nasal continuous positive airway pressure (CPAP) (Sullivan et al 1981) is the current 
treatment of choice for SANS. This is a mechanical device that consists of a nasal 
mask connected via tubing to an air pump. CPAP blows a gentle stream of positive 
pressure air into the patients airway, and mechanically splints the upper airway open. 
The desired pressure is calibrated by an overnight lab study to find the optimum 
pressure for each individual considering each sleep stage and posture. Benefits with 
CPAP can often be seen immediately, but continued use each night at home is 
required to maintain therapeutic benefit. CPAP has been shown to improve daytime 
function (Engleman et al 1994a), and long term survival (He et al 1988). In a 
randomised crossover study, improvements in objective sleepiness, symptoms and 
cognitive function were found when patients were treated with CPAP rather than an 
oral placebo (Engleman et al 1994a). A crossover study is currently underway 
comparing CPAP at optimum pressure and `sham' CPAP at a suboptimal pressure, in 
an attempt to confirm the results obtained using a tablet as a placebo. Preliminary data 
indicates that CPAP improves daytime alertness compared to the `sham' CPAP 
(Stradling et al 1998). `Intelligent' CPAP machines are currently undergoing 
investigation. These provide a variable CPAP pressure to allow for night to night 
variability seen in the sleep disordered breathing caused by changes in weight, prior 
alcohol consumption, sleep stage and posture. Intelligent CPAP should therefore 
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abolish more respiratory events and hence increase therapeutic effects and therefore 
compliance. To date, these machines are not routinely available for home use in the 
UK. 
Not all patients will tolerate CPAP as it is an obtrusive device that has to be worn 
every night. Side effects tend to be minimal though, with nasal stuffiness and pressure 
sores from masks being the main problems. Patients often comply poorly with CPAP 
if their initial trial night is not a complete success, or they do not notice subjective 
improvements in daytime symptoms. Utmost care needs to be taken in educating the 
patient about CPAP, fitting the correct mask, finding the optimum pressure and 
providing adequate follow up care. If a patient still does not comply, alternative 
therapies should be considered. 
In the last few years there has been a considerable increase in the number of oral 
devices on the market (Lowe 1994). These appliances increase upper airway size by 
repositioning of the mandible (mandibular advancement devices) and /or the tongue 
(tongue retaining devices). Schmidt -Nowara et al (1995) reviewed 21 publications on 
oral devices, looking at SAHS patients, pre and post treatment. The summarised data 
reported that oral devices significantly reduced both snoring and sleep disordered 
breathing, but not always to normal levels. More recently, a prospective randomised 
crossover study (Ferguson et al 1996) has been performed. Here SAHS patients used 
a mandibular device for 4 months and CPAP for 4 months, in a randomised order. 
Both treatments reduced AHI, with CPAP significantly more so than the oral device. 
Conversely, side effects and patient satisfaction were greater with the mandibular 
device. Objective compliance was not measured in this study, and would have been 
interesting to examine, because with objective compliance taken into consideration, 
would CPAP still have been the most beneficial therapy? At the current state of play, 
oral devices may provide a useful alternative to CPAP, especially in sleepy snorers 
and mild SAHS patients, who may not tolerate CPAP (Schmidt -Nowara et al 1995, 
Ferguson et al 1996). 
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In summary, the clinician has to first decide whom requires treatment, and then which 
treatment to recommend. SANS severity, symptoms and individual patient 
requirements all need to be considered. Mechanical therapies such as CPAP and oral 
devices have the advantage here, because they can be used on a trial basis and then 
removed if no benefit is derived, and alternatives considered. 
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Chapter 2 
Daytime Function in the Sleep Apnoea /Hypopnoea Syndrome 
2.1 Introduction 
Patients with SAHS frequently suffer from impaired daytime function (Roth et al 
1980, Greenberg et al 1987). The first part of this chapter introduces these daytime 
impairments, which can loosely be classified into excessive daytime sleepiness, 
cognitive dysfunction and psychopathology. In addition, the effects of daytime 
dysfunction on driving performance are discussed. Possible causative effects of 
repetitive nocturnal sleep fragmentation and hypoxaemia on daytime dysfunction are 
then described by examining studies on normal subjects and in other disease states, 
and previous work on SAFTS patients (Greenberg et al 1987, Roehrs et al 1989, 
Cheshire et al 1992, Poceta et al 1992). Treatment related improvements in daytime 
function are also discussed. 
2.2 Excessive Daytime Sleepiness 
Excessive daytime sleepiness is the most common daytime feature associated with 
SANS, reported in 78 -87% of patients surveyed (Guilleminault et al 1978, Whyte et al 
1989). In addition to the direct problems caused by daytime sleepiness, SANS patients 
have further indirect consequences of sleepiness in the form of an increased risk of 
vehicle accidents (George et al 1987, Findley et al 1988), decreased subjective work 
performance (Ulfberg et al 1996), and decreases in cognition and psychological well- 
being (Greenberg et al 1987, Cheshire et al 1992). These consequences indicate that 
sleepiness needs to be quantified. 
Sleepiness is often poorly recognised by SANS patients who seem to be unaware of 
their degree of sleepiness (Dement et al 1978, Engleman et al 1997b), or may not 
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admit to their sleepiness because of its potential effect on their ability to drive or earn 
their living. Various tests have been devised to try and quantify daytime sleepiness 
using both subjective and objective measures. 
2.2.1 Subjective daytime sleepiness 
The Stanford sleepiness scale (SSS) is a simple 7 point scale from which a patient has 
to rate their level of sleepiness at a single point in time (Hoddes et al 1973). Early 
validation studies found SSS scores to correlate with performance measures in normal 
subjects before, during and after a period of sleep deprivation (Hoddes et al 1973). 
The success of the SSS in normal subjects is not reproduced in SANS patients. 
Dement et al (1978) studied a group of normal subjects and SANS patients using both 
the SSS and a physiological measure of sleepiness, the multiple sleep latency test 
(MSLT). A significant relationship existed between the SSS and the MSLT in 
normals, but not in the sleep apnoeics. SAHS patients often cannot accurately rate 
their own level of sleepiness, and have been observed scoring a high level of alertness 
on the SSS scale whilst literally falling asleep (Roth et al 1980). The role of the SSS 
nowadays tends to be in the research field measuring mood state changes under 
different experimental conditions. 
The Epworth sleepiness scale (ESS) has become a widely used measure of subjective 
sleepiness (Johns 1991, 1992, 1993 & 1994). This scale was devised by Johns in 1991 
and differs from the SSS in that it asks an individual to rate their general level of 
sleepiness in 8 everyday situations in the recent past, rather than at that particular 
moment. Validation studies performed by Johns (1991, 1993, 1994) demonstrated 
that the ESS could distinguish between patients with excessive sleepiness and 
controls, and between snorers and SANS patients. In addition, ESS scores from sleep 
apnoeic patients have been reported to be significantly correlated with the MSLT and 
measures of SANS severity (Johns 1993, 1994). Reliability studies found the ESS to 
be reproducible in medical students after 5 months, and to be significantly lower in 
sleep apnoeics on CPAP therapy compared to baseline (Johns 1992), as has also 
recently been described by Hardinge et al (1995). Based on Johns' work (1991, 1993, 
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1997), an ESS score of less than 10 is considered normal, with normals averaging a 
score of 5, and sleep apnoeics averaging a score of 12. 
Sleepiness questionnaires provide useful information for including in the initial clinical 
assessment of a patient, but caution is required as patients are not always reliable 
assessors of their own sleepiness. Objective measures of sleepiness may quantify 
daytime sleepiness better. 
2.2.2 Objective daytime sleepiness 
The limitations of the SSS led to the development of the multiple sleep latency test 
(MSLT) which measures physiological sleep onset (Dement et al 1978, Carskadon et 
al 1986, Thorpy 1992). This test was based on the assumption that patients who are 
physiologically sleepy will fall asleep faster than patients who are not sleepy when 
instructed to do so, and will therefore measure degrees of sleepiness severity. The 
MSLT consists of four or five daytime nap opportunities at 2 hour intervals. For each 
nap an individual lies down on a bed in a quiet, dark room and is instructed to try and 
sleep. Sleep is recorded polygraphically using electroencephalography (EEG), electro- 
oculography (EOG) and electromyography (EMG), and is measured in 30 second 
epochs. A nap is terminated after 20 minutes if no sleep is seen. If the test is to assess 
a patient for the occurrence of REM sleep, the test is continued for 15 minutes after 
the first epoch of sleep. In experimental studies measuring sleep tendency, each nap is 
terminated after 3 consecutive epochs of stage 1 sleep or the first epoch of any other 
sleep stage (Carskadon et al 1986). The time from lights out to the first 30 second 
page of sleep is the sleep onset latency, which is averaged across the whole day to 
give a mean sleep onset latency (SOL). 
The MSLT is considered the `Gold Standard' measure of objective sleepiness and is 
well -validated and used in both clinical and research situations. An early case -control 
study (Roth et al 1980) compared hypersomnolent sleep apnoeics with age- matched 
normals using the MSLT. The apnoeic group were significantly sleepier than the 
normal control group (mean±SD MSLT= 2.6 ±1.7 mins vs. 12.9 ±7.9 mins; p <0.05). 
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However, these mean results show overlap exists between the patient and control 
group's levels of sleepiness. Normal values for the MSLT have been described as an 
average sleep latency greater than 10 minutes and pathological sleepiness as less than 
5 minutes (Carskadon et al 1986, Thorpy 1992) . Mean sleep latencies of between 5 
and 10 minutes fall into the `grey zone', in which both SAHS patients and normals 
have been shown to overlap (Carskadon et al 1986). The small number of severe sleep 
apnoeics described by Roth et al (1980) fell asleep within the pathological range, 
whereas the 466 SAHS patients studied by Roehrs et al (1989) fell asleep in 6 minutes 
on average on the MSLT, which falls into the grey zone. Therefore medical 
judgement rather than absolute latency values are required for interpretation (Van den 
Hoed et al 1981, Carskadon et al 1986). Small but significant treatment related 
improvements in sleepiness have been reported using the MSLT in patients with 
SANS (Engleman et al 1994a). 
More recently, a variant of the MSLT has been developed (Mitler et al 1982, Poceta 
et al 1992), known as the maintenance of wakefulness test (MWT). In this instance 
the patient is seated comfortably upright on the bed or in an armchair, in a dimly lit 
room, and is instructed to try and stay awake for four or five tests, evenly spaced 
across the day. Patients are instructed to remain still and not to sing or read or do 
anything physical to try and remain awake. Original test protocols performed the 
MWT for 20 minutes (Browman et al 1983). More recently, studies have run the 
MWT for 40 minutes to minimise ceiling effects (Poceta et al 1992, Sangal et al 1992 
a). Sleep onset is defined as for the MSLT, as the first occurrence of 3 consecutive 
epochs of stage 1 sleep or a single epoch of any other sleep stage (Poceta et al 1992). 
It has been suggested (Mitler et al 1982, Sangal et al 1992a) that the MWT measures 
a different physiological ability to the MSLT, that is, the ability to stay awake. 
Therefore, the MWT may be a more appropriate clinical measure for SAHS patients 
who have problems staying awake in their daily routine. The MWT remains a 
relatively new test and so normative values and validation work are still scarce. A 
recent report on 64 normal individuals found a mean ±SD MWT sleep latency of 35 ±8 
minutes (Doghramji et al 1997), compared to a latency of 26 ±12 minutes in 322 
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SAHS patients (Poceta et al 1992). Treatment related improvements in MWT 
sleepiness have also been demonstrated in groups of 24 (Poceta et al 1992) and 26 
(Sangal et al 1992b) SANS patients, respectively. 
Both the MSLT and MWT are time consuming and expensive to perform. Arguably 
though, these objective tests are useful measures of daytime sleepiness, especially 
when patients find it hard to differentiate between quiet wakefulness and sleep 
(Browman and Mitler 1988). 
Previous studies have examined the relationship between the ESS and the MSLT 
(Johns 1991 & 1994, Chervin et al 1997) in patients with disorders of excessive 
somnolence, including SAHS. Moderately significant relationships were found 
between these two measures of sleepiness, explaining between 14 and 25% of the 
variance (Johns 1991 & 1994, Chervin et al 1997). It is possible that relationships are 
not stronger, due to the ESS being a trait assessment, and the MSLT, a state 
assessment. 
In conclusion, subjective and objective measures identify excessive daytime sleepiness 
in the SANS population. However, the cause of this sleepiness is not fully understood 
(Section 2.8). 
2.3 Coznitive Function 
An early qualitative study by Guilleminault et al (1977) documented that 60% of 
SAHS patients self -reported poor attention and an inability to concentrate. A 
quantitative study by Kales et al (1985) measured cognitive dysfunction in 50 SAHS 
patients using the Bender Gestalt test and the Wechsler adult intelligence scale 
(WAIS) or the Wechsler memory scale. 76% of patients displayed some evidence of 
cognitive impairment, identifying decrements in visuospatial skills, memory and visual 
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perception. However, this study was uncontrolled, with cognitive measures only 
compared to standardised normative values. 
Case -control studies have since been performed (Greenberg et al 1987, Bedard et al 
1991a, Naegele et al 1995), but all were on a small number of subjects. Greenberg et 
al (1987) examined 14 SAHS patients, 10 sleepy controls with other disorders of 
excessive somnolence and 14 healthy controls, matched for age, years of education 
and premorbid intelligence. All groups underwent a diverse range of psychological 
tests, including the WAIS -R, Bender visual -motor test, trail making B, Purdue 
pegboard and the Wechsler memory scale. Results found the SANS group to have 
greater decrements in attention, motor efficiency and graphomotor ability and to 
perform significantly worse on a rating of global neuropsychological impairment 
compared to the sleepy controls and non -sleepy controls. 
Bedard et al (1991a), compared a group of 10 severe sleep apnoeics to a group of 10 
moderate sleep apnoeics and 10 age and sex -matched controls. All subjects underwent 
the MSLT and a measure of vigilance, the four choice reaction time test (FCRTT), 
along with a battery of cognitive function tests. The moderate apnoeic patients 
performed significantly worse than controls on tests of attention, planning and manual 
dexterity. These decrements were worse in the severe patient group in whom there 
were additional decrements in IQ and executive functioning. The study suggested that 
perhaps discontinuity exists in the progression of sleep apnoea, with some cognitive 
dysfunction developing with moderate sleep apnoea and worsening with disease 
severity, with additional new cognitive decrements appearing only in severe disease 
cases. This group did not measure the frequency of microarousals or hypopnoeas. It 
would have been interesting to determine whether these two nocturnal measures 
differed between the 2 groups of sleep apnoeics. 
In another study (Naegele et al 1995), SAHS patients and controls, matched for age, 
education and verbal IQ, were administered cognitive tests measuring executive 
functioning. Of the tests measuring attention decrements, only one of the three 
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(STROOP- colour test) was significantly worse in the SAHS group than controls. 
Conversely, all of the short term memory task scores were significantly worse in the 
patient group. For long term memory tasks, the patient group were significantly worse 
on the learning part of the tasks and minimally worse on frontal lobe sensitive tasks. 
In agreement with Bedard et al (1991a), the study concluded that executive functions 
are impaired in SANS patients and some decrements are thought to be related to 
frontal lobe dysfunctions which the authors suggest may be a consequence of 
hypoxaemia. 
Redline et al (1997) performed a case -controlled study comparing mild SAHS patients 
(RDI of 10 -30, n =32) and normals (RDI <5, n =20) controlling for age, IQ and sex. All 
individuals underwent cognitive testing examining measures of attention, memory, 
executive functioning and information processing. Patients performed significantly 
worse compared to the controls on only 2/13 of the cognitive tests. These two tests 
were a 10 minute continuous performance test measuring attention and the WAIS -R 
digit backwards test measuring working memory. In agreement with Bedard et al 
(1991a), the study concluded that small cognitive decrements are observed in mild 
SAHS patients, and large, often more complex decrements of executive functioning, 
are found in more severe patients. 
Thus sleep apnoeics probably suffer from a diverse range of cognitive decrements in 
areas of attention, memory and executive functions. Section 2.8 goes on to discuss the 
possible aetiology of these dysfunctions and the roles played by nocturnal 
hypoxaemia, sleep fragmentation and daytime sleepiness. 
2.4 Psychopatholozy 
2.4.1 Personality and mood states in SAHS 
Psychological impairments have been reported in SANS patients (Cheshire et al 
1992). Personality traits and mood states are frequently assessed using the Minnesota 
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multiphasic personality inventory (MMPI). Studies using the MMPI on SAHS 
patients have found 28 -56% of patients to have elevated depression scores 
(Guilleminault et al 1977, Beutler et al 1981, Kales et al 1985). In addition, Kales et al 
(1985) also documented 35% of patients to have elevated hypochondriasis scores and 
29% elevated conversion hysteria scores on the MMPI. The Zung self -rating 
depression scale (SDS) has also been used in SAHS patients, where 45% of patients 
scored ratings considered symptomatic of depression (Millman et al 1989). Similar 
results were reported by Cheshire et al (1992) using the hospital anxiety and 
depression (HAD) scale (Zigmond & Snaith 1983) with 12 of 29 SAHS patients 
reporting significant levels of anxiety or depression. These studies identify depression 
ratings in excess of levels found in normal healthy subjects. 
Personality traits have also been documented, for example Klonoff et al (1987) 
described neurotic personalities in 10 SAHS patients, whilst Platon and Sierra (1992) 
found 23/35 SAHS patients to suffer from emotional and psychosocial distress 
compared to matched controls. 
The above studies identify depression as the most frequently reported mood state in 
SAHS patients. It is not known if this possible depression is a direct result of SAHS in 
terms of sleep fragmentation and hypoxaemia, or whether it is a secondary effect as a 
result of daytime sleepiness, a low quality of life and low self esteem. Klonoff et al 
(1987) and Cassel (1993) suggested that the high incidence of depression may be 
caused by 2 additional features other than primary depression, (1) the type of 
questions asked in the depression scales and (2) the timing of administering the 
questionnaires. If the depression scale contains sleep specific questions, such as the 
Zung self -rating questionnaire, which asks about fatigue, task performance and sleep 
disruption, answers could be positive if an SAHS patient has either depression, or as a 
direct result of the nocturnal effects of SAHS. However Cassel (1993) found no signs 
of clinical depression in a sample of SANS patients given the Freiburger personality 
inventory, which contains 138 items, of which only 2 items are related to sleep. The 
timing of administering the questionnaires may also effect the level of depression 
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scored. Being given a diagnosis of a long term condition such as SAHS is likely to 
increase depression ratings rather than the depression being specific to sleep apnoea. 
This is especially the case in early studies where the only available treatment for 
SAHS would have been a tracheostomy (Klonoff et al 1987). It is interesting to note 
that Cassel (1993) assessed the patient group prior to their SAHS diagnosis, and 
found no evidence of clinical depression. 
Irritability is another characteristic seen in some sleep apnoeics (Whyte et al 1989) 
and reported by family members (Guilleminault et al 1978). Irritability, mood changes 
and excessive sleepiness can lead to marital problems. Marital stress is commonplace, 
with couples spending less time together due to patient's irritability, sleepiness and 
sometimes the spouse moving to a separate bedroom to avoid snoring (Cartwright & 
Knight 1987). In the case series described by Kales et al (1985), 64% of SAHS 
patients reported marital and family problems. 
These problems of daytime sleepiness, cognitive dysfunction and psychopathology 
also lead to a decrease in the patient's quality of life and sense of well- being, which 
are probably the most recent symptoms of SAFTS to be formally quantified. 
2.4.2 Quality of life 
Measures of quality of life, in terms of general health and functional status, have 
become frequently used in outcome research in recent times. The short-form 36 health 
status questionnaire (SF -36) is a generic measure of quality of life (Ware & 
Sherbourne 1992). It contains 8 domains of health status such as vitality, physical 
functioning and pain (Section 3.5.1). Smith and Shneerson (1995) used the SF -36 in a 
group of 233 snorers and sleep apnoeics to try and identify whether this questionnaire 
was sensitive to sleep -related problems. Participants were grouped into snorers, mild 
SAHS and SAHS patients requiring therapy, based on home oximetry. SF -36 values 
were compared to normative scores, and the SAHS group requiring therapy scored 
significantly worse on the SF -36, especially in the dimensions of social functioning 
and vitality. Only the dimension of general health was not significantly different from 
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the normative values. Neither the simple snorers or the mild SAHS patients differed in 
SF -36 scores from the normative values. So although the SF -36 does not have a 
dimension specific to sleep, there seems to be an indirect effect of sleep apnoea on 
health status (Smith & Shneerson 1995). A similar study was performed in 108 SAFTS 
patients (Jenkinson et al 1997). Three quality of life questionnaires were given to the 
patients, (1) the SF -36, (2) the functional limitations profile (FLP) and (3) the 
EuroQol (EQ -5D). FLP measures the effect of illness on daily activities and can be 
split into 12 dimensions, and the EQ -5D measures the following domains of mobility, 
self -care, usual activity, pain and anxiety /depression. Questionnaires were given at 
baseline and compared to population norms. Scores on the SF -36 and the FLP were 
low compared to population norms at baseline, indicating that SANS individuals 
suffer from an impaired quality of life. This was not found using the EuroQol 
questionnaire. Both Smith & Shneerson (1995) and Jenkinson et al (1997) identified a 
range of domains which were affected in SAHS patients that are likely to have an 
effect on many aspects of an individual's life. 
Recently a functional outcomes questionnaire has been designed and validated which 
is specific for disorders of excessive somnolence (DOES) (Weaver et al 1997). This 
30 item questionnaire is known as the functional outcomes of sleep questionnaire 
(FOSQ), and unlike other non -generic sleep questionnaires (ESS, SSS) does not focus 
on the sleepiness in isolation but measures how the sleepiness affects daily functioning 
and quality of life. As part of the questionnaire's validation, the FOSQ could reliably 
distinguish normals from DOES patients (Weaver et al 1997). Factor analysis 
identified 5 subscales on the questionnaire, namely activity level, vigilance, intimacy 
and sexual relationships, general productivity and social outcome. The questionnaire 
therefore appears to identify a range of functional areas affected by daytime sleepiness 
in SAHS patients. With further studies at baseline and on therapy, this measure of 
functional outcomes can be utilised further. 
Both the generic (SF -36) and non -generic (FOSQ) functional status measures used in 
SAHS have advantages. Generic questionnaires can allow cross -disease comparisons, 
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which can be useful, especially when convincing health purchasers of the 
consequences of a disease and improvements with treatment. Non -generic measures 
are also advantageous because of their specificity to the disease and usefulness in 
identifying who needs therapy. 
The results discussed here indicate that sleep apnoeics suffer from a wide range of 
psychological decrements affecting a diverse range of daily functions and activities. 
Results depend largely on self -assessed questionnaires and therefore should be 
interpreted with care, as it is possible some individuals may enhance their scores in an 
attempt to increase their chance of therapy. 
2.5 Driving and performance 
A severe consequence of daytime dysfunction in sleep apnoeics is an increased risk of 
vehicle accidents (George et al 1987, Findley et al 1988) and impaired driving 
performance (Findley et al 1989, Haraldsson et al 1990a, George et al 1996). 
2.5.1 Vehicle accident rates 
Population studies 
Home & Reyner (1995) performed a general population study by surveying police 
databases for accident reports and on- the -spot police interviews in England. The 
study found that between 16 and 23% of the reported accidents were sleep related. In 
addition, these sleep related accidents were thought to have a higher rate of morbidity 
and mortality than other vehicle accidents, due to no prior braking and therefore a 
greater impact speed (Home & Reyner 1995). This evidence is supported by Parsons 
(1986) who found that 25% of vehicle accidents were caused by falling asleep at the 
wheel, and that these accidents accounted for 83% of all fatalities. However, these 
studies cannot identify the proportion of sleep- related accidents caused by sleep 
apnoea patients. Most recently, Young et al (1997) performed a large study 
examining vehicle accident rates in the general population. Polysomnography was 
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performed in 913 individuals to evaluate sleep disordered breathing (SDB), and 5 year 
accident rate was obtained from state databases. The study found that men with SDB 
(AHI >5) were more likely to have one accident every 5 years than subjects with no 
SDB. Also men and women with an ARE >15 were more likely to have multiple 
accidents than subjects with no SDB. Such associations were independent of age, 
miles driven/year, and alcohol. BMI and education were ruled out as confounders. 
This population based study is not open to the clinic selection bias, and shows rather 
disturbingly that people at the mild end of the SDB continuum are more likely to have 
accidents than normals. This mild group are often not treated even if they present with 
sleepiness. 
SANS patient studies 
Studies in sleep apnoeics (George et al 1987, Findley et al 1988) have also examined 
government databases of accidents in matched case -control studies. George et al 
(1987) found sleep apnoeics to have over twice the number of reported vehicle 
accidents compared to controls, although 7 of the 27 patients studied did not undergo 
polysomnography to define their SAHS. Findley et al (1988) reported a 7 fold 
increase in accident rate in sleep apnoeics compared to controls, and 2.6 times the rate 
of accidents seen in all licensed drivers in Virginia. 
Accident reports are likely to provide an underestimation of vehicle accidents because 
minor accidents are often not reported, and in some cases even severe accidents are 
not reported, possibly due to criminal activities or insurance purposes. 
Studies using self -reported data on SAHS accident rates have also been conducted 
(Haraldsson et al 1990b, Engleman et al 1997b). Haraldsson et al (1990b) performed 
a questionnaire based study comparing data from self -reported sleep apnoeics and 
controls. Both groups had similar rates of multiple vehicle accidents, whereas single 
vehicle accident rates were 7 times higher in SANS patients. The main problem of 
using self -reported data is that patients are likely to underreport their accident rates 
for fear of losing their driving licence. A retrospective study by Engleman et al 
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(1997b) requestioned SANS patients on CPAP about their driving habits prior to 
starting therapy. Originally 23% of patients admitted driving impairment due to 
sleepiness, whereas this value increased to 37% (p =0.01) when questioned on CPAP 
about their pretreatment accident rate. Thus suggesting that retrospective questioning 
of SAHS patient accident rate may decrease the underreporting of accidents reported 
at baseline. 
2.5.2 Driving performance tests 
Driving- related performance can also be monitored using driving simulators and 
vigilance tasks. Findley et al (1989) compared the performance of sleep apnoeics and 
control subjects on two different performance tasks. The Doron simulator used road 
films of highway, city and rural driving, and monitored steering, signalling, braking 
and accelerating, whilst the computer simulator, Steer Clear, involves the monotonous 
task of avoiding obstacles on a two lane road using one computer key to change 
lanes. Patients with sleep apnoea performed significantly worse than controls on both 
types of simulator. The authors also reported that the sleep apnoeics performed worse 
on the more monotonous Steer Clear programme, although only 4 sleep apnoeics 
used both simulators. Haraldsson et al (1990a) compared 15 SAHS patients and 10 
age and sex -matched controls using an advanced driving simulator, in the shell of an 
actual car. The sleep apnoeic group demonstrated a longer brake reaction time, and 
increased deviations from the lateral road position than the normal subjects. George et 
al (1996) developed a simulator known as a divided attention driving test (DADT), 
which measured both tracking ability (keeping within the road boundaries) and visual 
search (to look for pedestrians, traffic signals etc.). Sleep apnoea patients performed 
significantly worse than age- matched controls on all measures, with the greatest 
difference being in tracking error. SAHS patients were also significantly worse than 
controls under the influence of alcohol, indicating the severity of driving problems in 
sleep apnoeics. Driving simulators and vigilance tasks are not the same as real driving 
and so simulator results may not directly link to driving ability. For example, some 
individuals may find the simulators entertaining and increase their alertness, while 
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others may manage to upgrade their performance for 30 minutes for the sake of 
maintaining their driving licence. 
2.6 Aetiology of Daytime Dysfunction 
There is much debate as to what determines the decrements in daytime function seen 
in SAHS patients, and this is the main question of this thesis. Correlational studies in 
sleep apnoeics have suggested that both sleep fragmentation (Guilleminault et al 
1988b, Roehrs et al 1989, Poceta et al 1992) and nocturnal hypoxaemia (Bedard et al 
1991b) play causative roles in daytime dysfunction. Before this literature is reviewed, 
the individual contributions of nocturnal SAHS events will be discussed by examining 
studies using experimental models of sleep fragmentation and hypoxaemia and their 
effects on daytime function. 
2.7 Experimental Models 
The sleep apnoea/hypopnoea syndrome consists of a cycle of nocturnal events 
(Section 1.2.4) including breathing pauses, brief arousals from sleep, oxygen 
desaturations and sleep stage changes. These nocturnal variables are all interrelated to 
a certain degree and so identifying possible causative roles of each individual 
nocturnal variable on daytime function is a complicated task. By experimentally 
modelling the two most likely causative variables of sleep disruption and hypoxaemia, 
their contribution to daytime dysfunction can be explored. 
2.7.1 Sleep deprivation 
Many experimental studies have interfered with sleep quality and quantity in normal 
subjects in an attempt to identify daytime effects in terms of sleepiness, performance 
and mood. 
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One of the first sleep deprivation studies was performed in 1896 by Patrick and 
Gilbert, where 3 subjects underwent 90 hours of sleep deprivation. EEG was not 
available, but physiological changes were noted such as a decreased body 
temperature, brief lapses into sleep along with decreased vigilance and slower reaction 
times. In 1949, Bjerner used EEG to physiologically monitor sleep patterns during 
deprivation experiments. The study found that during sleep deprivation there was a 
decrease in alpha waves along with the emergence of high amplitude slow waves 
(since termed `microsleeps' by Harrison & Home 1996a). Bjerner (1949) found a 
decrease in daytime performance associated with the occurrence of these 
`microsleeps'. Wilkinson (1964) performed sleep deprivation studies and used 
performance tasks as outcome measures of sleep loss. He designed reaction time and 
vigilance tasks which were long, and therefore dull and boring, and found that the 
longer the monotonous task, the worse the performance, following a period of sleep 
deprivation. 
Total sleep deprivation studies have demonstrated that if you deprive someone of 
sleep, their sleepiness and performance on monotonous tasks will be impaired, 
although performance levels may be influenced by motivational factors to a point. For 
example, Home & Pettitt (1985a) offered normal subjects a cash incentive to maintain 
a good performance over a 72 hour sleep deprivation period. Subjects managed to 
maintain a high level of performance for 48 hours, after which it decreased. Total 
deprivation studies are important fundamental experiments, but what is the minimum 
amount of sleep required on which individuals can still function normally? 
Wilkinson (1969) performed a comprehensive sleep restriction study where subjects 
spent 6 weeks in the sleep laboratory. Within each group, sleep was restricted to a set 
level of sleep for two nights. The levels of sleep were 7.5, 5, 3, 2, 1 and 0 hours. All 
subjects were randomly given each level of sleep restriction over the six week period. 
During the periods of sleep restriction, subjects performed the Wilkinson auditory 
vigilance task (WAVT), the Wilkinson addition task and a coding test. Results 
demonstrated that following one night of sleep restriction, performance remained 
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unchanged unless sleep was below 3 hours. Following 2 nights of sleep restriction, 
performance decreased when sleep was below 5 hours. However, Wilkinson did not 
measure EEG, and so we have to assume that subjects slept well during their various 
sleep opportunities. Similar studies to Wilkinson (1969) have since been performed 
(Carskadon & Dement 1981, Dinges et al 1997). Both studies restricted sleep to 5 
hours a night for a 7 night period, and included baseline measurements and a recovery 
period after the sleep restriction. Carskadon & Dement (1981) found MSLT 
measured sleepiness to increase from the second to the last day of sleep restriction. 
Dinges et al (1997) found sleep restriction to cause an increase in sleepiness (SSS), 
fatigue, tension and mood disturbance, and a decrease in attention (as measured by a 
vigilance task). A subgroup of 8 subjects underwent MSLTs and in this group sleep 
onset latencies also decreased with sleep restriction. It appears that as the sleep 
restriction continues, subjects show decreases in performance and increases in 
sleepiness. It has been suggested that there is a build up of restorative slow wave 
sleep debt (Wilkinson 1969, Home 1987) which cumulatively affects daytime 
function, with continued sleep restriction. 
Sleep restriction experiments reduce sleep quantity, but are not simulating the sleep 
pattern seen in a sleep apnoeic, which consists of regular brief fragmentation of sleep, 
disrupting sleep continuity and quality. 
2.7.2 Sleep disruption 
Bonnet and colleagues performed a number of sleep disruption studies in the 1980's. 
One such study in 1985 aimed to model the disrupting effects of sleep apnoea by 
causing an awakening after each minute of sleep over two consecutive nights. 11 
normal subjects underwent a baseline night, two sleep disruption nights, and two 
recovery nights. During the sleep disruption nights, each tone -induced arousal was 
acknowledged by the subjects who either completed a sleepiness scale, or pressed a 
button on awakening. The sleep disruption caused non -restorative sleep with 
increases in stage 1 and wake, and significantly less total sleep, especially slow wave 
sleep (SWS) and REM. After the two nights of sleep disruption there was a significant 
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decrease in general performance and an increase in subjective sleepiness compared to 
baseline (Bonnet 1985). 
Bonnet (1986) then asked the question of whether this decreased performance was 
due to a disruption of sleep continuity or lack of restorative slow wave sleep. On one 
limb regular sleep disruption occurred, and on the other limb sleep disruption also 
occurred, but in addition slow wave sleep was eliminated. Experimentally induced 
awakenings were equal in both conditions. The study found no difference in 
performance, mood or sleepiness between conditions. Therefore results suggest that 
the decrease in daytime function is due to the frequency of sleep disruption and not 
the quantity of slow wave sleep. 
In 1987, Downey and Bonnet investigated what level of sleep disruption causes 
daytime dysfunction. There were 4 experimental conditions: (1) total sleep deprivation 
for 64 hours, (2) awakened every minute, (3) awakened every 10 minutes and (4) 2.5 
hours of undisturbed sleep followed by awakenings at 10 minute intervals for the 
remainder of the disruption night. For each awakening subjects gave a verbal response 
and then did a simple performance test. Performance declined across both nights and 
subjects performed best in the 10 minutes disruption condition after the 2.5 hours of 
uninterrupted sleep and worst after total sleep deprivation. Interestingly, TST, REM 
and SWS were greater when fragmented every 10 minutes, than in the 2.5 hour 
uninterrupted condition, yet performance was better when subjects were allowed a 
period of continuous sleep. In agreement with Bonnet's 1986 experiment, this study 
concluded that it is the disrupting of sleep continuity and not the type or quantity of 
sleep that causes a decreased performance. From Bonnet's set of experiments the 
sleep continuity theory was developed where an individual needs continuous periods 
of sleep of greater than 10 minutes to restore function during the day. 
A similar study was performed by Magee et al (1987), whose three sleep disruption 
conditions were (1) an undisturbed night, (2) disruption every minute, (3) disruption 
every 4 minutes. Daytime sleepiness was assessed by the MSLT. Results showed that 
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disrupting sleep every minute caused a significant increase in sleepiness. There was no 
difference in sleepiness between the undisturbed condition and the 4 minute condition. 
These results might suggest that an individual needs continuous periods of sleep of 
approximately 4 minutes for sleep to be restorative. This is a lower cut off than that 
described above by Bonnet (1986). 
The experimental sleep disruption in the above studies caused full conscious 
awakenings requiring behavioural responses. These awakenings led to a decrease in 
total sleep time (TST) compared to undisturbed control nights and therefore any 
daytime dysfunction caused by this sleep disruption may be attributed to a lower TST. 
Thus these awakenings do not closely mimic the sleep fragmentation found in SAHS 
individuals where arousals tend to be brief ( <15 seconds) and therefore only disrupt 
sleep continuity and not TST (Dement et al 1978). 
2.7.3 Sleep fragmentation 
In 1987 Bonnet studied eleven subjects who underwent 2 nights of sleep 
fragmentation, with auditory tones administered at 2 minute intervals. There were 3 
conditions of response to arousal, and subjects completed all three conditions over a 
three week period, (1) a brief awakening followed by a subjective response (Bonnet 
1985), (2) a 1/4 body turn in response to the tone, and (3) a change in the EEG (sleep 
stage change, return of alpha rhythm, or an increase in EEG frequency). The EEG 
condition was the least disruptive to sleep, having the highest TST, but still eliminated 
stage 4 sleep along with the other two conditions. Compared to baseline, all three 
conditions of arousal decreased morning vigilance, nap latency and mood. Therefore it 
was concluded that a change in the EEG is sufficient to cause daytime dysfunction. 
The EEG condition of arousal was most representative of SANS patient's arousals, 
who tend to have very few remembered awakenings, but many brief arousals (Bonnet 
1987). However, there is no record of the actual duration of the changes in EEG 
frequency in this experiment. 
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Recent studies (Philip et al 1994, Roehrs et al 1994, Martin et al 1996) have more 
closely modelled the fragmentation pattern seen in sleep apnoeics and have also taken 
into consideration the fact that individuals tend to adapt to auditory tones as the night 
progresses. 
Philip et al (1994) applied auditory tones for 5 seconds and immediately determined if 
there was an arousal response based on a 3 second return to alpha rhythm on the 
EEG. If no arousal was observed then another 10 second tone was given. Again if no 
arousal response was observed further tones were given for 10 seconds with gradual 
increases in sound intensity. One minute of sleep was allowed between arousals. The 
arousal threshold significantly changed from the first to the third part of the night. 
Wake time was also monitored to make sure TST was extended on the fragmented 
night, to match the baseline nights. In the daytime subjects underwent the MSLT and 
performance tests. Sleep fragmentation caused a significant increase in stage 1 sleep 
and a decrease in SWS and REM sleep. Fragmentation also increased daytime 
sleepiness but there was no change in performance measures. A major criticism of the 
study is that the authors only reported the number of auditory stimulations given, and 
not the number or maximum length of the resulting EEG arousals, as it is likely that 
not all stimulations produce the desired arousal. 
In a study by Roehrs et al (1994) 36 subjects underwent two consecutive nights of 
sleep fragmentation, with the MSLT and performance tests carried out on both days. 
Fragmentation results were compared to an undisturbed night and test day prior to the 
fragmentation limb, with no difference in TST between both limbs. The auditory tones 
were created by a computerised tone generator which varied the frequency and 
intertone interval to decrease adaptation. Tones were given, on average, every 2 
minutes on both fragmentation nights. There was no difference in TST between the 
two fragmentation nights. Results found one night of sleep fragmentation caused an 
increase in sleepiness as measured by the MSLT, but this did not change any further 
after the second night of fragmentation. Sleep fragmentation caused no change in 
performance as measured by a divided attention task. These differences in daytime 
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sleepiness and lack of performance differences, between unfragmented and 
fragmented nights have to be interpreted with caution because the unfragmented limb 
always occurred prior to the fragmented limb and results may be explained by a 
possible order effect. 
To overcome any possible order effect, Martin et al (1996) performed a study on 16 
normal subjects using a randomised crossover design. On one limb subjects slept 
normally, and on the other limb they were fragmented by auditory tones at 2 minute 
intervals. Both study nights were preceded with an acclimatisation night. Tones were 
manually administered causing brief arousals from sleep (between 3 and 15 seconds 
long). Each arousal was preceded by an intertone interval of 2 minutes of stage 2 
sleep. If an auditory tone did not produce a visible EEG arousal, a 10 second interval 
occurred, before a louder or longer tone was given. Both study nights were followed 
by extensive daytime tests measuring subjective and objective sleepiness, mood and 
cognitive function. There was no difference in total sleep time between the two study 
nights, but the fragmented sleep significantly reduced slow wave sleep and REM 
sleep, and more than doubled the number of microarousals compared to the non - 
fragmented night. Both objective sleepiness latency, on the MSLT and MWT, and 
mood were lowered with sleep fragmentation. In addition, performance on trail 
making B and PASAT (4 secs) were significantly impaired as a result of sleep 
fragmentation, suggesting decreases in mental flexibility and sustained concentration. 
This is in contrast to previous studies (Philip et al 1994, Roehrs et al 1994) where no 
changes in cognitive performance scores were found. This study improves on previous 
sleep modelling studies by including a control limb, acclimatisation nights on both 
limbs, and a randomised crossover design. 
In summary, sleep fragmentation studies have demonstrated that repetitive brief 
arousals of a similar duration to those found in SAHS (Martin et al 1997c) cause 
increased sleepiness (Bonnett 1987, Philip et al 1994, Roehrs et al 1994, Martin et al 
1996), and impaired mood and cognitive dysfunction (Martin et al 1996). This leads 
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to the speculation that sleep fragmentation may play a causative role in SAHS daytime 
dysfunction. 
2.7.4 Modelling hypoxaemia 
The repetitive breathing pauses of SAHS lead to falls in arterial oxygen levels. As 
with experiments modelling sleep loss, modelling hypoxaemia may shed some light 
onto the possible causative relationships in SAHS patients between hypoxaemia and 
daytime function (Greenberg et al 1987, Bedard et al 1991b, Cheshire et al 1992). 
Studies on the cerebral effects of acute hypoxaemia have been performed on normal 
subjects at high altitudes. Cognitive dysfunction has been identified at 4,000- 6,200m 
compared to baseline altitudes in measures of constructional ability, problem solving 
(Nelson 1982a), complex abstract reasoning and verbal fluency (Peteit et al 1988). In 
addition, psychological changes have been identified including increased paranoia, 
obsessive -compulsive behaviour, hostility (Nelson 1982a) and psychosocial 
dysfunctioning (Peteit et al 1988). However, unlike the acute hypoxaemia seen at high 
altitude, SAHS patients may have suffered long -term hypoxic effects and therefore 
perform differently on cognitive tasks. Furthermore, SANS patients tend to have 
intermittent nocturnal hypoxaemia, not 24 hour hypoxaemia. In addition other factors 
may contribute to changes in psychological state at altitude, such as feelings of 
isolation. 
An alternative approach is to study the sustained hypoxia seen in patients with chronic 
obstructive pulmonary disease (COPD), although again, this tends to result in 24 hour 
hypoxaemia. Case control studies have identified decrements in cognitive function and 
psychological well -being in hypoxic COPD patients (Grant et al 1982, McSweeney et 
al 1982, Prigatano et al 1983). One such study (Grant et al 1982) consisted of 203 
hypoxic COPD patients involved in the nocturnal oxygen therapy trial (NOTT), along 
with 74 age, sex and education -matched healthy controls who underwent a cognitive 
battery measuring motor ability, attention, perceptual -motor performance, sensory 
function, verbal skills and memory. 42% of COPD patients demonstrated moderate to 
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severe cerebral impairments compared to only 14% of controls. The higher cognitive 
functions of abstract thinking and complex perceptual motor integration were most 
affected, and the authors suggest this could be due to the decreased availability of 
oxygen to the brain. Prigatano et al (1983) measured a similar diverse range of 
cognitive functions on a group of 100 mildly hypoxaemic COPD patients and 25 
healthy controls. Mild neuropsychological decrements in abstract reasoning, memory 
and mental flexibility were seen in the COPD group compared to controls. The level 
of cognitive deterioration was less than that described by Grant et al's (1982) more 
severely hypoxic group. Patients involved in the NOTT study were also compared to 
controls using quality of life measures (McSweeney et al 1982), with COPD patients 
demonstrating decrements in ratings of social functioning, and increases in ratings of 
depression, anxiety and fatigue. These studies have identified that individuals with 
COPD frequently suffer from decrements in cognitive function and quality of life. 
However, as with altitude studies, direct comparisons with sleep apnoea cannot be 
made. Not only is the pattern of hypoxaemia different, but also COPD patients have 
poor quality sleep with frequent awakenings (Calverley et al 1982, Fleetham et al 
1982). 
More recently Roehrs et al (1995) compared cognitive function and sleepiness in 
SAHS and COPD patients. The SANS group were sleepier, as measured by the 
MSLT. Both groups of patients were cognitively impaired when compared to 
normative scores. The measures of complex and abstract reasoning and motor skills 
were sensitive to hypoxic deficits, whereas tests measuring attention, tracking, 
memory and learning were sensitive to sleepiness. The SAHS group performed 
significantly worse on an attention type task, whereas the COPD group performed 
significantly worse on a psychomotor task, with the two groups not differing in their 
tests for memory or complex reasoning. The study therefore suggested that some 
cognitive deficits are disease specific but others are non -specific. This study again 
supports the evidence that COPD does not provide an ideal model of SAHS, as the 
different disease states produce different cerebral impairments. The two groups were 
not age- matched and age negatively effects cognitive performance (Lezak 1983). 
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The only study to date which has modelled the intermittent hypoxaemia seen in SAHS 
patients without either the short term effects of acute hypoxia or the daytime effects 
of COPD, has induced nocturnal hypoxia in a group of sleep apnoea patients. Colt et 
al (1991) performed a randomised crossover study on 7 SAHS patients. On one limb 
of the study, patients were administered CPAP to abolish apnoeas, sleep 
fragmentation and hypoxaemia for two nights. On the other limb patients were given 
CPAP to abolish apnoeas and sleep fragmentation for two nights, but this time were 
also given intermittent additions of 100% nitrogen gas to air to induce repetitive 
desaturations. Both experimental limbs and two baseline nights were followed by the 
MSLT to measure sleepiness. Results demonstrated that sleepiness decreased on 
CPAP compared to baseline, but did not differ between the two CPAP conditions. 
Therefore the study suggested that hypoxaemia had no independent effect on daytime 
sleepiness in the absence of sleep fragmentation. The hypoxaemic limb naturally had 
significantly more desaturations, but there was no difference in arousal frequency 
between the two study conditions. This study used only a small sample size and a 
Type II error is thus not excluded. 
2.7.5 Conclusion 
Modelling studies provide some useful information about the independent roles of 
sleep fragmentation and hypoxaemia on daytime function. The sleep modelling 
experiments demonstrated that sleep fragmentation leads to deficits in sleepiness, 
mood and cognitive function (Martin et al 1996), and that sustained hypoxaemia may 
lead to wide spread decrements in cognitive function and quality of life, and altered 
mood states (Grant et al 1982, McSweeney et al 1982). 
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2.8 Relationships between nocturnal SAHS measures and daytime 
dysfunction. 
The next stage of this chapter is to focus on the possible relationships between 
nocturnal sleep and breathing events and daytime function, examining relationships 
within individuals from the whole continuum of sleep disordered breathing. These 
possible causative relationships comprise the main focus of this thesis. 
To clearly present the evidence, the daytime function measures have been subdivided 
into daytime sleepiness (section 2.8.1), cognitive function (2.8.2) and 
psychopathology (2.8.3). Obviously there is considerable overlap between these 
daytime measures, but there are also considerable interrelationships between the 
nocturnal variables and I felt this was the clearest way to present these results. 
2.8.1 Relationships with daytime sleepiness 
Many previous research studies have focused on identifying relationships between the 
nocturnal disturbances associated with sleep apnoea and daytime sleepiness, in an 
attempt to find a cause of excessive daytime sleepiness (Table 2.1). 
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Table 2.1; Major correlational studies of daytime sleepiness in SAHS patients 
Author Subjects Daytime measures Study Findings 
Roth et al 1980 10 severe SAHS 
10 controls 
MSLT In sleep apnoeics, RAR 
related to stage 2 sleep 
on MSLT, no 
relationships with stage 
1 sleep on MSLT 
Stepanski et al 
1984 
15 SAHS 




MSLT In SAHS group, only a 




100 SAHS MSLT Sleep variables (SWS 
& st 1 sleep) related to 
MSLT 
Roehrs et al 1989 466 SAHS MSLT RAR best predictor of 
MSLT 








predictors of MSLT 
Poceta et al 1992 322 SANS MWT RAR best predictor of 
MSLT 
Cheshire et al 
1992 
29 SANS MSLT (+ cognitive 




parameters and MSLT 
(only with cognitive 
function) 
MSLT = Multiple sleep latency test; RAR= Respiratory related arousals; SWS =Slow wave sleep; 
FCRTT =Four choice reaction time test. 
Subjective sleepiness 
An early study (Orr et al 1979) compared 4 sleepy and 4 asymptomatic patients as 
defined by the Stanford sleepiness scale and self/family reports. The symptomatic 
group had lower arterial oxygen tension on waking and during sleep, but no 
differences in apnoea index or sleep disruption. The study therefore suggested that 
daytime sleepiness is not influenced by apnoea severity or sleep variables but maybe 
by hypoxaemia, although the study was very small and results should be interpreted 
with caution. Johns (1993) examined relationships between nocturnal SANS measures 
and subjective sleepiness as part of the validation of the Epworth sleepiness scale 
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(ES S) and found sleepiness to relate to AHI and hypoxaemia, but recorded no 
measure of microarousal frequency. These two studies show relationships with 
sleepiness when measured subjectively. However, subjective sleepiness is not always 
compatible with measures of objective sleepiness (Dement et al 1978). 
Objective sleepiness 
The following set of studies all measured daytime sleepiness using objective 
techniques recording physiological sleep onset. Roth et al (1980) studied 10 severe 
sleep apnoeics (mean AI = 58) and 10 age- matched controls. All participants 
underwent full polysomnography followed by sleep latency naps the following day. 
Correlational analysis found a significant relationship between sleep disruption (shifts 
to stage 1 sleep, r= -0.57; and % stage 1 sleep, r= -0.52, no p values reported in text) 
and daytime sleepiness. When the two groups were analysed independently, the 
controls showed relationships between shifts to stage 1 sleep and % stage 1 and 
daytime sleepiness. Whereas in the sleep apnoeic group, no nocturnal sleep or 
breathing parameter correlated with stage 1 sleep on the daytime naps, only 
respiratory related arousals correlated with stage 2 latency on the daytime naps 
(r=- 0.67). The authors provided two possible explanations for their lack of findings in 
SAHS patients. Firstly, the current nocturnal measures are not sensitive enough to 
detect the nocturnal cause of daytime sleepiness. This may be the case, because since 
this early paper, hypopnoeas and EEG microarousals have been described. Secondly, 
there may be a lack of variability in the sleepiness of the patient group which is hard 
to differentiate using the daytime nap latency. In addition, the data was only acquired 
in 10 severe sleep apnoeics and these numbers are far too small to rely on 
correlations. 
Stepanski et al (1984) focused on the contribution of sleep fragmentation on daytime 
sleepiness by measuring a range of arousal definitions. Sleep fragmentation was 
examined in 55 subjects (15 sleep apnoeics, 15 patients with myoclonus, 15 
insomniacs and 10 normal subjects) using increasing levels of arousal: (1) increased 
EEG and chin EMG frequency, (2) alpha burst in EEG of 0 -29 secs, (3) sleep stage 
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shift to a lower stage, (4) a 30 second awakening. Arousal frequencies were 
correlated with a sleepiness index as measured by the MSLT. All four groups of 
subjects had significantly different numbers of arousals across all 4 levels. The sleep 
apnoeic group had more level 1 -3 arousals and the least level 4 (awakenings) arousals. 
The authors suggested this is due to the sleep apnoeic group being the most sleepy 
and therefore less likely to have full awakenings, possibly due to a higher arousal 
response from years of adapting to their disease, or simply that they are too sleepy to 
wake up for more than 29 seconds. In the total sample of 55 subjects, significant 
correlations existed between total arousal frequency and sleepiness (r =0.48, p <0.001), 
but this was not reproduced in the individual groups. In the sleep apnoeics, there was 
no significant relationship between total arousals and sleepiness on the MSLT. Like 
Roth et al (1980), these authors suggest that there may not be enough variability in 
sleepiness within each subject group, masking any possible correlations that are seen 
in the more diverse whole population. The sample size studied here is too small to rely 
on correlational analysis. Despite this, Stepanski et al's (1984) paper provides useful 
information about the importance of the brief microarousals and their effect on sleep 
continuity in sleep apnoea. 
Bedard et al (1991b) and Cheshire et al (1992) also examined nocturnal predictors of 
daytime sleepiness as measured by the MSLT in small samples of sleep apnoeics. 
Bedard et al (1991b) measured both sleepiness and alertness (reaction time test) in 20 
patients with moderate to severe sleep apnoea. Sleepiness correlated with minimum 
oxygen saturation (r =0.54, p <0.05) and % sleep time under 90% oxygen saturation 
levels (r= -0.46, p <0.05). Sleepiness did not significantly correlate with sleep 
disruption or the apnoea index. The microarousal frequency was not measured, so its 
contribution is not known. Relationships may have been seen with hypoxaemia rather 
than any other nocturnal measure because the selected population had a minimum 
desaturation <- 80 %. Conversely, Cheshire et al (1992) found no such relationships 
between nocturnal SANS measures and objective sleepiness. This group studied 29 
symptomatic SAHS patients (median AHI = 46) who underwent full 
polysomnography, a battery of cognitive tests and the MSLT. In addition to measures 
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of apnoeas, hypoxaemia and sleep disruption, Cheshire et al (1992) also measured the 
frequencies of microarousals and hypopnoeas, yet still none of the nocturnal variables 
correlated significantly with objective daytime sleepiness. This lack of relationships 
may be due to the small sample size. Both Bedard et al (1991b) and Cheshire et al 
(1992) also looked at cognitive function measures and these are discussed in section 
2.8.2. 
Correlational studies with larger numbers and therefore greater statistical power have 
also been performed (Guilleminault et al 1988b, Roehrs et al 1989, Poceta et al 1992, 
Chervin & Aldrich 1998). Guilleminault et al (1988b) studied 100 unselected patients 
presenting with symptoms of sleep apnoea (mean RDI = 50) using full 
polysomnography and the MSLT. Only sleep architecture (amount of stage 3 & 4, and 
stage 1) significantly correlated with sleep latency on the MSLT. There were no 
significant correlations with respiratory disturbances, hypoxaemia or R & K 
awakenings (more than 15 seconds of wakefulness). Various post hoc analyses were 
performed on this SAHS population. Patients were divided into non -sleepy, mildly 
sleepy and severely sleepy as determined by the MSLT and using analysis of variance 
no significant differences in sleep variables were seen between the three subgroups. 
When this population was split into two groups determined by MSLT ( >8 mins and 
<= 8mins), the groups differed in RDI (p= 0.001), stage 1 sleep (p <0.001), SWS 
(p= 0.002), REM sleep (p =0.04) and awakenings (p= 0.003) but not for measures of 
hypoxaemia (all p >0.42). Cluster analysis was also performed and could define two 
groups of SAHS patients as `sleepy' and `alert' as measured by the MSLT. This study 
has shown that only sleep structure could predict sleepiness, and that breathing 
pauses, hypoxaemia and awakenings failed to correlate. This represented a finding 
similar to that of Roth et al (1980). The cluster analysis could differentiate sleepy and 
non -sleepy patients, but interestingly, the sleepier group had a lower respiratory 
disturbance index than the non -sleepy group. This study did not measure microarousal 
frequency, only >15 second awakenings and % stage 1, which provide only limited 
evidence of SANS sleep fragmentation. 
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In a recent retrospective study (Chervin & Aldrich 1998), the relationship between 
AHI and the MSLT was studied. Relationships with the AHI and not microarousal 
frequencies were examined because this is the variable most often used to clinically 
define sleep apnoea severity. In 1,146 patients with SDB (mean AHI =31), linear 
regression analysis found that AHI explained less than 12% of the variance in MSLT 
measured sleepiness. 
Roehrs et al (1989) did incorporate the role of sleep fragmentation to some extent 
when they performed a large correlational study on 466 sleep apnoeics (mean AI 
=42), using both polysomnography and the MSLT. Sleepiness significantly correlated 
with arousals, stage 1 sleep and measures of hypoxaemia. These nocturnal variables 
themselves were highly interrelated, and using multiple regression, the best single 
predictor of daytime sleepiness was found to be respiratory related arousals. The 
measures of hypoxaemia provided `little or no independent predictive information' 
(Roehrs et al 1989). The authors therefore concluded that sleep fragmentation causes 
daytime sleepiness in sleep apnoeics. The population sample used in this study is not 
well defined and no entry or exclusion criteria were given. The arousal definition used 
in the study (3 sec or greater increase in EEG or submental EMG or both at 
termination of respiratory event) does not require a change in EEG to score an 
arousal. This study provides some evidence of the relationship between sleep 
fragmentation and daytime sleepiness accounting for 13% of the overall variance in 
MSLT. Poceta et al (1992) performed a similar study in 322 SAHS patients who had 
an RDI >5. The mean RDI of the group was 39. All patients underwent 
polysomnography and the MWT the next day. Pearson correlations found that the 
arousal frequency, RDI and minimum saturation all significantly correlated with mean 
MSLT (all r >0.28, p <0.05). Stepwise regression analysis identified the respiratory 
related arousals as the most important correlate of the MWT, explaining 12% of the 
variance, a similar value to that found by Roehrs et al (1989) using the MSLT. The 
studies by Roehrs et al (1989) and Poceta et al (1992) have found the strongest 
relationships between nocturnal SANS measures and daytime sleepiness, 
predominantly with measures of sleep fragmentation. However, as previously 
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mentioned, such relationships explain less than 13% of the variance in objective 
sleepiness, which are only relationships of a moderate strength. There are a few 
possible explanations as to why these two studies found relationships and others did 
not. The most obvious of these are the larger sample sizes used, and the use of 
microarousal definitions. 
Research has also focused on the mild end of the disease spectrum, studying 
individuals with upper airway resistance and snoring. Epidemiological studies 
(Stradling et al 199 lb, Jennum et al 1994) in general community populations have 
found that self reported snoring relates to subjective daytime sleepiness, independent 
of SAFTS confounders (Stradling et al 199 lb). Although these studies contain only 
subjective reports of snoring and sleepiness, they are large number studies. 
A small number of physiological studies (Guilleminault et al 1991, 1993) have also 
been performed. Guilleminault et al (1991) studied 15 male heavy snorers with an 
RDI <5 and normal oximetry, and found the RDI and the arousal frequency (EEG 
arousals of 2 -10 seconds) both correlated with sleepiness as measured by the MSLT. 
In a further experiment (Guilleminault et al 1993), 15 patients diagnosed with 
idiopathic hypersomnia were found to be objectively sleepy with a mean MSLT of 5.1 
minutes and had an elevated arousal frequency of 31 per hour slept. These individuals 
demonstrated an increase in inspiratory effort prior to a decrease in flow, causing 
microarousals from sleep. The authors concluded that the daytime sleepiness was not 
idiopathic, but likely to be caused by the increased upper airway resistance leading to 
sleep fragmentation in the form of brief microarousals. 
The above group of studies provide evidence of the contribution of sleep 
fragmentation to excessive daytime sleepiness in patients with mild respiratory 
irregularities. This group of individuals very rarely desaturate at night, therefore the 
contribution of hypoxaemia is unlikely to be relevant in this sub -population. 
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In summary, this section has demonstrated that it is likely that causative relationships 
exist between sleep fragmentation and daytime sleepiness, but that the relationships, at 
best, are only moderate in strength, and in some cases appear weak or non significant. 
Thus this area remains controversial and requires further investigation. 
2.8.2 Relationships with cognitive dysfunction 
Both Greenberg et al (1987) and Bedard et al (1991b) found relationships between 
hypoxia and measures of cognitive function in 14 and 20 SAHS patients, respectively. 
Greenberg et al (1987) found significant relationships in only 4 out of a possible 72 
correlations, and stated that it is difficult to establish robust relationships between 
hypoxia and cognitive function. In Bedard et al's (1991b) severe SAHS patients, 
respiratory and sleep variables (apnoea frequency, awakenings, % wake and hypoxia) 
together explained 66% of the variance in psychomotor performance. Neither 
Greenberg et al (1987) or Bedard et al (1991b) used measures of sleep fragmentation 
in their studies, nor controlled for age in their correlations. 
Yesavage et al (1985) only studied one nocturnal feature of SAHS, the AHI, in a 
group of 41 elderly men with SAHS. All correlations were partially controlled for age, 
education, depression and subjective sleepiness. AHI significantly correlated with 5 
cognitive function tests measuring visuospatial reasoning, memory and psychomotor 
speed. 
In a group of 29 SAHS patients, Cheshire et al (1992) found significant relationships 
between measures of hypoxaemia, AHI, arousals and cognitive function (all r >0.36, 
p <0.05). All of these correlations were partial, controlling for age and pre- existing 
anxiety and depression. Using multiple regression analysis, AHI was the best predictor 
of performance in terms of visuospatial organisation, sustained attention, visuomotor 
coordination and vigilance. Sleep fragmentation and hypoxaemia made minor but 
significant contributions to the multiple regression model. This study suggests that all 
three important measures of sleep apnoea contribute to relationships and therefore 
should be measured wherever possible. 
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Findley et al (1986) examined possible causal relationships using a different approach. 
26 sleep apnoeics were divided into 2 groups, with and without hypoxaemia. The 
hypoxaemic group had lower cognitive performance scores on a number of tests, even 
when adjusted for age. Correlational relationships were found between the median 
level of oxygen saturation and overall cognitive dysfunction, but not with the number 
of desaturations per hour, the number of nocturnal awakenings or movement arousals. 
However, the hypoxic group were also hypoxic during the daytime, suggesting 
coexisting lung disease, which would influence the results found. In addition, this 
study consists of a small sample of patients, making it difficult to rely on the 
correlational results found. 
Studies examining cognitive decrements in snorers and patients with mild SDB have 
also been performed. A large scale qualitative study (Jennum et al 1994) was 
performed in 3,323 men from the general community. Subjects self -reported their 
snoring, sleepiness, memory and concentration problems. No relationships existed 
between snoring and reported memory or concentration problems, although excessive 
sleepiness was associated with snoring, memory and concentration problems. This 
study suggested that the cognitive impairment in snorers may be secondary to 
sleepiness. 
Studies using quantitative measurements and cognitive function tests have also been 
performed in snorers, although in smaller sample sizes. Studies in snorers (Berry et al 
1986, Telakivi et al 1988) found relationships between hypoxia and cognitive 
function. Berry et al (1986) found that in comparison to normative values, the 46 self - 
reported snorers (mean AHI =3.2) were only impaired on a few cognitive function 
scores. In a correlational analysis controlling for age, weight:height ratio and 
education, the AI, AHI and 4% desaturations all significantly related to the cognitive 
function measures of intelligence, memory and verbal fluency. The stronger 
correlational relationships were associated with the nocturnal hypoxia. Although the 
data was not presented, EEG sleep disruption was also measured, but added nothing 
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to the existing relationships. The AHI criteria used in the study incorporated a 10% 
desaturation, which is quite severe, and therefore this study would give a lower than 
usual AHI. Thus this study population may have also included SAHS patients in 
addition to the mild SDB patients. Telakivi et al (1988) studied 106 middle aged men 
from the general community, classified as habitual snorers (46), occasional snorers 
(38) and never snorers (22), along with 60 age- matched controls, on the basis of a 
limited sleep study. All underwent a battery of cognitive tests (measuring verbal and 
performance IQ, memory, psychomotor function and mental flexibility). Hypoxia 
significantly correlated with memory and spatial orientation decrements in habitual 
snorers. 
Kim et al (1997), in a population study of 841 individuals, examined whether SDB 
resulted in similar cognitive decrements to those patients with clinically diagnosed 
SDB. The neuropsychological test battery used measured memory, visuomotor 
coordination, attention, motor function and mental flexibility, and using principal 
factor analysis 2 factors were identified: psychomotor efficiency and a memory score. 
Regression modelling analysis found Log AHI to be associated with psychomotor 
efficiency, independent of age, gender and educational status (coefficient of Log 
AM= -0.07, p= 0.017). No such relationship was seen with the memory score. The 
study therefore concluded that in the general adult population, SDB is prevalent and 
relates to a decrease in psychomotor performance. Measures of hypoxaemia and sleep 
fragmentation were not measured, and whether or not they would have related to 
memory score is unknown. 
In summary, the general consensus seems to be that measures of hypoxia relate to 
decrements in cognitive function. Hypoxia may be the best nocturnal predictor or 
alternatively it may be because many of the above studies did not measure the 
respiratory events, sleep stages and microarousal frequency. Also hypoxia is a robust 
physiological measure which can be reproducibly measured, whereas scoring 
measures of sleep fragmentation are far more variable, making comparisons more 
difficult. The cognitive tests measuring areas of attention, memory and psychomotor 
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performance were the most common areas to relate to hypoxaemia in the studies 
presented here. Such cognitive decrements are important in daily functioning, 
especially in the vehicle or the workplace. Thus further work examining the predictors 
of cognitive function is important to pursue. 
2.8.3 Relationships with psychopathology 
There are limited data on the aetiology of psychopathology. This may be because 
psychological decrements are only subjectively quantified and therefore lack the 
strength of more robust physiological tests. 
Millman et al (1989) measured depression in sleep apnoeics and found no 
relationships between the Zung self rating depression scale and AHI or hypoxaemia. 
The study did not measure sleep fragmentation. Using the Beck depression rating, 
Watson et al (1985) did find a relationship between AHI and depression. However, it 
was paradoxical in direction, i.e. the more severe the SAHS disease, the less 
depressed the individual. Also using Beck's depression rating, Borak et al (1996) 
found no relationship between sleep and respiratory variables and depression, but did 
find AHI to significantly correlate with emotional status in terms of anxiety and 
mental stress. 
Smith and Shneerson (1995) studied the possible predictors of quality of life, as 
measured by the SF -36. Weak but significant relationships were seen between 
hypoxaemia and the SF -36 dimensions of vitality, general health and physical 
functioning (all r values < -0.2). The authors speculated that if a measure of sleep 
fragmentation had been measured, stronger relationships may have been observed. 
Daytime sleepiness has also been found to relate to general health in the community as 
measured by the SF -36 (Briones et al 1996). Daytime sleepiness was measured by the 
ESS and MSLT, and quality of life using the SF -36. Subjective sleepiness significantly 
correlated with SF -36 general health, vitality and emotional role (all r> -0.29, 
p <0.001). Objective sleepiness correlated with vitality alone (r= -0.19, p <0.05). 
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Greater relationships may have been observed with subjective sleepiness because of 
the similarity of subjective measures referring to the recent past. The study concluded 
that both subjective and objective sleepiness have an effect on quality of life. 
In summary, section 2.8 has presented evidence that suggests relationships do exist 
between nocturnal SAHS variables and daytime function measures, but relationships 
are frequently only weak or moderate in size, and performed on small study samples. 
This evidence indicates that there are possible causative effects of nocturnal measures 
on daytime function, and as such, are worth examining further in this thesis. 
Justification for yet another correlational study is discussed in section 2.10 based on 
the aforementioned studies. Prior to this, the effect of CPAP therapy on daytime 
function is briefly discussed. 
2.9 Improvements in daytime function with CPAP therapy 
A further method of identifying causative relationships between nocturnal SAHS 
variables and daytime function is by examining which daytime measurements improve 
with CPAP therapy. 
Subjective sleepiness as measured by the Epworth sleepiness scale (ESS) has been 
shown to significantly improve with CPAP therapy in a group of uncontrolled and 
non -randomised controlled studies (Johns 1992, Hardinge et al 1995, Smith & 
Shneerson 1995). In addition, Engleman et al (1998) have demonstrated that the ESS 
significantly improves with CPAP therapy when controlling for the placebo effect in a 
randomised single blind, placebo controlled crossover study. 
The response to CPAP therapy of objective sleepiness has also been studied in 
uncontrolled trials (Lamphere et al 1989, Bedard et al 1993, Sangal et al 1992b, 
Poceta et al 1992). Lamphere et al (1989) studied three groups of sleep apnoeics 
whose sleepiness was measured at baseline, and then after either 1, 14 or 42 nights of 
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CPAP therapy. Objective sleepiness significantly improved after one night of CPAP 
therapy, from 3 to 6 minutes, and from 3 to 10 minutes after 14 nights on CPAP. No 
greater improvement in sleepiness was found after 42 days on CPAP. In this study 
sleepiness reached normal values after 14 days of CPAP therapy. Bedard et al (1993) 
also found significant improvements in MSLT with CPAP. Baseline values of 5 
minutes, increased to 9 minutes on CPAP. Although a mean sleep onset latency of 9 
minutes was significantly lower than the 14 minutes found in the age- matched control 
group. 
Studies have also examined the change in the MWT as an indicator of sleepiness. 
Sangal et al (1992b) performed a study on 47 patients with disorders of excessive 
somnolence, of which 26 had sleep apnoea. The SAHS patients underwent the MSLT 
and MWT at baseline and on therapy. Results found no improvement in the MSLT 
score with therapy (from 6 to 7 minutes), but did find significant improvements in the 
MWT score (from 24 to 32 minutes). Therapy in this study consisted of either CPAP 
or surgery, and treatment efficacy was poor (mean on- treatment AHI of 23 /hr slept), 
so the lack of findings with the MSLT should be interpreted with caution. Poceta et al 
(1992) found a similar treatment response with the MWT in 24 sleep apnoeics, all 
treated with CPAP therapy. 
Parallel group studies have also been performed using a conservatively treated group 
of patients for comparison. Engleman et al (1993) compared 21 SAHS patients who 
were given CPAP therapy, with 16 patients who followed a mild intervention 
programme of weight reduction, alcohol and sedative avoidance. Sleepiness as 
measured by the MSLT significantly improved in the CPAP group, although only to a 
value of 5.5 minutes. This improvement could be due to CPAP therapy or because the 
CPAP group were significantly sleepier at baseline in this non -randomised study. 
Following on from this study, Engleman et al (1994a) performed a randomised, 
placebo controlled crossover study, therefore minimising the influence of treatment 
order, learning, placebo effects and interindividual variability. 32 patients spent 4 
weeks on CPAP and 4 weeks on a placebo tablet, with daytime testing on the last day 
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of each treatment limb. The study found significant improvements in daytime 
sleepiness with CPAP therapy. However this sleepiness, as measured by the MSLT, 
on CPAP was only 7.2 minutes, which is in the `grey area' of sleepiness, rather than 
>10 minutes (Carskadon et al 1986). This may be caused by the fact that the mean 
objective CPAP compliance as measured by mask time (hours the CPAP pressure is 
within 2cm water of pressure prescribed) was only 3.4 hours per night, and maybe 
sleepiness can further be improved by greater compliance. In a more recent group of 
patients, following the same protocol (Engleman et al 1998), the mean MSLT latency 
on CPAP was 9.2 minutes, which is nearer the normal range, yet the mean effective 
CPAP use was lower at 2.8 hours per night. Engleman et al (1997a) used the same 
protocol to perform a placebo controlled crossover study on 16 patients with mild 
SAES, defined as having an AHI 5 -14.9 and two or more SAHS symptoms. There 
were no significant improvements in sleepiness, measured either by the ESS or 
MSLT, although effective CPAP use (mask time) was only 2.8 hours per night, so 
would not be abolishing all events. Preliminary work by Stradling et al (1998) has 
used a `sham CPAP' device as a placebo in a randomised parallel group study. One 
group of patients were given CPAP at their prescribed pressure to abolish all 
nocturnal events, whereas the other group were given `sham' CPAP at a suboptimal 
pressure. This design aims to overcome the differences in therapies in terms of an 
obtrusive CPAP device versus a placebo tablet. Preliminary findings indicate that the 
CPAP user group demonstrate significant improvements in alertness, as measured by 
a maintenance of wakefulness type test, compared to the `sham CPAP' group 
( Stradling et al 1998). 
Significant improvements in cognitive function with CPAP have also been found in an 
uncontrolled study on severe sleep apnoeics (Borak et al 1996). Cognitive function 
tests measuring concentration and memory (visual, verbal and spatial) improved with 
CPAP therapy. Bedard et al (1993) also found improvements in cognitive function 
test scores with CPAP therapy. Verbal memory, attention and constructional abilities 
improved, to values similar to the age, sex and education -matched control group. 
Some tests of executive functioning also significantly improved, but not to normative 
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levels, whilst other executive functioning tasks measuring verbal fluency and mental 
flexibility demonstrated no improvement with CPAP therapy. Bedard et al (1993) 
suggest that the cognitive deficits not reversed by CPAP may be caused by hypoxic 
injury. It could equally be that CPAP may not have been working effectively because 
hypopnoeas were not measured in this study, or that all night use was not undertaken. 
In a parallel group study, Engleman et al (1993) found no improvements in cognitive 
performance with CPAP therapy. Conversely, in the crossover studies (Engleman et al 
1994a, 1997a) both the moderate to severe SAHS patients and the mild SANS 
patients demonstrated improvements in cognitive performance with CPAP therapy 
compared to placebo. The moderate to severe SANS patients demonstrated 
improvements in vigilance, coding speed and mental flexibility, and the mild group 
demonstrated improvements in mental flexibility alone. Although the improvements in 
cognitive function are small in these studies, their randomised crossover design, along 
with psychometric test familiarisation, minimises the effect of learning, which are 
likely to influence findings in the parallel and uncontrolled studies (Bedard et a 1993, 
Borak et al 1996). Studies looking at driving ability using performance measures have 
also found improvements with CPAP therapy (Findley et al 1989, Engleman et al 
1994a, George et al 1997). 
Both uncontrolled (Millman et al 1989) and parallel group studies (Derderian et al 
1988, Engleman et al 1993) have found improvements in depression scores with 
CPAP therapy. Improvements in quality of life as measured by the SF -36 (Smith & 
Shneerson 1995, Jenkinson et al 1997) and function limitations profile (Jenkinson et al 
1997) have also been found with CPAP therapy. Redline et al (1998) performed a 
parallel group study on 97 patients with mild SAHS (RDI 5 -30) who were randomly 
assigned to CPAP therapy or conservative therapy (nasal dilator). Greater treatment 
responses were found on CPAP therapy for measures of mood and well -being 
compared to conservative therapy. However, at baseline, the CPAP group 
demonstrated significantly lower SF -36 physical role scores, and hence greater 
improvements may be due to regression to the mean and not to CPAP intervention. 
Engleman et al (1994a, 1997a) found significant improvements in mood and quality of 
57 
life scores with CPAP therapy in randomised placebo crossover studies, for both 
moderate and mild SAHS patients. 
This section has provided evidence that CPAP therapy improves daytime function in 
terms of sleepiness, cognitive function, psychological mood and well- being. Complete 
reversibility of symptoms to normative values is often not found. Studies have 
demonstrated that CPAP compliance is well below the length of an average 7 hour 
night in bed, with values quoted as 3 hours /night in mild patients (Engleman et al 
1997a), and 4 -5 hours /night in moderately severe sleep apnoeics (Kribbs et al 1993). 
It is possible that because CPAP therapy is not used all night, normalisation of 
daytime function is not found. 
Patients who are feeling better on CPAP therapy in terms of daytime symptoms, may 
reduce the hours that they use their machine, or miss out nights altogether and so may 
not be abolishing all SANS nocturnal events. Alternatively the incomplete reversibility 
of symptoms could be due to the fact that nocturnal sleep and breathing parameters 
only explain part of the variance (Roehrs et al 1989, Poceta et al 1992) in daytime 
dysfunction and that there are likely to be other unknown causative factors acting on 
daytime function which are not reversed by CPAP. Or maybe the daytime dysfunction 
in SANS is to some extent irreversible, such as permanent hypoxic damage. 
2.10 Summary & indications for current investigation 
This chapter has demonstrated that patients with the sleep apnoea/hypopnoea 
syndrome suffer from excessive daytime sleepiness (Roth et al 1980, Whyte et al 
1989), cognitive decrements (Greenberg et al 1987, Bedard et al 1991b) and impaired 
psychological well -being (Cheshire et al 1992, Smith & Shneerson 1995). These 
daytime effects lead to an increased risk of vehicle accidents (George et al 1987, 
Findley et al 1988). Studies have also found daytime decrements to improve with 
CPAP therapy (Engleman et al 1994a, 1997a). Sleep fragmentation studies have 
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demonstrated that brief arousals from sleep produce sleepiness (Philip et al 1994, 
Roehrs et al 1994, Martin et al 1996), and impair daytime function (Martin et al 
1996). 
Correlational studies have described possible causative relationships between the 
nocturnal factors of SAHS and daytime function. Nocturnal measures have been 
found to be either not related to sleepiness (Cheshire et al 1992), or to predict less 
than 13% of the variance in sleepiness (Roehrs et al 1989, Poceta et al 1992). 
However, all studies are either based on older definitions of arousal (Guilleminault et 
al 1988b, Roehrs et al 1989, Bedard et al 1991 b) or small numbers of subjects 
(Cheshire et al 1992) or both (Roth et al 1980). The current study therefore used a 
newer, shorter definition of arousal, large numbers of consecutive patients and newer 
measures of sleepiness (MWT) and quality of life (SF -36) to determine the nocturnal 
SAHS factors affecting daytime function. By taking a correlational approach, the 
current study plans to allow a broad survey of which nocturnal abnormalities predict 
daytime features of SAHS and therefore hopes to provide some guidance as to who 
will benefit from CPAP therapy. 
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Chapter 3 
Methods of Measurement 
This chapter describes the tests and techniques used in this thesis to diagnose SAHS 
and to measure daytime function. Polysomnography was used to identify the nocturnal 
features of SAHS, and to measure objective daytime sleepiness. The psychometric 
measures used to quantify levels of cognitive performance and psychopathology are 
also described. 
3.1 Polysomnokraphy 
After undergoing an initial clinic consultation, patients suspected of having SAHS 
underwent nocturnal polysomnography. Studies were performed in sound -proofed 
and electrically- screened bedrooms in the hospital -based Edinburgh sleep centre. 
Sleep was monitored using electroencephalography (EEG), electro- oculography 
(EOG) and electromyography (EMG) using bipolar signals from silver chloride 
surface electrodes. EEG was recorded from 2 scalp sites, Cz/Pz, using the 
international 10/20 electrode placement system (Cooper et al 1980). `Mixed' channels 
consisting of EEG/EOG signals (Cz/Fpl, Cz/Fp2) were also used to monitor frontal 
EEG. Eye movements were measured from electrodes placed at sites on the outer 
canthus of each eye and Fp 1 and Fp2. This allowed both horizontal and lateral eye 
movements to be monitored. Submental EMG was recorded using 2 electrodes placed 
under the chin, on the belly of the genioglossus. In addition, a grounding electrode 
was placed at Fpz. Leg EMG was measured from electrodes placed over the right and 
left anterior tibialis. All of these signals were filtered using a high and low bandpass to 
reduce artefact, along with 50 Hz notch filtering. Electrode impedances of less than 5 
kOhms was achieved before the start of each test. 
In addition, other nocturnal variables were recorded. Thoracic and abdominal 
movements were measured by inductance plethysmography, oro -nasal airflow using 
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thermocouples, and arterial oxygen saturation using pulse oximetry (Ohmeda Biox 
3700). Body position was monitored using a mercury switch, in addition to an 
electrocardiogram, and snoring sounds (using an inbuilt microphone on the bed 
headboard). All signals were recorded onto a computerised polysomnography system 
(Compumedics S, Australia) using a 16 channel polygraph configuration. 
3.2 Off line analysis 
All nocturnal events were manually scored with the exception of oxygen saturation. 
All events were identified and marked using standard in -lab definitions (Gould et al 
1988, Cheshire et al 1992). 
3.2.1 Sleep Staging 
Sleep was scored from the EEG, EOG and EMG using standard Rechtschaffen and 
Kales (R & K) (1968) criteria, on an epoch by epoch basis, each epoch length being 
30 seconds. This scoring `window' of 30 seconds creates an averaging of sleep rather 
than second by second changes in sleep. Rechtschaffen and Kales (1968) classified 
sleep into 7 stages: 
Stage wake : When an individual is wide awake, fast beta activity is seen on the EEG, 
accompanied by high EMG tone and EOG blinks. Quiet wakefulness consists of alpha 
(8 -11Hz) waves. 
Stage 1 : This transient stage displays theta activity (4 -7Hz) on the EEG and is 
characterised by vertex sharp waves. Rolling eye movements are seen on the EOG, 
often accompanied by a decrease in EMG. 
Stage 2 : EEG frequencies are in the theta range (4 -7Hz) with the associated EEG 
phenomenon of sleep spindles and K complexes. Sleep spindles are fast bursts of 
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activity (0.5 -2 seconds) of 12 -15 Hz, and K complexes consist of a negative EEG 
deflection followed by a positive one (Figure 3.1). 
Rechtschaffen and Kales (1968) recommend that stage 1 is scored after a page of 
wake, before stage 2 can be scored. SAHS patients repeatedly wake up briefly, then 
return straight into stage 2 sleep, rather than passing through stage 1 sleep. Due to 
this phenomenon, in -house scoring criteria have been made. If an epoch is 
characteristic of stage 2 (sleep spindles and K complexes), then it is scored as stage 2 
rather than stage 1 as suggested by R & K rules (Rechtschaffen and Kales 1968). 
Stages wake, 1 and 2 are scored on an epoch if they occupy more than 50% of that 
epoch. 
Figure 3.1; A 30 second epoch of stage 2 sleep, with examples of K complexes 
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Stage 3 : This transitional stage is scored when 20 -50% of an epoch contains delta / 
slow waves (0 -3 Hz) of at least 751,tV in amplitude. 
Stage 4 : This stage is scored when more than 50% of an epoch contains delta waves. 
Stages 3 and 4 are often collectively called slow wave sleep (SWS) or delta sleep 
(Figure 3.2). The quantity of SWS is often reduced or even omitted in a patient with 
moderate or severe SAHS. The repetitive arousals from sleep prevent a patient from 
passing from the lighter sleep stages of 1 and 2, through to stages 3 and 4, before 
another arousal occurs. 
Stages 1 to 4 can be grouped together as non -REM sleep. 













REM sleep : This sleep stage has similar EEG frequencies to stage 1 sleep, along 
with characteristic waves resembling saw teeth. The EMG tone is at its minimum 
except for phasic bursts of higher activity. Rapid eye movement activity is seen on the 
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EOG, giving this sleep stage its characteristic name (Figure 3.3). These eye 
movements often occur in bursts, and are not always present on each epoch. If the 
epoch fulfils the other characteristics of REM sleep, it can be scored as such, 
providing a rapid eye movement has occurred within the last 3 minutes. 
Movement time : This is scored in a study when the EEG and EOG channels are 
obscured by large movement / equipment artefacts. This does not include large bursts 
of muscle activity seen when a person wakes up from sleep. 
Figure 3.3; A 30 second epoch of REM sleep, with characteristic eye 














3.2.2 Respiratory events 
The sleep apnoea/hypopnoea syndrome is characterised by 2 types of respiratory 
event which are scored routinely. 
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An obstructive apnoea is defined as a complete cessation of airflow for a minimum 
of 10 seconds, associated with continued thoracoabdominal movement (Guilleminault 
et al 1978) (Figure 3.4). 
A hypopnoea is defined as a reduction in thoracoabdominal movement of at least 
50% for a minimum of 10 seconds (Gould et al 1988) (Figure 3.5). This definition 
does not require the coexistence of either arousals or oxygen desaturations. 
The total number of apnoeas plus hypopnoeas is calculated, and divided by total sleep 
time (TST) to give the apnoea + hypopnoea index (AHI). 
3.2.3 Arousals 
Using R & K scoring rules, only awakenings of greater than 15 seconds are noted. In 
sleep apnoea, patients frequently have brief arousals ( <15 seconds) from sleep, on 
termination of respiratory events. These ` mcroarousals' alter sleep quality and are 
therefore important. Microarousals may be scored from the EEG/EMG 
polysomnography channels. In this thesis, the in -house Cheshire definition was used 
(Cheshire et al 1992) which has been validated against other microarousal definitions 
(Martin et al 1997c). An arousal was defined as a return to alpha or theta for at least 
1.5 seconds associated with a transient rise in EMG, however brief (Figures 3.4 & 
3.5). The total number of arousals were divided by TST to give an arousal frequency 
per hour slept. In this thesis, no distinction was made between `spontaneous' and 
respiratory-related arousals. Arousals that are classified as `spontaneous' are by 
definition not associated with a scored hypopnoea or apnoea. But they may be 
associated with a snore or a period of flow limitation. Therefore defining an arousal as 
`spontaneous' and excluding it from further analysis would overlook the fact that the 
arousal may have an unseen physiological cause, not detected by standard 
measurement techniques. `Spontaneous' arousals can cause sleep fragmentation, 
regardless of their cause. 
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Figure 3.4; A 120 second epoch of two obstructive apnoeas, with associated 























The frequency of oxygen saturation (SaO2) dips of 2, 3 and 4% from the running 
peak, along with minimum overnight saturation were analysed using an automatic 
desaturation detection algorithm (Compumedics S, Australia). In addition, oxygen 
saturation whilst awake was measured manually from the oximetry channel prior to 
sleep onset on the overnight polysomnography (saturation trace shown on Figures 3.4 
and 3.5). 
3.3 Reproducibility of polysomnojiraphic scorinj 
Although nocturnal SANS events are all scored according to strict criteria, there is 
still a subjective element in marking such events. This is likely to be due to variability 
in the quality of overnight recordings, along with the unpredictability in the 
occurrence of respiratory events, arousals and changing sleep patterns found in SANS 
compared with a normal text book pattern. Therefore scoring reproducibility for 
arousals, respiratory events and total sleep time (TST) was tested. 
Twenty overnight polysomnography records were randomly selected for reanalyses. 
Ten of these records were originally scored by the senior lab technician and ten by 
myself, to test inter -rater and intra -rater reproducibility, respectively. Records were 
rescored at least 12 months after the first score with patient details and original results 
unknown to myself. The results of the inter- and intra -rater reproducibility 
correlations are shown in Table 3.1. Both inter- and intra -rater reproducibility 
correlations were high, with r valuesn.88 (p- 0.001). In addition, the mean 
differences between score 1 and score 2 are shown in Table 3.1, again demonstrating 
high reproducibility. 
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Table 3.1; Reproducibility of AHI, arousal frequency and TST. 




r -value mean(SD) score 
difference 
(score 1 -score 2) 
Inter -rater reproducibility 
AHI (per hr slept) 47.5 (38.3) 51.0 (38.4) 0.99 * ** -3.5 (3.6) 
Arousals (per hr slept) 54.9 (35.4) 58.9 (35.8) 0.88 ** -4.0 (8.5) 
TST (mins) 322.1 (88.9) 318.7 (87.2) 0.96 * ** 3.4 (9.6) 
Intra -rater reproducibility 
AHI (per hour slept) 49.3 (30.9) 52.1 (30.9) 0.95 * ** -2.8 (3.9) 
Arousals (per hour slept) 63.6 (29.1) 60.7 (30.4) 0.88 ** 2.9 (7.9) 
TST (mins) 347.9 (90.1) 343.9 (92.3) 0.96 * ** 4.0 (11.0) 
** p<0.01; ***p<0.001 
Figures 3.6 (a) and (b) graphically display the differences between the two arousal 
scores (with pooled data from all 20 rescored records). The scatter plot (Figure 3.6 a) 
demonstrates a close relationship between the first and second arousal scores. The 
Bland Altman plot, shown in Figure 3.6 (b), better demonstrates the differences 
between first and second arousal scores. The mean (SD) % error in arousal frequency 
between the two scores, using score 1 as the `standard' was -3.7(22) per hour slept. 
This mean error between arousal scores is generally small, although can be relatively 
large at the milder end of the disease spectrum, where less events are scored. 
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Figure 3.6 (a); A scatterplot of the relationship between the first and second 
arousal frequency score for all 20 rescored records (p =0.90, p <0.0001). Also 
displayed on the graph is the line of identity 
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Figure 3.6 (b); A Bland Altman plot demonstrating relationships between the 
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Martin et al (1997c) examined arousal reproducibility by correlational analysis, and as 
demonstrated above, found high inter -rater reproducibility (all r >0.96, p <0.0001). The 
study by Martin et al (1997c) and the current analysis demonstrate that arousals can 
be scored with reasonable reproducibility for a complex physiological measurement. 
As anticipated, scoring of the arousals was the least reliable of the 3 nocturnal 
measures studied here. It is possible that arousal scoring has the greatest variance 
because it requires a minimum EEG change of only 1.5 seconds in duration. In 
comparison, respiratory events and sleep stage scoring require longer periods of 10 
and 15 seconds, respectively. Also, by definition, arousals have a greater probability 
of occurring, thus increasing their chances of scoring error. 
3.4 Measuring daytime sleepiness 
Daytime sleepiness (Section 2.2) can be measured either by subjective questionnaires 
or objectively using polysomnographic variables. 
3.4.1 Subjective measures 
Stanford Sleepiness Scale (SSS) (Hoddes et al 1973) 
This is a self -completed 7 point scale, where a patient has to rate their level of 
sleepiness at that particular moment in time. Sleepiness is rated from feeling wide 
awake (1) through to struggling to remain awake (7). This scale therefore measures 
instantaneous sleepiness. 
Epworth Sleepiness Scale (ESS) (Johns 1991) 
This self -completed scale asks a patient to rate their sleepiness in recent times in 8 
everyday situations. The 8 everyday situations were carefully selected by Johns (1991) 
to allow for people's differing daily routines. Rather than just asking if a patient feels 
sleepy, the ESS provides 8 real -life situations in which a patient has to rate their level 
of sleepiness. This provides some guidance and standardisation for quantifying 
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sleepiness. These real -life situations differ in their soporific nature, with some being 
highly soporific, such as `sitting quietly after lunch without alcohol', or `lying down to 
rest in the afternoon', and others are non -soporific, such as `sitting and talking to 
someone' or `in a car whilst stopped for a few minutes in the traffic'. In these non - 
soporific situations one would expect only a sleepy person to fall asleep. Sleepiness is 
rated using a four -point ordinal scale from (0) would never doze, (1) slight chance of 
dozing, (2) moderate chance or (3) a high chance, therefore allowing scores to range 
from a minimal level of sleepiness of 0, to a maximum level of sleepiness of 24. An 
example of this scale is shown in Chapter 4 which describes a validation study on the 
ESS. 
3.4.2 Objective measures 
Daytime sleepiness was measured objectively using both the multiple sleep latency test 
(MSLT) (Carskadon et al 1986, Thorpy 1992) and the maintenance of wakefulness 
test (MWT) (Poceta et al 1992). Both of these tests evaluate daytime sleepiness by 
physiologically measuring an individual's tendency to fall asleep. Very few studies 
have run both the MSLT and MWT on the same day (Sangal et al 1992a & 1992b, 
Martin et al 1996 & 1997b). In this thesis both tests were performed on the same day, 
to compare these objective measures with each other, and against the battery of 
psychometric measures (Chapter 6). 
The MSLT and the MWT require polysomnographic recording of the EEG, EOG, 
and EMG (electrode placement as described in Section 3.1). Tests were performed at 
evenly spaced intervals across the test day to account for circadian differences in 
sleepiness. For the MSLT, naps were run at 10.00, 12.00, 14.00 and 16.00. The 
patient was asked to lie comfortably on a bed in a quiet, dark room and instructed to 
"close their eyes and try and sleep" for 20 minutes. For the MWT, naps were run at 
11.00, 13.00, 15.00 and 17.00. This time the patient was seated comfortably upright 
on the bed, with the head and neck supported and instructed to "try and stay awake" 
for forty minutes. Patients were also instructed not to use any extraordinary measures 
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to promote alertness, such as singing, exercising or reading. The room was quiet and 
dimly lit (to a set level) for each MWT. 
Original MSLT guidelines (Carskadon et al 1986) for the research version of the test 
recommended that each nap is terminated after the first three consecutive epochs of 
stage 1 sleep, or a single epoch of any other sleep stage. In this thesis a modified 
definition of test termination to the first epoch of any sleep stage, including stage 1, 
was used for both the MSLT and MWT. This modified definition was used for two 
reasons. Firstly, this allows for SAHS patients who have frequent respiratory related 
arousals at sleep onset. These patients may not be capable of maintaining stage 1 for 3 
consecutive epochs. Secondly, due to 8 tests being performed across the day, this 
short test termination prevents patients gaining additional sleep in the daytime. To 
prevent premature termination of these naps, in many cases 2 consecutive epochs of R 
& K sleep were noted by myself before the test was terminated. If no sleep was 
observed, the MSLT was terminated after 20 minutes, and the MWT after 40 minutes. 
Scoring of these tests was performed on a separate day. Sleep onset latency (SOL) is 
defined as the elapsed time from lights -out to the first epoch of any sleep stage, 
including stage 1 sleep (Thorpy 1992). The sleep onset latencies across the day are 
averaged for the MSLT and MWT, respectively, to provide two outcome measures of 
objective daytime sleepiness. 
3.4.3 Reproducibility of MSLT & MWT scoring 
All 1,200 MSLTs and MWTs were scored by myself To determine intra -rater 
reproducibility of sleep onset latency scoring, 20 sets of MSLTs and MWTs (160 
records) were rescored by myself, at least 12 months after the original scoring. The 
records were chosen at random by a colleague and I was blind to the patient 
information and original score in each case. Reproducibility correlations for the mean 
SOL of each hourly test was high, as were the overall means (Table 3.2). In addition, 
the mean differences between score 1 and score 2 are in Table 3.2, again 
demonstrating high reproducibility. 
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Table 3.2; Reproducibility of MSLT and MWT sleep onset latency scoring* 




r -value mean (SD) score 
difference 
(score 1 - score 2) 
10:00 MSLT (mins) 13.0 (6.1) 13.7 (6.3) 0.97 -0.7 (1.4) 
12:00 MSLT (mins) 10.4 (6.0) 10.9 (6.2) 0.98 -0.5 (1.1) 
14:00 MSLT (mins) 7.7 (5.6) 8.2 (5.7) 0.98 -0.5 (1.1) 
16:00 MSLT (mins) 9.7 (5.9) 10.0 (5.8) >0.99 -0.3 (0.8) 
mean MSLT (mins) 10.2 (5.1) 10.7 (5.1) 0.99 -0.5 (0.8) 
11:00 MWT (mins) 30.5 (11.1) 30.6 (10.8) >0.99 -0.1 (0.9) 
13:00 MWT (mins) 21.7 (12.4) 22.2 (12.4) >0.99 -0.5 (0.9) 
15:00 MWT (mins) 25.2 (12.1) 26.0 (12.1) 0.98 -0.8 (2.5) 
17:00 MWT (mins) 25.2 (14.7) 25.0 (14.3) 0.96 0.2 (4.3) 
mean MWT (mins) 25.4 (10.5) 25.9 (10.6) >0.99 -0.5 (0.9) 
* r values all p <0.000 
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3.5 Psychometric Measures 
A range of daytime function measures were used in this thesis. Daytime testing was 
performed after a normal night's sleep at home, within one month of the overnight 
polysomnography. Patients were instructed to withdraw from caffeine on the evening 
prior to daytime testing, and throughout the test day, decaffeinated drinks were 
provided. All tests were applied at the same time of day in all subjects. 
General patient information and body measurements were taken for each patient. 
These included anthropometric measurements of Body Mass Index (BMI = weight 
/[height']), collar size (at the level of the cricothyroid membrane) and waist 
circumference (midway between the lower rib margin and the superior anterior iliac 
spine). Information concerning past medical history, medications, years of education 
and smoking and drinking habits were also taken. 
3.5.1 Self -ratings of daytime function 
Self -administered questionnaires were given to SAHS patients in the morning of the 
daytime session. Patients were shown how to complete the questionnaires, and then 
left alone to fill them in, with any queries answered once all were attempted. 
Short Form 36 Health Survey (SF -36) (Ware & Sherbourne 1992) 
This generic questionnaire measures functional status, well -being and health 
perception. The SF -36 consists of 36 questions grouped into 8 multi -item dimensions. 
Raw scores are transformed to create minimum scores of 0 through to the best 
possible health status of 100 %. Responses given are either yes /no, frequency 
responses or true /false statements. The main 8 domains of the survey are described in 
Table 3.3. 
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Table 3.3; SF -36 Domains 
SF -36 Domain No of 
questions 
Area of quality of life 
Physical Functioning 10 The level by which health limits a range of 
physical activities 
Social Functioning 2 The effect that physical / emotional problems 
have on social activities 
Vitality 4 Refers to how energetic one is feeling 
Role Limitations - 
physical 
4 The effect physical problems have on the range 
and extent of work 
Role Limitations - 
emotional 
3 The effect emotional problems have on the 
range and extent of work 
General Health 5 Refers to an individuals rating of their own 
health & how it compares to others 
Bodily Pain 2 Refers to the severity of pain and its effect on 
daily life 
Mental Health 5 Refers to the degrees of nervousness, 
happiness, calmness, sadness 
An additional dimension known as health transition remains unscored. This single item 
compares health now to one year ago. Recently two principal components were 
extracted from the SF -36. These are known as the physical components summary 
(PCS) and the mental components summary (MCS). These summary scores reduce 
the chance of Type 1 error due to multiple comparisons. 
Hospital Anxiety and Depression (HAD) Scale (Zigmond & Snaith 1983) 
This mood scale measures levels of anxiety and depression. 7 statements measure 
anxiety levels (e.g. I can sit at ease and feel relaxed) and 7 measure depression (e.g. I 
feel cheerful). Patients have to rate their agreement with each statement on a 4 point 
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scale (0 -3), to reflect the frequency or intensity of agreement. Rating scores for 
anxiety and depression therefore range from a minimum of 0 to a maximum of 21. 
Scores of 11 or over are considered clinically significant cases of anxiety or 
depression, and scores between 8 and 10 are considered suspicious cases. 
Nottingham Health Profile (NHP) Part 2 (Hunt et al 1984) 
This well -being questionnaire provides a list of health problems found in daily living. 
These are subdivided into problems at work, in the home, social life, sex life and 
hobbies. For example, problems include `I'm getting irritable with the people I live 
with' and `I'm having difficulty concentrating at work'. Patients answer yes /no to 
each statement. The outcome score ranges from a minimum of 0 (reflecting no 
impairment) to a maximum decrease in well -being of 20. 
Symptoms Questionnaire 
Symptoms of sleep apnoea were measured using an in -house questionnaire (Appendix 
A). Patients rated the frequency of symptoms on a 5 point scale from never, through 
to every night. Symptoms measured were heavy snoring; choking during the night; 
witnessed breathing pauses; difficulty staying asleep at night; unrefreshing sleep; 
daytime and evening napping and feeling sleepy and falling asleep whilst driving. 
Eysenck Personality Scale (Eysenck et al 1985) 
This revised scale contains 48 yes /no questions, that relate to the 3 personality 
domains of neuroticism, psychoticism, extraversion, plus a lie scale. Questions 
include: `Would you call yourself a nervous person ?' ( neuroticism domain), or `Are 
you rather lively ?' (extraversion domain). 
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3.5.2 Cognitive Performance Tests 
Cognitive tests were performed in the afternoon of the daytime testing day. 
Digit Symbol Substitution (Wechsler 1981) 
Digit symbol is a subtest of the Wechsler Adult Intelligence Scale - revised version 
(WAIS -R). It measures coding speed. This pen and paper test requires the patient to 
write appropriate characters underneath numbers by referring to a given code key. 
Patients are initially given a practice trial of 7 substitutions. Patients then have 90 
seconds to complete as many substitutions as possible in the order presented on the 
sheet (Figure 3.7a). The number of correct substitutions in 90 seconds is noted and 
converted into a scaled score. 
Block Design (Wechsler 1981) 
This subtest of the WAIS -R measures visuospatial ability. In this test patients have to 
reproduce printed designs using coloured blocks. Each test is to be completed as 
quickly as possible, with bonus points available for quick completion, although any 
error in the design results in zero points. Time to completion is measured and 
converted into a scaled score (Figure 3.7b). 
Performance IQ 
The scores from the WAIS -R subtests, digit symbol and block design, are scaled 
according to Wechsler (1981). These scaled scores are then added together and 
multiplied by 2.5 to give a scaled score estimate. This value is then converted into an 
estimated performance IQ value using age -specific tables (Wechsler 1981). 
National Adult Reading Test (NART) (Nelson 1982b) 
To try and identify if intellectual abilities have changed with a disease state, a 
premorbid measure is required. Current reading ability and previous familiarity of 
certain words is hypothesised to be a well -maintained skill even in patients with 
dementia, for example (Nelson & O'Connell 1978, O'Carroll et al 1987). Such a test 
can be used to estimate a premorbid level of intelligence. The national adult 
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reading test (NART) was devised to estimate this pre- morbid level of general 
intellectual functioning. It consists of a list of 50 words which are slowly read out 
loud by the subject whilst pronunciation is noted by the examiner. All the words on 
this list are phonetically irregular words (example in Figure 3.7c) and can only be 
pronounced correctly if the subject has previous familiarity with them. Words are 
listed in increasing order of difficulty. The total number of incorrect pronunciations 
are then totalled and converted using Nelson's (1982b) tables to provide an estimate 
of premorbid intelligence levels. Nelson (1982b) demonstrated the NART IQ is highly 
correlated with the WAIS IQ in normal subjects. 
IQ Decrement (Langan et al 1991) 
A measure of the change in IQ since early adult life can be estimated by subtracting 
the WAIS -R performance IQ from the premorbid NART IQ. 
Paced Auditory Serial Addition Task (PASAT) (Gronwall 1977) 
This test measures attention and information processing. Patients listen to a tape 
recording of single digit numbers presented at a rate of one number every 4 seconds. 
The patient has to add up the last two numbers called out and give the answer. For 
example, if the numbers presented were 2 then 3 the answer would be 5, if next 
number was 7 then the answer would be 10 (3 + 7), and if the next number was 9, the 
answer would be 16 (7 + 9), and so on. The test consists of 61 consecutive numbers, 
and is read out once at a 4 second presentation rate, and then again at a 2 second 
presentation rate. Outcome scores on both runs are the total correct additions. 
Trail Making A & B (Reitan 1958) 
This is a two part pen and paper test. Twenty five circles are randomly printed on a 
side of A4 paper. In part A of the test, these circles are numbered 1 -25. The patient is 
required to draw connecting lines between the circles in numerical order. In part B, 
half of the circles are numbered 1 -13, and the others contain letters A -L. This time the 
patient has to connect consecutively numbered and lettered circles by alternating 
between the two, e.g. 1 to A to 2 to B etc. In both tests patients are required to 
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complete the trials as quickly as possible, and scoring is based on time to completion. 
If an error occurs, this is pointed out by the examiner and must be corrected. Both 
parts measure orientation and attention, and part B also measures mental flexibility 
(Figure 3.7d). 
Simple Unprepared Response Time (SURT) Task (Wilkinson & Houghton 1982) 
This is a 10 minute computerised reaction time task. Patients sit in front of a black 
computer screen. At random, between 1 and 10 second intervals, a white square 
appears in the centre of the screen. When each visual stimuli appears, patients respond 
by pressing the keyboard space bar as quickly as possible. Outcome measures from 
this test include mean reaction time, number of false responses and number of gaps 
(when reaction time response >1 sec). This test measures information processing time 
and attention. 
Steer Clear (Findley et al 1989) 
This is a computerised vigilance task measuring attention and reaction time. In this 
task a computer screen displays a bird's eye view of a two lane motorway. The patient 
is in control of a vehicle moving along the motorway. Cows intermittently appear on 
the motorway moving towards the oncoming vehicle. To avoid hitting the cows, the 
patient must press the keyboard spacebar for the vehicle to change lanes. The test is 
long and monotonous, being run for 30 minutes in a dimly lit quiet room. On three 
occasions during the test, the cows disappear for 2 minutes, further testing attention 
span. The outcome score is the percentage of cows hit by the car within the 30 minute 
time period. 
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Figure 3.7; Examples of Psychometric Measures 
















1 2 0 3 a 
5 4 2 7 6 3 5 7 2 5 4 6 3 7 2 8 
6 
;, , 5 6 2 5 9 2 8 3 7 4 6 5 9 4 8 3 2 



















The polysomnography and off line analysis methods described in this chapter are the 
standard procedures used in the Edinburgh sleep centre. Any deviation from the 
normal procedures will be mentioned in the methods section of the relevant chapters, 
otherwise all methods described in the remaining chapters will be referred back to this 
chapter. 
I have summarised each of the daytime function measures I used in the following 
experiments. These particular tests were chosen for a number of reasons. Firstly, to 
provide a broad range of daytime function measures. Previous studies have tended to 
focus on single areas of daytime function (Roehrs et al 1989, Poceta et al 1992), 
whereas I wanted to include a range of measures to allow for comparisons between 
them. Secondly, I wanted to incorporate similar tests as used in the previous 
correlational study from the Edinburgh sleep centre (Cheshire et al 1992), with the 
addition of the quality of life and sleepiness scales and the MWT, which were not 
used then. Thirdly, other studies from the Edinburgh sleep centre have demonstrated 
improvements in these daytime function measures with CPAP therapy (Engleman et al 
1994a), and changes in these measures as a result of experimental sleep fragmentation 
(Martin et al 1996). 
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Chapter 4 
The Epworth Sleepiness Scale (ESS): Patient versus Partner 
Assessments 
4.1 Introduction 
As discussed in the introduction to this thesis, excessive sleepiness is the most 
common daytime feature of the sleep apnoea/hypopnoea syndrome (Whyte et al 
1989). Daytime sleepiness frequently interferes with an individual's daily routine. In 
particular, sleepiness may lead to problems whilst driving, with studies reporting sleep 
apnoeics to have an increased risk of vehicle accidents compared to control subjects 
(George et al 1987, Findley et al 1988). These detrimental consequences to the 
patient, and other road users, highlights the need to quantify this excessive daytime 
sleepiness. 
The multiple sleep latency test (MSLT) (Carskadon et al 1986) and the maintenance 
of wakefulness test (MWT) (Mitler et al 1982) are commonly used objective measures 
of daytime sleepiness (Section 3.4.2). These tests measure a patient's ability to fall 
asleep by monitoring physiological sleep onset. However, these tests are labour 
intensive and expensive to conduct, and are therefore hard to justify in routine clinical 
practice. 
More simply, self -reporting questionnaires assessing sleepiness have been devised, 
which are cheap and easy to use. The Epworth sleepiness scale (ESS) (Johns 1991; 
Figure 4.1) is the most widely used scale to assess recent sleepiness in SAHS patients 
(Section 3.4.1). Johns (1991) examined the discriminative validity of the scale and 
found that ESS scores differed significantly between normal controls and groups of 
patients with a variety of sleep disorders. ESS scores <10 were considered normal, 
with a mean ESS value of 4.6 reported in a group of 72 middle aged normal subjects 
(Johns & Hocking 1997). The ESS score significantly correlated with the respiratory 
disturbance index (r =0.4, p <0.001), and the minimum oxygen saturation level 
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(r= -0.5, p <0.001) in SAHS patients (Johns 1991, 1993). These results suggest that 
the ESS score might predict SAHS disease severity to some extent. 
The ESS is routinely used in the Edinburgh sleep centre, and both the patient and their 
witnessing partner are asked to independently rate the patient's sleepiness using this 
scale. Anecdotally, there is frequently a discrepancy between a patient's and their 
partner's ESS assessment, and between ESS scores and the severity of nocturnal 
SAHS symptoms. Therefore, the first aim of this study was to compare the patients' 
and partners' assessments of the patient's sleepiness, using the Epworth sleepiness 
scale. The second aim was to determine if either the patient's or their partner's rating 
on the ESS is a better predictor of SANS disease severity. 
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Figure 4.1; The Epworth Sleepiness Scale (Johns 1991) 
How likely are you to doze off or fall asleep in the following situations, in contrast to 
feeling just tired? This refers to your usual way of life in recent times. Even if you 
have not done some of these things recently, try to work out how they would have 
affected you. Use the following scale to choose the most appropriate number for 
each situation: 
Scale 
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
Situation 
Sitting and reading 
Watching TV 
Sitting inactive in a public place 
(e.g. a theatre or a meeting) 
As a passenger in a car for an hour 
without a break 
Lying down to rest in the afternoon 
when circumstances permit 
Sitting and talking to someone 
Sitting quietly after a lunch without alcohol 
In a car, when stopped for a few minutes 
in the traffic 
Thank you for your co- operation 
Chance of dozing 
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4.2 Methods 
4.2.1 Study Design 
This study was retrospective in design, collecting questionnaire and sleep study data 
from a consecutive group of patients referred to the sleep centre with symptoms of 
the sleep apnoea/hypopnoea syndrome. An in -house sleep /wake questionnaire was 
sent to patients to complete prior to their initial outpatient consultation (Appendix B). 
This patient questionnaire includes sections on past medical history, social 
background, sleep hygiene and sleep disorder symptoms. A separate questionnaire 
was sent to the partner (or parent of a young individual) with questions on the 
patient's caffeine and alcohol intake, napping habits, general daytime sleepiness, 
sleepiness whilst driving, and personality changes. Both the patient and partner 
questionnaires also contain Epworth sleepiness scales (ESS) for the patient and 
partner to independently rate the patient's sleepiness. These questionnaires were 
reviewed in the clinic by a physician. If answers were incomplete or incorrectly filled 
in, patients and partners were helped to complete the questionnaire. From the 
questionnaire details, referral information and the clinic consultation, subjects 
suspected of having SAHS underwent diagnostic polysomnography to measure sleep 
and respiratory variables. The nocturnal variables defined and measured followed the 
standard laboratory protocol, as described in Chapter 3. The only exception to this 
was that polysomnography was performed on paper chart recorders (SLE) prior to 
the installation of the computerised system. From the overnight polysomnography, the 
apnoea + hypopnoea index (AHI), arousal frequency and the minimum oxygen 
saturation were calculated. 
From the ESS, a total score is calculated by adding up the scores from the 8 real -life 
situations (Figure 4.1). Scores range from a minimum sleepiness score of 0, to a 
maximum sleepiness score of 24. In addition, the minimum ESS (minESS) and the 
maximum ESS (maxESS) values for each couple were analysed. 
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4.2.3 Statistics 
Patient and partner ESS scores were normally distributed, and therefore the mean 
difference between them was compared to zero using a 2- tailed paired t -test. 
Relationships between nocturnal sleep and breathing variables and ESS scores were 
evaluated by Spearman rank correlations. Statistical significance was accepted as p< 
0.05. All analysis was performed using SPSS +PC. The statistically significant results 
in this chapter are represented in the tables in bold type for clarity. 
4.3 Results 
4.3.1 Study population 
This retrospective study collected data from 103 patients (87 men) (Table 4.1) and 
their witnessing partners. 
Table 4.1; Patient Details (n =103) 
Measurements mean (SD) Range 
Age (years) 48 (13) 14 - 89 
BMI (kg/m2) 30 (5) 21 - 50 
AHI (per hour slept) 28 (22) 0 - 95 
Arousal frequency (per hour slept) 25 (18) 2 - 101 
Min Sat ( %) 84 (12) 11 - 96 
BMI =Body mass index; AHI= Apnoea +hypopnoea index; Min sat = Minimum oxygen saturation 
All patients were referred because of possible SAHS. As can be seen from the AHI 
range in Table 4.1, not all individuals had SAHS. However, all are included in the 
initial analysis, as the second aim of the study was to examine patient and partner ESS 
scores as possible predictors of SAHS severity. 
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4.3.2 Comparisons between patient and partner mean ESS scores 
There was no consistent difference in ESS scores between patients and their partners 
(patient ESS(SD) 12(5), partner ESS 12(4); p =0.8). The correlational relationship 
between patient and partner ESS scores is shown in Figure 4.2. 
Figure 4.2; A scatterplot of patient versus partner ESS scores (r =0.56, 
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Individual discrepancies between patients and their partners are more clearly 
demonstrated when this data is represented graphically using a Bland and Altman plot 
(Figure 4.3). Only 10 of the 103 couples show 100% agreement in their ESS scores. 
At the other extreme, 13 couples differ by more than 6 points on their ESS score. 
This graph also demonstrates that there is no tendency for discrepancies between 
couples to vary with ESS score severity. For example, those patients who score highly 
on the ESS are not more likely to have a greater discrepancy than those with non - 
sleepy ESS scores. 
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A subanalysis was performed on the group of patients (n =66) whose 
polysomnography found an AHI>_15, comparing patient and partner ESS scores. As 
with the whole population, there was no consistent difference in ESS scores (patient 
ESS 12(5), partner ESS 11(4); p =0.1). 
4.3.3 Relationships between ESS scores and nocturnal SAHS variables 
There were no significant relationships between the nocturnal SAHS measures and 
patient or partner ESS scores in the whole sample (Table 4.2; Figures 4.4 -4.7). In 
fact, the relationships were very weak. 
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Table 4.2; Spearman rank correlation matrix of relationships between 





Max ESS Min ESS 
Whole sample (n =103) 
AHI 0.02 -0.07 -0.13 0.10 
Arousal frequency -0.01 -0.05 -0.06 0.03 
Minimum saturation 0.09 -0.01 0.09 -0.00 
AHI? 15 (n =66) 
AHI 0.14 0.27 ** 0.11 0.32 ** 
Arousal frequency -0.001 0.07 0.04 0.04 
Minimum saturation 0.04 -0.14 0.00 -0.09 
* *p <0.01 
In the patient subgroup with an AHI .15, again patient ESS did not correlate 
significantly with nocturnal SANS variables. Partner ESS and the minimum ESS score 
of each couple correlated weakly, but significantly, with AHI (Table 4.2), but 
explained less than 11% of the residual variance. 
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Figure 4.4; Scatterplot of the relationship between AHI and patient Epworth 
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Figure 4.5; Scatterplot of the relationship between AHI and partner Epworth 
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Figure 4.6; Scatterplot of the relationship between arousals and patient 
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Figure 4.7; Scatterplot of the relationship between arousals and partner 
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Results found that the patient and partner ESS scores were moderately correlated 
(r =0.56, p <0.0001). This correlation is congruent with a study by Johns (1994) 
published during the current investigation, where a significant correlation was found 
between 50 sets of patients and their partner ESS scores (p =0.74, p <0.001). The 
current study also demonstrated that the patient and partner ESS scores are not 
significantly different in either the population as a whole, or in the subgroup with an 
AHI > -15. However, Johns (1994) found a small difference in patient and partner ES S 
scores when using the Wilcoxon t -test (patient ESS(SD) 13(5), partner ESS 14(5); 
p= 0.04). 
The results of the current study indicate that the patient or their partner can equally 
assess the patient's sleepiness. Examining individual couple differences (Figure 4.3), 
most couples will openly discuss the patient's sleepiness and so are likely to show 
similar scores on the ESS. However, in a few cases, there are large discrepancies 
between patient and partner scores (Figure 4.3) and such differences are discussed in 
Section 4.4.1. 
The current study improves on Johns' study (1994) by examining possible 
relationships between patient and partner ESS scores and nocturnal SAHS variables. 
This study found that in the whole population (n =103) presenting at the sleep clinic, 
there were no significant correlations between ESS variables and nocturnal SANS 
variables. This was for both patient and partner ratings of sleepiness. In the subgroup 
of SAHS diagnosed patients (AHI > -15), the patient's ESS rating was not significantly 
related to AHI. This contrasts with an earlier study (Johns 1993) where significant 
correlations (r =0.4, p <0.001) were found between the SAHS patient's ESS score and 
the RDI. Partner ESS and MinESS did significantly relate to AHI, but as such, these 
relationships are highly dubious clinically as one cannot predict who will have an 
92 
AHI > -15 at this stage. These results do not therefore answer the question of whether 
the patient or partner scores are more reliable assessors of daytime sleepiness. 
There are two possible reasons for the lack of correlational relationships between 
nocturnal SAHS variables and ESS scores. The first is that the ESS reflects problems 
with subjective ratings. The second is that the polysomnography is not measuring 
variables that predict daytime sleepiness. 
4.4.1 Problems with subjective ratings 
Individuals have different perceptions of the severity of their sleepiness, making cross - 
subject comparisons difficult. The variability in ESS scores is reflected in the 
individual patient and partner differences (Figure 4.3). There are many possible 
reasons for this variability. Some patients will maximise their symptoms, whilst others 
will minimise their symptoms, but one cannot prospectively predict which group a 
patient might belong to. Patients often have no insight into the severity of their 
sleepiness. Many patients have felt sleepy for so many years that they lose their frame 
of reference, and it is not until they are established on treatment that they realise how 
sleepy they were in the untreated state. This has been documented by Engleman et al 
(1997b), where patients on CPAP scored their untreated sleepiness as significantly 
higher than their previous baseline estimation. Similarly, patients may not admit to 
having problems whilst driving, as they feel this may jeopardise their job. Also some 
patients may not drive very often, or at all, and thus find it hard to imagine themselves 
in that situation. 
There are also difficulties with partners completing the ESS. Partners are not always 
present in the 8 ESS situations, and so may provide false estimates of sleepiness. For 
example, with the item `falling asleep whilst stopped at traffic lights', if the partner is 
present in the car, the patient driver may be more likely to stay awake due to the 
presence of a passenger, rather than when driving alone. Patient's complaints about 
sleepiness may also influence partner's scoring, with some patients discussing their 
sleepiness and others not. 
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General causes of variability also exist in the ESS items due to not following the ESS 
instructions carefully. To try and overcome different lifestyles, the ESS states that if 
an individual has not been in one of the situations recently, they have to "try and work 
out" how the situation would affect them. If a patient does not regularly participate in 
one of the daily items, they may score zero, rather than imagining themselves in that 
situation. For example, `lying down to rest in the afternoon when circumstances 
permit'. Some patients may have very demanding jobs, and so never lie down in the 
afternoon, and score zero, rather than imagining what would actually happen if the 
situation did arise. Individuals may misinterpret their tiredness as sleepiness and so 
overrate their scores despite being asked to differentiate between these two feelings in 
the questionnaire. Item 8 (In a car, when stopped for a few minutes in the traffic) may 
be misinterpreted by some individuals. There is confusion as to whether this question 
is in the context of being a driver or a passenger. 
There are many reasons for ESS scores to vary, and one cannot predict who is going 
to over or underestimate their sleepiness for any of the above reasons. One can argue 
that the patient score is more important, as it is their symptoms that require treatment. 
However, if patients are unaware of their sleepiness, the partner may be the more 
reliable assessor, yet they are not always present in all ESS situations. Therefore the 
information from both the patient and partner ESS assessments may provide the best 
all -round estimate of sleepiness. 
4.4.2 Lack of relationships with polysomnography 
The lack of significant relationships between ESS scores and polysomnography 
measures could also be due to polysomnography not providing useful measures of 
SAHS disease severity. Some correlational studies have found significant relationships 
between SANS polysomnographic variables and measures of daytime sleepiness 
(Roehrs et al 1989, Johns 1991, Poceta et al 1992), whereas other studies have not 
(Dement et al 1978, Cheshire et al 1992). Therefore further work on the relationships 
between nocturnal SANS measures and daytime sleepiness is required (Chapter 5) to 
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determine whether the most appropriate measures of SANS severity and daytime 
function are being used. 
4.4.3 Conclusion 
This study suggests that both the patient and partner ESS scores should be used to 
provide information about the patient's sleepiness. If there are large discrepancies 
between the two ESS scores, then this should be discussed with the couple in the 
clinic to determine the cause of this discrepancy. 
The lack of relationships between the ESS and nocturnal SAHS measures presented 
here can lead to two possible conclusions. The first is that the ESS is a measure of 
sleepiness open to great variability in interpretation by both the patient and the 
partner, and that it is better to perform nocturnal polysomnography and measures of 
objective daytime sleepiness whenever possible. Alternatively, the scores given by the 
patient and their partner may accurately represent the level of sleepiness suffered by 
the patient, and regardless of the AHI or arousal frequency laboratory based evidence, 
it is the ESS measure, the degree of daytime sleepiness, that is important and should 
determine who receives CPAP therapy. One study (Maycock 1996) surveyed self - 
reported driving problems and ESS sleepiness and found the ESS score to 
significantly relate to the frequency of reported road accidents and tendency to doze 
at the wheel. Self -reported outcomes such as these play an important role in public 
health safety. 
It is most likely that the role of the ESS lies somewhere in the middle. As mentioned 
by Johns (1991), a high ESS score by itself is not diagnostic. The ESS score alone 
cannot be used to determine the mode of investigation or the likelihood of an 
individual having SAHS. The ESS does provide helpful information when used in 
conjunction with other questions (Appendix B) and discussion at the initial clinic 
consultation. It is all this information together which has clinical predictive value and 
not the ESS alone. This predictive information can then allow limited sleep studies to 
sometimes be performed rather than full polysomnography and allows labour intensive 
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MSLTs and MWTs to only be used for special cases in SAHS and not as routine 
measurements. 
The main aim of this thesis, to determine factors affecting daytime function, will 
include a further correlational analysis of the ESS and nocturnal SAHS measures in a 
larger sample (Chapter 5). In this protocol, the MSLT and the MWT are used along 
with the ESS and this study will determine if the ESS relates to these objective 
measures of daytime sleepiness (Chapter 6). Also Chapter 7 examines the use of the 
ESS in CPAP therapy follow -up and determines how the ESS and other baseline 
SAHS measures relate to CPAP use. 
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Chapter 5 
Nocturnal Correlates of Daytime Function in SANS Patients 
5.1 Introduction 
As discussed in Chapter 2, patients with the sleep apnoea/hypopnoea syndrome suffer 
from excessive daytime sleepiness (Roth et al 1980, Whyte et al 1989), cognitive 
decrements (Greenberg et al 1987, Cheshire et al 1992), and decreased psychological 
well -being (Smith & Shneerson 1995). Previous correlational studies have examined 
the possible causative relationships between nocturnal features of SANS and daytime 
function (Roth et al 1980, Yesavage et al 1985, Guilleminault et al 1988b, Roehrs et 
al 1989, Millman et al 1989, Bedard et al 1991b, Poceta et al 1992, Cheshire et al 
1992, Chervin et al 1995, Smith & Shneerson 1995, Kim et al 1997). Despite the 
number of correlational studies, there is still controversy as to whether daytime 
sleepiness in SAHS is primarily due to sleep fragmentation (Roehrs et al 1989, Poceta 
et al 1992), to repetitive nocturnal hypoxaemia (Bedard et al 1991b), both or neither 
(Cheshire et al 1992, Chervin et al 1995). Studies examining relationships between 
nocturnal SANS variables and cognitive function tests also found varying results. 
Significant relationships with cognitive decrements have been related to both 
hypoxaemia (Greenberg et al 1987, Bedard et al 1991b, Cheshire et al 1992) and sleep 
fragmentation (Cheshire et al 1992). Relationships have also been found between 
nocturnal hypoxaemia and psychological decrements (Millman et al 1989, Smith & 
Shneerson 1995). 
The reasons for performing a further correlational study are based on the poor 
methodology of some of the previous studies. The nocturnal SAHS features of 
respiratory events, arousals and oxygen desaturations are interrelated, due to the 
repetitive cyclical nature of the syndrome (see Figure 1.1), yet previous studies have 
often focused on the causative role of just one or two of the major nocturnal SAHS 
variables. For example, Bedard et al (1991b) found significant correlations between 
minimum oxygen saturation and sleepiness and performance, and between % 
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awakenings and performance (all r >0.5, p <0.05). The number of awakenings is a 
crude measure of sleep fragmentation and had microarousal frequency been measured, 
perhaps significant relationships with sleepiness would have been found, and that 
hypoxaemia may actually covary with arousal frequency. Other studies have also 
limited the number of major nocturnal variables used in correlational analysis, often 
omitting some important measures. Studies have not measured AHI (Smith & 
Shneerson 1995), hypopnoeas (Roth et al 1980, Bedard et al 1991 b), microarousals 
(Yesavage et al 1985, Chervin et al 1995, Smith & Shneerson 1995, Kim et al 1997), 
or hypoxaemia (Yesavage et al 1985, Kim et al 1997). It is therefore possible that 
significant relationships reported in the above studies are not the only important ones. 
Other unmeasured nocturnal variables could contribute to the causal variance. Unless 
nocturnal SAHS variables are experimentally isolated, as discussed in section 2.7, it is 
important to examine the contributing role of all the routinely measured nocturnal 
SAHS variables. This was done in the current study. 
Previous studies have also used older definitions of arousal (Roth et al 1980, 
Guilleminault et al 1988b, Roehrs et al 1989, Bedard et al 1991b). For example, 
studies have measured the number of 15 second (R & K) awakenings ( Guilleminault 
et al 1988b, Bedard et al 1991b, Chervin et al 1995), rather than microarousals. Such 
microarousals affect daytime function in experimental sleep fragmentation studies 
(Philip et al 1994, Roehrs et al 1994, Martin et al 1996) and occur frequently in 
SAHS (Martin et al 1997c). Therefore in the current study, microarousals were 
measured. 
Many studies have focused on single areas of daytime function such as daytime 
sleepiness (Roehrs et al 1989, Poceta et al 1992, Johns 1993, Chervin et al 1995), 
cognitive performance (Yesavage et al 1985, Kim et al 1997), and psychopathology 
(Millman et al 1989, Smith & Shneerson 1995). In keeping with the previous 
correlational study from Edinburgh (Cheshire et al 1992), the current study aims to 
include a broad range of daytime function tests. In addition to those measures used by 
Cheshire et al (1992), more recent tests have been incorporated, such as the 
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maintenance of wakefulness test (MWT) ( Poceta et al 1992) and the short form (SF) 
36 questionnaire (Ware & Sherbourne 1992). 
Large patient populations are also required to perform convincing correlational 
studies. Previous case -control studies have used relatively small numbers of patients 
(Roth et al 1980, n =10 SANS patients; Stepanski et al 1984, n =15 SAHS patients), 
and the correlational analysis has followed. Other small sample correlational studies 
have also been performed a priori (Bedard et al 1991b, n =20 SAHS patients; 
Cheshire et al 1992, n =29 SAHS patients, Chervin et al 1995, n =28 SANS patients). 
Conversely, large scale correlational studies by Roehrs et al (1989) and Poceta et al 
(1992) used 466 and 322 SAHS patients, respectively. In the current study, I aimed to 
study a large number of patients, limited by the time constraints of the project, and 
availability of suitable patient referrals. 
The patient samples previously studied have also varied in their recruitment criteria. A 
homogenous sample of patients may mask potential correlations by attenuating the 
variance. For example, Roth et al (1980) and Bedard et al (1991b) studied patients 
with moderate to severe disease only, and so may have reduced the ability to detect 
potential correlations. In the current study it was planned to recruit an unselected, 
consecutive, heterogeneous patient sample with a wide range of disease severity. 
The major hypothesis of this investigation was that brief microarousals from sleep 
cause the sleepiness and impaired daytime function found in SANS. The current study 
compares overnight polysomnography with daytime measures of objective sleepiness, 
cognitive performance and psychopathology, in a large, unselected, consecutive 
patient sample. By examining the possible predictors of daytime dysfunction, this 
study aims to identify which nocturnal features affect daytime function, and therefore 
predict who requires CPAP treatment. 
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5.2 Methods 
5.2.1 Patient recruitment 
Participants in the study were an unselected consecutive sample of clinical patients 
suspected of having SAHS, who were referred to the Edinburgh sleep centre by 
general practitioners and hospital specialists. Prior to the initial outpatient 
consultation, all patients and their partners completed an in -house sleep /wake 
questionnaire (Appendix B). The information from the questionnaire, in addition to 
the clinical interview and the referral letter, determined that patients who gave a 
convincing history suspicious of SAHS underwent diagnostic overnight 
polysomnography. 
Some patients were excluded from the study prior to their polysomnography, as they 
did not fulfil the recruitment criteria (Table 5.1). For inclusion, patients had to be 
between 18 and 75 years old and live within 50 miles of the Edinburgh sleep centre. 
This distance restriction was to ensure that patients did not have to arise exceptionally 
early on their daytime test day in order to arrive at the sleep centre for 9:00 am and 
possibly influence daytime sleepiness results. From casenote and sleep questionnaire 
evaluation, patients were also excluded who had evidence of coexisting causes of 
daytime sleepiness, such as night or rotating shift workers, or patients who regularly 
self -reported a sleep duration of less than 5 hours per night. Patients who described 
symptoms highly suspicious of other sleep disorders were also excluded at this stage. 
Patients with major psychiatric and neurological disorders and coexisting causes of 
hypoxaemia were also excluded (e.g. COPD, nocturnal asthma; Table 5.1). 
On the morning after overnight polysomnography, consecutive patients who had not 
given a prior history of the above exclusion criteria (Table 5.1) were approached by a 
sleep physician and then by myself to ask if they would participate in the study and 
return for daytime tests. Overnight records were then scored to confirm an absence of 
periodic limb movement disorder (PLMD) and an AHI .5, for the patients to remain in 
the study and return for daytime testing. 
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Table 5.1; Patient recruitment criteria 
Inclusion Criteria 
Self -reported symptoms of either sleepiness (ESS>_8) or 2 other major 
symptoms of SAHS 
Aged 18 -75 
Living within 50 miles of the sleep centre 
All -5 
Exclusion Criteria 
Coexisting causes of daytime sleepiness 
Self -reported average sleep duration of <5 hours per night 
Coexisting sleep disorders 
Major psychiatric and neurological disorders 
Coexisting causes of hypoxaemia 
167 patients were eligible for the study and 150 (136 men; Table 5.2) agreed to 
participate. Fifteen declined because of work pressures (n =14) and family 
commitments (n =1), and two patients were further excluded from the study due to 
having a poor night's sleep ( <6 hours, subjective rating of total sleep time) prior to 
daytime testing. 
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Table 5.2; Patient population data (n =150) 
Measurement mean (SD) range 
Age (years) 50 (10) 22 - 71 
BMI (kg/m2) 32 (7) 20 - 64 
AHI (per hr slept) 45 (31) 7 - 144 
Arousal frequency (per hour slept) 51 (28) 8 - 141 
Minimum oxygen saturation ( %) 83 (11) 34 - 95 
%Wake* 22(12) 2 -61 
Stage 1 sleep* 8 (7) 0.3 - 35 
%Stage2sleep* 44(11) 15 -72 
% Slow wave sleep* 11 (7) 0 - 38 
% REM sleep* 15 (6) 1.6 - 30 
Epworth sleepiness scale (mean) 12 (5) 0 - 24 
MSLT - mean SOL (mins) 9.7 (4.7) 2.5 - 20 
MWT - mean SOL (mins) 27 (12) 2.6 - 40 
BMI =Body mass index; AHI= Apnoea +hypopnoea index; REM =Rapid eye movement; 
MSLT= multiple sleep latency test; MWT= maintenance of wakefulness test; SOL =sleep onset 
latency; * Values for sleep stages are expressed as a percentage of sleep period time. 
The study patients all had self -reported symptoms of either sleepiness or two other 
major symptoms of SAHS (Whyte et al 1989), listed in Table 5.3. Sleepiness was 
defined as an ESS >_8, as used in previous studies from this sleep centre (Engleman et 
al 1994a, 1997a). The symptom ratings were taken from in -house symptom and 
sleep /wake questionnaires (Appendices A & B). The percentages of SAHS symptoms 
reported by patients are documented in Table 5.3. 
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Table 5.3; Percentages of self -reported patient symptoms 
Self -reported symptoms* % patients reporting symptom 
Snoring 100 
Unrefreshing sleep 77 
Daytime sleepiness (ESS>_8) 75 
Witnessed breathing pauses 49 
Choking episodes 33 
Sleepiness whilst driving 21 
Nocturia 9 
ESS= Epworth sleepiness scale; *All symptoms reported from in -house symptom and sleep /wake 
questionnaires (Appendices A & B). 
5.2.2 Nocturnal Measurements 
Full nocturnal polysomnography (PSG) and subsequent off line data analysis were 
performed as outlined in Chapter 3. New off line measures of sleep quality were also 
used in addition to the routine PSG measures. The frequency of sleep stage shifts to 
an R & K defined wake page was recorded per hour of sleep (stage shifts to wake 
index; SSWI). Sleep continuity was also measured by identifying the longest period of 
uninterrupted sleep using an in -house computer program. This program marked the 
longest run of sleep epochs terminating in a wake epoch, in addition to the longest 
uninterrupted period for each sleep stage in turn. The same procedure was also used 
to find the median length of continuous sleep for all sleep stages together, and for 
each individual sleep stage. 
The total numbers of arousals, stage shifts to wake, respiratory events and 2,3, and 
4% desaturations were all divided by total sleep time (TST) to give frequencies per 
hour slept. 
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5.2.3 Daytime Assessments 
Daytime assessments were chosen to measure a wide range of functional areas 
thought to be affected by SAHS (Cheshire et al 1992, Engleman et al 1994a) (Table 
5.4). All assessments are described in Chapter 3, and were performed and scored 
according to standard recommendations. All patients underwent an identical test 
battery (Table 5.5), performed at the same time of day in all subjects. Tests were 
undertaken after a normal night's sleep at home within one month of the overnight 
polysomnography. 
Body mass index, collar and waist circumferences were recorded on the morning of 
the test day. A background questionnaire was completed by myself, asking the patient 
about their medication, medical history, tobacco and alcohol consumption, occupation 
and educational history. 
Objective sleepiness was measured using both the MSLT and MWT following the 
protocol described in section 3.4.2. The sleep onset latency (SOL) was determined 
from `lights out' until the first 30 second epoch of any sleep stage (Thorpy 
The questionnaires (Table 5.5) were given to each patient in the morning after the 
10:00 MSLT. Each patient was guided through the questionnaires and then left alone 
for 20 minutes to complete them, with any queries answered at the end. 
Cognitive function tests were explained by myself, following the standard instructions 
given for each test. Patients were instructed to withdraw from caffeine on the evening 
prior to the daytime testing, and throughout the test day decaffeinated drinks were 
provided. 
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Table 5.4; Daytime function measures 
Questionnaires 
Self reported sleepiness 
Self reported SAHS symptoms 
Well -being and quality of life 
Personality 
Cognitive performance measures 
Premorbid intelligence 
General cognitive function 
Attention & concentration 
Information Processing Time 
- Stanford sleepiness scale 
-Epworth sleepiness scale 
-in house symptom questionnaire 
-Hospital anxiety and depression 
(HAD) scale 
-Nottingham health profile (NHP) 
part 2 
Short Form (SF)36 
-Eysenck personality questionnaire 
revised (EPQ -R) 
-National adult reading test (HART) 
-Digit symbol 
-Block design 
-Trail making A & B 
-Paced auditory serial addition 
task (PASAT) 
-Steer Clear 
-Simple unprepared reaction time 
task (SURT) 
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Table 5.5; Daytime function testing schedule 
09:00 Wire up patient, anthropometry, background information 
questionnaire 
(minimum 20 minutes free time) 
10:00 MSLT 
Questionnaires 
(minimum 20 minutes free time) 
11:00 MWT 
(minimum 20 minutes free time) 
12:00 MSLT 
Lunch 
(minimum 40 minutes free time) 
13:00 MWT 
Reaction time task 
(minimum 10 minutes free time) 
14:00 MSLT 
Cognitive function battery 
(minimum 10 minutes free time) 
15:00 MWT 
(minimum 20 minutes free time) 
16:00 MSLT 
Steer Clear for 30 minutes 
(minimum 10 minutes free time) 
17 :00 MWT 
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5.2.4 Statistical Analysis 
The majority of variables were non -normally distributed. Therefore non -parametric 
statistics were used throughout for consistency. The relationships between nocturnal 
SAHS variables and daytime function measures were evaluated by Spearman rank 
correlations. Both age and awake oxygen saturation correlated significantly with a 
number of daytime variables, therefore all correlations were partial, controlling for age 
and awake oxygen saturation. Multiple regression analysis on ranked variables was 
used to identify independent predictors when an outcome measure significantly 
correlated with more than one variable. As age (Lezak 1983) and awake oxygen 
saturation (Grant et al 1982) affect daytime function, they were entered into the 
multiple regression analysis prior to stepwise regression of the significant correlates. 
All tests were 2- tailed and a probability value of less than 0.05 was accepted as 
statistically significant. All data were analysed using SPSS for Windows 6.1. The 
statistically significant results in this chapter are represented in the tables in bold type 
for clarity. 
5.3 Results 
5.3.1 Relationships with measures of daytime sleepiness 
Sleep quality 
The arousal frequency did not correlate significantly with either subjective or 
objective measures of daytime sleepiness (Figures 5.1, 5.2, 5.3; Table 5.6). 
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Percentages of sleep stages and stage shifts to wake demonstrated significant 
relationships with both the MSLT and MWT in the unexpected direction, i.e. a better 
nocturnal sleep quality was associated with shorter latencies on the MSLT and MWT 
(Table 5.6; Figures 5.4 -5.7). Paradoxical relationships were also found between 
measures of sleep continuity and objective sleepiness (Table 5.6; Figures 5.8 & 5.9). 
For example, a greater median length of uninterrupted sleep was associated with a 
shorter latency on the MSLT (Figure 5.9). To reduce the number of nocturnal 
variables, only the median and longest period of all sleep stages together are reported 
in Table 5.6 rather than continuity data for each individual sleep stage. No significant 
relationships were found between subjective sleepiness as measured by the ESS and 
sleep quality variables (Table 5.6). 
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Table 5.6; Spearman rank correlation matrix of relationships between 
nocturnal SAFIS sleep quality measures and daytime sleepiness. All correlations 
are controlled for age and awake oxygen saturation 
MSLT MWT ESS 
Arousal Frequency 0.12 0.08 0.03 
% wake 0.31 * ** 0.24 ** -0.05 
stage 1 sleep 0.22 ** 0.16 -0.01 
% stage 2 sleep -0.26 ** -0.15 -0.03 
% slow wave sleep -0.16 -0.07 -0.04 
REM sleep -0.17 -0.15 0.08 
TST -0.38 * ** -0.20* 0.06 
SSWI 0.28 ** 0.18* -0.05 
longest length of sleep -0.20* -0.16* 0.002 
median length of sleep -0.23 ** -0.30 * ** 0.06 
MSLT = multiple sleep latency test; MWT= maintenance of wakefulness test; ESS = Epworth sleepiness 
scale; REM =rapid eye movements; TST =total sleep time; SSWI =stage shifts to wake index; *p <0.05, 
* *p <0.01, * * *p <0.001 
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Figure 5.7; Scatterplot of % slow wave sleep versus mean MWT (p= -0.07, 
p =0.38) 
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Figure 5.9; Scatterplot of the median length of uninterrupted sleep versus mean 
MWT (p= -0.30, p <0.0001) 
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Breathing pattern 
AHI did not significantly correlate with objective or subjective measures of daytime 
sleepiness (Figures 5.10 -5.12; Table 5.7). 
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Figure 5.11; Scatterplot of AHI versus mean MWT (p =0.05, p =0.55) 
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Table 5.7; Spearman rank correlation matrix of relationships between 
nocturnal SANS breathing and oxygenation measures and daytime sleepiness. 
All correlations are controlled for age and awake oxygen saturation 
MSLT MWT ESS 
AHI 0.02 0.05 -0.04 
2% desats 0.12 0.03 0.06 
3% desats 0.07 -0.03 0.07 
4% desats 0.07 -0.03 0.06 
Minimum SaO2 -0.06 0.19* -0.22* 
MSLT = multiple sleep latency test; MWT = maintenance of wakefulness test; ESS = Epworth sleepiness 
scale; AHI= apnoea +hypopnoea index; *p <0.05 
Oxygenation 
Minimum oxygen saturation correlated weakly, but significantly, with MWT (Figure 
5.14) and Epworth score (Figure 5.15) in the expected direction (Table 5.7). No other 
measures of oxygenation significantly correlated with MSLT, MWT or ESS (Table 
5.7; Figures 5.13, 5.16- 5.18). 
Figure 5.13; Scatterplot of % minimum oxygen saturation versus mean MSLT 
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Figure 5.14; Scatterplot of % minimum oxygen saturation versus mean MWT 
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Figure 5.15; Scatterplot of % minimum oxygen saturation versus mean 
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5.3.2 Relationships with cognitive function measures 
Sleep quality 
The arousal frequency significantly correlated with reaction time gaps (1 gap = 
reaction time response >1 sec) i.e. a higher arousal frequency was associated with a 
greater number of reaction time responses over 1 second. No other cognitive function 
score significantly related to the arousal frequency (Figure 5.19; Table 5.8). 
Percentage stage 1 sleep significantly correlated with digit symbol (r= -0.19, p <0.05) 
and PASAT 2 secs (r= -0.17, p <0.05) in the expected direction, i.e. greater % stage 1 
sleep (an indication of sleep fragmentation) was associated with better performance 
scores. Percentage SWS significantly correlated with reaction time gaps (r= -0.21, 
p <0.05), i.e. greater % SWS (an indication of sleep continuity), the better the 
performance. TST also significantly correlated with digit symbol (r =0.19, p <0.05), 
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and SSWI with Steer Clear % hits (r= -0.19, p <0.05). The median and longest runs of 
continuous sleep significantly correlated with Steer clear % hits (r =0.23, p <0.01) and 
counterintuitively with reaction time gaps (r =0.19, p <0.05), respectively. All of these 
significant correlations were weak, each explaining less than 6% of the variance. 
Figure 5.19; Scatterplot of the arousal frequency versus the performance IQ 
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Table 5.8; Spearman rank correlation matrix of relationships between 
nocturnal SAHS arousal, breathing and oxygenation measures and cognitive 
function measures. All correlations are controlled for age and awake oxygen 
saturation 








Block Design -0.03 -0.09 -0.13 -0.13 -0.10 0.09 
Digit Symbol -0.07 -0.12 -0.18* -0.15 -0.12 0.11 
Steer Clear % hits -0.01 0.03 0.08 0.04 0.02 -0.06 
IQ decrement 0.06 0.14 0.19* 0.20* 0.18* -0.18* 
PASAT 2 secs -0.14 -0.14 -0.15 -0.10 -0.09 0.09 
PASAT 4 secs -0.08 -0.12 -0.17* -0.14 -0.13 0.15 
Performance IQ -0.10 -0.17* -0.23 ** -0.22 ** -0.19* 0.19* 
SURT false -0.03 -0.03 -0.03 -0.03 -0.07 0.02 
SURT gaps 0.19* 0.12 0.13 0.14 0.12 -0.17* 
SURT mean -0.07 -0.10 0.03 -0.03 -0.03 -0.02 
Trail making A 0.07 0.02 0.06 0.07 0.06 0.04 
making B 0.06 0.13 0.15 0.16 -0.17* 
AHI= Apnoea +hypopnoea index; PASAT =Paced auditory serial addition task; SURT= Simple 
unprepared reaction time; *p <0.05; * *p <0.01; * * *p <0.001 
Breathing pattern 
AHI significantly, but weakly, correlated with performance IQ, i.e. higher disease 
severity was associated with a lower performance IQ (Figure 5.20). No other 
cognitive function score significantly related to AHI (Table 5.8). 
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Oxygenation 
Measures of hypoxaemia also significantly correlated with reaction time gaps and 
performance IQ (Figures 5.21 & 5.22), and also correlated with trail making B, IQ 
decrement, PASAT (4 secs) and digit symbol scores (Table 5.8). All significant 
relationships were in the expected direction, i.e. lower oxygen saturation levels were 
associated with poorer performance scores. 
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Figure 5.21; Scatterplot of % minimum oxygen saturation versus performance 
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5.3.3 Relationships with self -ratings of daytime function 
Sleep quality 
Arousal frequency weakly, but significantly, correlated with SF -36 measures of 
general health (Figure 5.23), health transition and the physical components summary 
(PCS) scores (Table 5.9), i.e. a higher arousal frequency was associated with a poorer 
functional status outcome. 
Figure 5.23; Scatterplot of arousal frequency versus SF -36 general health score 
(p= -0.24, p= 0.005) 
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No relationships were found between % sleep stages or sleep continuity and self 
ratings of daytime function. TST was significantly correlated with SF -36 general 
health (r =0.18, p <0.05). SSWI was also significantly correlated with SF -36 physical 
components summary (r= -0.20, p <0.05), and SF -36 general health (r= -0.19, 
p <0.005). These significant correlations were in the expected direction of better sleep 
quality associated with higher functional status scores. 
123 
Table 5.9; Spearman rank correlation matrix of relationships between 
nocturnal SAHS arousal, breathing and oxygenation measures and self -ratings 
of daytime function. All correlations are controlled for age and awake oxygen 
saturation 








ESS 0.03 -0.04 0.06 0.07 0.06 -0.22* 
EPQR -Extraversion 0.03 0.06 0.00 -0.02 -0.03 0.04 
EPQR -Lie scale -0.12 -0.10 -0.02 -0.03 -0.05 0.09 
EPQR -Neuroticism -0.12 -0.15 -0.05 -0.06 -0.06 0.00 
EPQR -Psychoticism -0.06 -0.04 0.07 0.03 0.01 -0.01 
HAD -Anxiety -0.02 -0.05 -0.01 0.00 -0.02 0.00 
HAD -Depression -0.05 -0.04 0.08 0.11 0.12 -0.21* 
NHP part 2 -0.02 0.05 0.16 0.19* 0.19* -0.26 ** 
SANS symptoms 0.10 0.16 0.23 ** 0.27 ** 0.27 ** -0.33 * ** 
SF36 - PCS -0.22* -0.20* -0.20* -0.23 ** -0.23 ** 0.21* 
SF36 - MCS 0.13 0.02 -0.06 -0.02 0.00 0.12 
SF36 - general health -0.24 ** -0.22* -0.29 ** -0.28 ** -0.27 ** 0.25 ** 
SF36 - health trans 0.20* 0.24 ** 0.29 ** 0.28 ** 0.28 ** -0.25 ** 
SF36 - physical func -0.09 -0.08 -0.18* -0.23 ** -0.22 ** 0.22* 
SF36 - social func -0.01 -0.05 -0.09 -0.11 -0.10 0.17* 
SF36 - bodily pain -0.05 -0.07 -0.04 -0.04 -0.05 0.12 
SF36 - mental health 0.11 0.05 -0.05 0.00 -0.01 0.08 
SF36 - role emotional 0.09 0.00 -0.05 0.00 0.03 0.04 
SF36 - role physical -0.10 -0.14 -0.14 -0.15 -0.15 0.12 
SF36 - vitality -0.05 -0.16 -0.22* -0.25 ** -0.25 ** 0.32 * ** 
SSS 0.03 0.04 0.07 0.10 0.12 -0.13 
AHI= Apnoea +hypopnoea index; ESS = Epworth sleepiness scale; EPQR= Eysenck personality 
questionnaire (revised); HAD= Hospital anxiety and depression (scale); NHP= Nottingham health 
profile; PCS = Physical components summary; MCS = Mental components summary; SSS= Stanford 
sleepiness scale; *p <0.05; * *p <0.01; * * *p <0.001 
124 
Breathing pattern 
AI-11 significantly, but weakly, correlated with the same quality of life measures as the 
arousal frequency (Table 5.9; Figure 5.24), but with no other self reported daytime 
measures. 
Figure 5.24; Scatterplot of AHI versus SF -36 general health score (p= -0.22; 
p=0.01) 
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Oxygenation 
Measures of hypoxaemia significantly correlated with a range of self ratings of 
daytime function, although all significant correlations were weak, each explaining less 
than 8% of the variance (Table 5.9; Figures 5.25 & 5.26). 
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Figure 5.25; Scatterplot of % minimum oxygen saturation versus SF -36 general 

















30 40 50 60 70 80 90 100 
% minimum oxygen saturation 
Figure 5.26; Scatterplot of 2% oxygen desaturations versus SF -36 general 














o 20 40 60 80 100 120 140 
2% oxygen saturation/per hour slept 
126 
Multiple regression analysis 
Seven self rating scales significantly correlated with multiple nocturnal SAHS 
variables. For these self rating scales, a stepwise multiple regression analysis was 
performed on ranked data. In each case the variance revealed by the analysis 
represents the percentage variance after forcing in age and awake oxygen saturation 
levels (i.e. regardless of the order of entering age and wake oxygen saturation). In the 
multiple regression of SF -36 physical components summary, with arousals, AHI, 2, 3, 
4% desats and the minimum oxygen saturation, the arousal frequency was identified 
as the single independent predictor of SF -36 PCS. However, the arousal frequency 
only accounted for 7% of the explained variance. The 2% oxygen desaturation index 
was the single independent predictor for the SF -36 health transition (10% of variance) 
and general health (8% of variance) scores. The 3% oxygen desaturation index was 
identified as the single predictor of SF -36 physical functioning (10% of variance). The 
minimum oxygen saturation was associated with self rated symptoms (9% of 
variance), SF -36 vitality (12% of variance) and the NHP score (8% of variance). 
5.4 Discussion 
This study has demonstrated that conventional variables measured from routine 
polysomnography do not closely relate to impairments in daytime function in SANS 
patients. In previous correlational studies moderate or weak relationships were 
reported. The current study differs from previous correlational studies in terms of the 
sample size used, the design and the outcomes assessed. Previous studies can be 
criticised for recruiting small patient samples (Roth et al 1980, Stepanski et al 1984, 
Greenberg et al 1987, Bedard et al 1991b, Cheshire et al 1992, Findley et al 1986, 
Borak et al 1996), and in some cases recruiting only selected severe patients (Roth et 
al 1980, Bedard et al 1991b). The current study improved on this by recruiting a 
large, consecutive, unselected patient population with wide ranging disease severity. 
In addition, this study controlled for age and awake oxygen levels in all correlations. 
It is well known that age (Lezak 1983) and awake oxygen saturation (Grant et al 
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1982) affect daytime function. In the current study, age significantly correlated with a 
range of nocturnal and cognitive function variables, self rating questionnaires and the 
mean MWT. Awake saturation significantly correlated with cognitive function 
measures. Of the correlational studies reviewed in Chapter 2, only Cheshire et al 
(1992), Yesavage et al (1985) and Kim et al (1997) controlled for age in their 
correlational analysis. Previous studies have also examined only a small number of 
nocturnal variables and outcome measures in their analysis. This may be to avoid 
multiple comparisons, and therefore type 1 error, for which the current study could be 
criticised. However, by limiting the variables measured, the significant relationships 
reported may be of a lower predictive value than another variable not measured, due 
to colinearity. 
5.4.1 Relationships with measures of daytime sleepiness 
Sleep Quality 
The major hypothesis, that microarousals from sleep cause daytime sleepiness, was 
not proven. This result is in keeping with previous small studies (Stepanski et al 1984, 
Cheshire et al 1992). Stepanski et al (1984) examined correlations between arousal 
and daytime sleepiness, as measured by the MSLT, in 15 sleep apnoeics. No 
significant relationship was found. The arousal definition included brief increases in 
EEG and EMG frequency. Cheshire et al (1992) used the arousal definition defined in 
Chapter 3, and found no significant relationship with MSLT measured sleepiness in 29 
patients. However, the sample sizes in these studies were small. In contrast, studies 
have also reported significant correlational relationships between arousals and daytime 
sleepiness (Roehrs et al 1989, Poceta et al 1992). Roehrs et al (1989) examined 
correlational relationships between nocturnal SAHS measures and daytime sleepiness, 
as measured by the MSLT, in 466 SAHS patients. Multiple regression analysis found 
the nocturnal measure of respiratory related arousals (RAR) to be the best single 
predictor of daytime sleepiness. However, this moderate relationship explained less 
than 13% of the residual variance, a level at which clinical relevance is questionable. 
Roehrs et al (1989) defined RAR's as >_3 second increases in EEG frequency or 
increases in EMG (or both), occurring at the termination of a respiratory event. This 
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definition of arousal frequency does not require a change in EEG frequency and 
therefore may be underestimating the degree of sleep fragmentation. Similar findings 
were presented by Poceta et al (1992) who examined the relationships between 
nocturnal SAHS measures and MWT measured sleepiness in 322 patients. Again, 
multiple regression analysis found respiratory related arousals to be the best predictor 
of daytime sleepiness, although explaining less than 13% of the variance. The criteria 
for scoring respiratory related arousals in that study (Poceta et al 1992) were not 
defined, and so is difficult to compare with the current findings. Many other 
correlational studies did not measure microarousals (Roth et al 1980, Guilleminault et 
al 1988b, Bedard et al 1991b, Chervin et al 1995). Therefore the contribution of 
microarousals as predictors of daytime sleepiness is unknown. In terms of study 
design, the current study was most similar to that of Cheshire et al (1992), with the 
addition of the MWT. The current study has confirmed those previous findings in a 
larger sample size. 
In the current study, paradoxical relationships were found between nocturnal sleep 
quality and continuity measures and objective daytime sleepiness. Previous studies 
have found mixed results with measures of sleep quality. Guilleminault et al (1988b) 
found significant relationships with SWS and % stage 1 and MSLT latencies in the 
expected direction. Roehrs et al (1989) measured a sleep parameter, only identified as 
`PSG1' (possibly stage 1 sleep) which correlated significantly with MSLT. Roehrs et 
al (1989) and Poceta et al (1992) also measured TST, which did not significantly 
relate to daytime sleepiness, although both of the r values were paradoxically 
negative, as in the current study. In large number studies, little predictive information 
is derived from sleep stage data. 
The smaller number studies (Roth et al 1980, Bedard et al 199 lb, Cheshire et al 1992, 
Chervin et al 1995) found no significant relationships with sleep stage variables and 
nap latency. A significant paradoxical relationship was reported in Roth et al's (1980) 
10 normal subjects. Percentage wake positively correlated with latency to stage 1 on 
the daytime naps. This paradoxical result from Roth et al's small study is supported by 
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recent data on the MWT in 64 normal subjects (Doghramji et al 1997). In a normative 
study, Doghramji et al (1997) observed no relationship between TST and MWT, but a 
paradoxical relationship was found between sleep efficiency and MWT (r= - 0.31, 
p <0.05). Roth et al (1980) explained their paradoxical findings by suggesting that, at 
least in normal subjects, sleep onset is `set' to some degree, regardless of nocturnal 
sleep patterns. Harrison & Horne (1996b) have since termed this phenomenon 
`sleepability', suggesting that some individuals have the ability to `switch off and 
sleep in a strange place on demand, despite having no daytime sleepiness or sleep 
debt. Does the same hold true for sleep apnoeics, where some individuals slept well at 
night and in the daytime under lab conditions, regardless of disease severity? There is 
no explanation for these paradoxical findings, except to speculate that the current 
study population may also contain individuals with different sleepiness thresholds. 
Breathing Pattern 
AHI did not significantly relate to objective daytime sleepiness. This is in agreement 
with the small correlational studies performed by Cheshire et al (1992) in 29 patients, 
and Chervin et al (1995) in 28 SAHS patients. The larger sample study of 
Guilleminault et al (1988b) in 100 SAHS patients found no significant relationships 
between AHI and the MSLT. The small sample studies by Roth et al (1980) and 
Bedard et al (1991b) also found no association, but only measured apnoeas, not 
hypopnoeas, so cannot be directly compared. Conversely, Poceta et al (1992) found 
the RDI to significantly correlate with MWT, although the authors suggest that this 
relationship may be due to the intercorrelation with measures of hypoxaemia. In 
addition, the RDI is not defined in their paper, so whether a coexisting desaturation is 
required, is not known. Roehrs et al (1989) also found the breathing pattern (AI) to 
significantly correlate with the MSLT. Both apnoeas and hypopnoeas were quantified 
by airflow reduction criteria rather than inductance plethysomography and therefore 
may be underestimated. 
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Oxygenation 
The minimum oxygen saturation significantly correlated with MWT. The relationship 
was weak and could be a type 1 statistical error due to the multiple comparisons made 
between PSG measures and objective daytime sleepiness. However, Bedard et al 
(1991b) also found a significant relationship between the MSLT and minimum oxygen 
saturation. As with AHI, the large number studies of Roehrs et al (1989) and Poceta 
et al (1992) also found significant relationships between measures of hypoxaemia and 
objective sleepiness. In their multiple regression analysis, Poceta et al (1992) found 
the mean oxygen saturation level to contribute to objective sleepiness, whereas 
Roehrs et al (1989) reported that hypoxaemia did not add important information to 
the existing relationships with arousal and AHI and daytime sleepiness. 
The lack of significant relationships between the ESS and AHI and arousal measures 
are in keeping with the findings of Chapter 4, and again contrasts with the work by 
Johns (1993), where significant relationships were found between the ESS and AHI 
(r =0.4, p <0.001) in 165 SAHS patients. However, in agreement with the current 
study, Johns (1993) also found a significant relationship between minimum oxygen 
and ESS. In John's study (1993), AHI criteria included an 
associated criteria of at least a 3% oxygen desaturation, thus Johns' patient sample 
may represent a more severe group than the current study. This may explain the 
differing results. 
5.4.2 Relationships with cognitive function measures 
In agreement with earlier studies, arousal frequency, sleep stage variables, AHI and 
especially measures of hypoxaemia weakly predict decrements in cognitive 
performance (Greenberg et al 1987, Bedard et al 1991b, Cheshire et al 1992). 
The arousal frequency was only associated with one cognitive function measure of 
information processing time. Cheshire et al's (1992) small number study found the 
arousal frequency to relate to a measure of visuospatial organisation. Other studies on 
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SAHS clinic patients (Yesavage et al 1985, Greenberg et al 1987, Bedard et al 1991b) 
and in the community (Kim et al 1997) did not measure microarousal frequency and 
so comparisons cannot be made. 
The current study also reported 6 significant relationships between measures of sleep 
quality and cognitive performance. Although significant, these relationships were 
weak, each explaining less than 6 % of the variance. There were 108 possible 
relationships sought between sleep quality and cognitive function, therefore 5 
significant associations would be expected by chance alone. Cheshire et al (1992) 
found % REM sleep to relate to simple reaction time and Bedard et al (199lb) found 
awakenings and stage shifts to wake to significantly correlate with choice reaction 
time, however, Bedard et al (199lb) did not control for age in their correlations. 
AHI was associated with one measure of performance IQ. In agreement, Cheshire et 
al (1992) found AHI to relate to measures of IQ, and Yesavage et al (1985) found 
AHI to relate to tests measuring visuospatial reasoning, memory and psychomotor 
speed. As in the current study, both Cheshire et al (1992) and Yesavage et al (1985) 
controlled for age in their correlations. This result is compatible with a recent large 
scale population study of 841 individuals, reporting significant, but weak, age - 
controlled relationships between AHI and psychomotor efficiency (Kim et al 1997). 
These authors did not present results for arousals and measures of hypoxaemia, so no 
comparisons with these measures can be made. 
In this study, measures of hypoxaemia weakly predicted decrements in mental 
flexibility, performance IQ, attention and response speed. Bedard et al (1991b) found 
a strong relationship between hypoxaemia and attention, explaining 58% of the 
variance. However, Bedard et al (1991b) used a selected sample of moderately severe 
patients with an inclusion criteria of a minimum oxygen saturation >_80 % and did not 
control for age or awake saturation levels in the correlations. Cheshire et al (1992) 
found hypoxaemia to be associated with reaction time, coding speed and IQ, which 
are functional areas similar to those reported in the current study. Greenberg et al 
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(1987) only reported 4/72 significant relationships between hypoxaemia and cognitive 
function tests, and these relationships could be due to chance alone. 
The current study is the largest correlational study to measure a wide range of 
nocturnal SAFTS measures and cognitive function tests in SAHS patients, and in 
agreement with the recent large scale population study by Kim et al (1997), weak 
relationships between nocturnal measures and cognitive function were identified. 
5.4.3 Relationships with self ratings of daytime function 
Nocturnal SAHS measures significantly related to a whole range of self ratings of 
daytime function, although the correlations identified were weak, in no case 
explaining more than 12 % of the observed variance. The stronger correlations were 
associated with oxygen saturation measures rather than measures of arousal, AHI, 
TST or SSWI. A similar pattern was also seen in the multiple regression analysis. 
Significant relationships with hypoxaemia were most frequently found with the 
questionnaire self reports of vitality, symptoms, general health and physical well- 
being. These items may be the area in which the patient is most aware of 
noticing a decrement. In agreement with the current study, Smith & Shneerson (1995) 
also examined ratings on the SF -36 questionnaire in snorers and SAHS patients and 
found 4% desaturations weakly correlated with physical function, general health and 
vitality. The authors speculated that if measures of sleep fragmentation had been made 
in their study, stronger relationships with quality of life may have been observed, but 
this was not found in the current study. 
Relationships were not found between nocturnal SAHS measures and the EPQR 
personality measures, HAD anxiety or the SF -36 mental health and emotional role 
dimensions. As mentioned above, the measures of physical functioning may be most 
prevalent in the eyes of the patient, who notices when he can't walk over a mile, while 
changes in personality and mood may be less noticeable. A significant relationship was 
found between minimum oxygen saturation and the HAD depression rating. This is in 
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contrast to the studies by Millman et al (1989) and Borak et al (1996) who found no 
significant relationships between hypoxaemia and depression using the Zung self 
rating depression score and Beck's depression rating, respectively. The HAD contains 
one depression statement which could be interpreted as being sleepy i.e. `I feel as if I 
am slowed down', and this may explain the relationship with the HAD scale. 
However, the Zung self rating depression scale also contains questions about fatigue, 
task performance and sleep disruption and demonstrated no relationship with 
nocturnal SAHS measures. 
This study found no relationships between nocturnal SAHS variables and the Stanford 
sleepiness scale (SSS). This is in accord with previous reports on the poor nocturnal 
relationships with the SSS (Dement et al 1978, Roth et al 1980) in SAHS patients. 
In summary, the current findings are difficult to compare with previous studies due to 
differences in methodology. Where comparisons can be made, there is both agreement 
and disagreement with previous findings. The main message from the current study is 
the lack of clinical PSG predictors of daytime dysfunction in SAHS patients. The 
following section goes on to further discuss the pros and cons of the current study 
design and to provide further evidence in support of the lack of significant 
relationships found. 
5.4.4 General discussion 
Multiple comparisons 
One potential criticism of this study is the large number of correlations performed. A 
total of 525 correlations were sought. Given this, it is inevitable that some of the 72 
significant correlations observed are due to chance alone, but only 26 such chance 
observations would be expected (525/20) given the significance value set at 0.05 in 
the current study. However, the main message of this study is not the number of 
significant correlations, but the weakness of the correlations observed. In fact 
significant relationships between nocturnal SAHS measures and daytime function all 
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explained less than 12% of the observed variance. There are a number of possible 
reasons for the lack of strong correlational relationships in the current study. 
Signal and scoring reliability 
The significant relationships between hypoxaemia and daytime function were stronger 
and more frequent than with other nocturnal measures in both correlational and 
multiple regression analyses. It is possible that hypoxaemic variables are the true 
causative factors of daytime function. Alternatively, this could be due to 
methodological factors. Oximetry is a reliable measure. It requires one channel of 
signal recording with good feedback if the signal is poor or the probe has fallen off. 
The scoring of oximetry is computer derived and so is highly reproducible. 
Conversely, the microarousal requires channels of EEG and EMG and is more 
susceptible to poor quality signal, as are the respiratory channels, with position 
influencing the quality of plethysomography traces, particularly in the obese patient. 
Scoring of both the AHI and microarousal frequency requires the following of strict 
criteria, which are always going to have a subjective element (Section 3.3 on 
reproducibility scoring). However, evidence suggests that reproducibility is good, at 
least for (Martin et al 1997c) and AHI (Whyte et al 1992) 
used in this thesis. Variation in signal reliability may also be the reason for Bedard et 
al (1991b) finding relationships with hypoxaemia and MSLT, and not with sleep stage 
variables or apnoea frequency. 
Arousal definition 
As mentioned previously, this thesis used the Cheshire arousal definition (Cheshire et 
al 1992). Using an in -house measure of sleep fragmentation may explain the weakness 
of the relationships in the current study. This is not likely to be the case, as the 
Cheshire definition has been well -validated against itself and other arousal measures, 
including the standard ASDA definition (Martin et al 1997c). 
The two large scale correlational studies (Roehrs et al 1989, Poceta et al 1992) which 
found significant relationships between arousals and objective sleepiness in SAHS 
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patients, both used definitions of respiratory related arousals. In the current study, all 
arousals were scored and used in the subsequent analysis, regardless of whether or not 
they were associated with an apnoea or hypopnoea. All arousals have the ability to 
cause daytime dysfunction, and it was the effect of sleep fragmentation on daytime 
function, that was the main hypothesis of the study. In addition, so called 
`spontaneous' arousals may in fact be associated with a snore crescendo or a period 
of increased respiratory effort which are not scored routinely, yet have been reported 
to affect daytime function (Guilleminault et al 1991, 1993). 
MSLT and MWT 
The MSLT and MWT are considered as `gold standards' for measuring daytime 
sleepiness. However both the MSLT and MWT are susceptible to influences other 
than physiological sleepiness levels. The MWT is highly susceptible to motivational 
factors, and instructing an individual to `try and stay awake' may activate a whole 
range of physiological processes such as motivation (Poceta et al 1992) 
competitiveness (Roehrs & Roth 1992) and attention ability (Poceta et al 1992). 
Interestingly, motivational factors have also been reported to effect the MSLT. 
Harrison et al (1996c) compared MSLT latency in two groups of normal subjects, 
both of whom completed baseline MSLTs under standard instructions. Then on a 
second occasion, one group was given financial incentives to `fall asleep quicker than 
the last time', and the other group normal instructions. The incentive group fell asleep 
significantly faster than the non -incentive group. Such psychological influences as 
these are likely to vary between individuals, regardless of disease severity. Other 
measures of daytime sleepiness and alertness, such as behavioural tasks (Bennett et al 
1997), or monitoring for EEG microsleeps during an individuals daily routine may 
prove more useful in the future (see Chapter 9). 
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Study population 
The population studied represent a heterogeneous, unselected, consecutive sample, 
both in terms of SAHS severity and age. This was done deliberately in order to 
provide the wide variance required to investigate potential correlations. The current 
sample included 23 individuals with AHI's in the 5 -15 range. This was due to 
previous work identifying that mild patients demonstrate daytime dysfunction (Young 
et al 1993 & 1997, Kim et al 1997), which can be improved with CPAP therapy 
(Engleman et al 1997a). 
To be included in the study, patients had to have an ESS4 and /or at least 2 other 
features of SAHS. Patients therefore did not have to be excessively sleepy, in terms of 
their ESS, to participate in the study. This was to avoid excluding sleepy patients, 
who have lost their frame of reference, and underestimate their score on the ESS 
(Chapter 4; Engleman et al 1997b). The fact that not all patients had an ESS > -8 may 
have contributed to the mean MSLT SOL of 9.7 minutes, compared to a mean value 
of 6 minutes in Roehrs et al's (1989) SANS sample. However, both of these mean 
MSLT values, and those in other studies (Guilleminault et al 1988b, Bedard et al 
1991b, Sangal et al 1992a, Cheshire et al 1992) lie within the `grey zone' of latencies 
between 5 -10 minutes. The studies that did find relationships between arousals and 
MSLT (Roehrs et al 1989, Poceta et al 1992) do not define any prior sleepiness 
criteria for inclusion in their studies, making comparisons difficult. However, 
sleepiness is more likely to have been a dominant clinical feature in these earlier 
studies. In all other aspects the patients in the current study were typical of an 
unselected SANS population. Patients had a mean AHI of 45, mean BMI of 32 and an 
MWT latency of 27 minutes, which was very similar to Poceta et al's (1992) value of 
26 minutes. 
To identify if relationships were not found in the current study due to the inclusion of 
patients with an AHI in the 5 -15 range, and an ESS <8, a post -hoc analysis was 
undertaken. A subgroup of patients (n =75) with both an AHI .15 and ESS?11(2SD 
above the normal mean level; Johns & Hocking 1997) were examined. The results 
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demonstrated that even in this subgroup, MSLT and MWT mean SOLs and ESS did 
not significantly correlate with measures of AHI, arousals and hypoxaemia (all p <0.2, 
p >0.12). 
Study Protocol 
The patients performed their daytime tests after a normal night's sleep at home and 
not on the day following overnight polysomnography. This is a potential criticism of 
the study, as this is not standard (Carskadon et al 1986). There were several reasons 
for this. Most importantly, this study wanted to examine how the sleep study results 
related to daytime function decrements in patients during a normal day, and not after a 
polysomnography (PSG) disrupted night. It is the level of daytime decrements 
experienced every day that need to be abolished with CPAP therapy, not PSG induced 
ones, thus these are the values which need measuring. Secondly, this study was 
designed to follow the same protocol as the previous correlational study by Cheshire 
et al (1992), who also performed the MSLT after a normal night's sleep at home. 
Thirdly, due to the design of the protocol, an elapse of time was needed to allow for 
the scoring of the PSG records to confirm that patients had an AHI > -5 and no 
coexisting sleep disorders (e.g. PLMS). As Cheshire et al (1992) also found no 
significant relationships with PSG variables and MSLT, it is possible that performing 
the daytime tests after a night's sleep at home could explain the current findings. It 
would have been useful to measure actimetry on patients on the night prior to their 
daytime tests to achieve an estimate of sleep quality and quantity with minimal 
interference. This question of performing tests after a night at home is the theme of 
Chapter 8 of this thesis, where an experiment compared objective sleepiness after a 
night at home and a night in the sleep centre. 
Another possible reason for the patients not being particularly sleepy in terms of their 
MSLT, is that the test day involved a busy schedule, and therefore may have increased 
alertness levels. When only an MSLT is performed on a day, it is a very long, 
monotonous and sedentary day, and it might be suggested that this could increase 
sleepiness levels compared to a normal working day. However, evidence suggests that 
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a behavioural activity will increase, rather than decrease sleepiness (Home & Minard 
1985b, Kribbs et al 1994). For example, Home & Minard (1985b) demonstrated in 
normal subjects that an active day caused an increase in subjective sleepiness 
compared to a monotonous lab based day. In agreement, Kribbs et al (1994) 
compared 10 minute nap opportunities before and after normals performed a vigilance 
task. Nap latency was found to decrease after the brief performance task. This 
evidence does not explain the MSLT of 9.7 minutes. Furthermore, the current daytime 
testing schedule more closely resembled a normal day, with both active and sedentary 
tasks. Previous studies have successfully performed the MSLT and MWT on the same 
day (Sangal et al 1992a & 1992b, Martin et al 1996, 1997b), with Martin et al (1996) 
finding significant changes in both the MSLT and MWT with experimental sleep 
fragmentation. 
Conclusion 
A correlational study involves analysis across patients and this is likely to maximise 
sample variance. It is probable that there are many unknown factors affecting daytime 
function in addition to the hypothesised sleep fragmentation. For example, it is 
possible that patients have differing thresholds for their level of inherent sleepiness, 
that is, their level of sleep need regardless of disease severity. In addition, sleepiness 
is context dependent and although patients perform the MSLT /MWT under identical 
conditions, they may differ in terms of their `sleepability' (Harrison & Home 1996b) 
and their normal daily routines. For example, some individuals find napping in the 
daytime unusual due to work and personal commitments, whereas others nap on a 
daily basis. Some patients may find alertness is increased due to the anxiety associated 
with undergoing these tests. Adaptation to SAHS is another factor. Some patients 
may adapt to their disease using behavioural means, by learning coping strategies to 
stay awake during monotonous tasks, or have the ability to upgrade performance and 
attention when necessary. Others may be physiologically adapted to their disease. For 
example, patients may have higher arousal thresholds. These could be patients who 
have had their condition for a long time, or have very severe disease, or who are 
pathologically sleepy in the daytime and therefore cannot afford to further disrupt 
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sleep. Experimental modelling studies (Colt et al 1991, Martin et al 1996, Brooks et al 
1997) may overcome some of the methodological problems of correlational type 
studies. Modelling studies have the advantage of allowing the nocturnal variables to 
be studied in isolation. For example, using the randomised crossover protocol 
described by Colt et al (1991), the current study could be repeated with patients 
administered CPAP to abolish all events on one limb, and on the other limb, patients 
could be administered CPAP plus 100% nitrogen to induce hypoxaemia in isolation, 
followed by daytime testing, to examine the effects of hypoxaemia alone on daytime 
function. In addition, modelling studies can often be performed on normal subjects 
(Martin et al 1996) or animals (Brooks et al 1997) and therefore reduce some of the 
interindividual variability specific to the SAHS patient group, such as the duration of 
their disease and the varying adaptation to it. Also using a crossover study design 
(Colt et al 1991, Martin et al 1996) allows each subject to be their own control, again 
reducing interindividual variability. Further modelling studies on larger sample sizes 
are required to determine the factors affecting daytime function in SAHS. 
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Chapter 6 
Interrelationships Between Measures of Daytime Function in SAHS 
6.1 Introduction 
This chapter focuses on the interrelationships between measures of daytime function 
in the sample of 150 SAHS patients previously described (Section 5.2). In particular, 
the relationships between the two measures of objective sleepiness, the MSLT and 
MWT, and their relationship with measures of cognitive performance and 
psychopathology are investigated. 
The first aim of this chapter was to repeat the comparison between the MSLT and 
MWT performed by Sangal et al (1992a), however, this time in a population solely 
comprised of SAHS patients. The second aim of this study was to compare both the 
MSLT and MWT to a diverse battery of psychometric measures with the hypothesis 
that the MWT demonstrates stronger relationships with other measures of daytime 
function and is therefore the more appropriate test to reflect baseline daytime function 
in SAHS patients. 
Previously, Sangal et al (1992a) closely examined the relationship between the MSLT 
and MWT, when performed on the same day. This was in a sample of 258 patients 
with disorders of excessive somnolence, of which 170 were sleep apnoeics. The study 
demonstrated a moderately strong correlation between the MSLT and MWT (r =0.41, 
p <0.001). However, when considering that these tests both measure EEG sleep onset, 
this moderate correlation suggests that the two tests may be measuring different 
physiological abilities of sleepiness and alertness, respectively. 
Previous studies have also compared the MSLT to self reports of daytime function. 
As part of the validation work on the ESS, two studies by Johns (1991, 1994) 
examined relationships between the ESS and the MSLT. In the first study (Johns 
1991), using 27 patients with disorders of excessive somnolence, a significant 
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relationship was found between the ESS and MSLT (r= -0.5, p <0.01). However, only 
two of the 27 patients were diagnosed with SAHS. In the second correlational study 
by Johns (1994), 44 patients with excessive daytime sleepiness were studied, this time 
using a Spearman rank correlation. In agreement, a significant relationship was found 
between the ESS and MSLT (p= -0.42, p <0.01). Again only a small proportion of the 
patients were diagnosed with SAHS (n =8). Chervin et al (1997) performed a similar 
study in a group of 60 patients with disorders of excessive sleepiness, of which 23 
were sleep apnoeics. There was a significant Spearman correlation of p= -0.37, 
p =0.004 between the ESS and MSLT. The above studies demonstrate moderately 
strong relationships between the ESS and the MSLT in a population of patients with a 
range of sleep disorders. 
In a community based study, Briones et al (1996) examined daytime relationships in 
129 individuals, using the general health measures of the SF -36, ESS and MSLT. The 
subjects consisted of normal controls, snorers and patients with sleep disordered 
breathing (total population mean ±SD RDI of 8 ±7 /hour slept). Results demonstrated 
that the ESS significantly correlated with SF -36 scores for general health, vitality and 
emotional role, whereas the MSLT only significantly related to SF -36 vitality 
(r= -0.19, p= 0.02). The ESS and MSLT were also significantly, but weakly, related to 
one another (r= -0.27, p <0.05). 
The current study further examines interrelationships between daytime function 
measures, by examining a wide range of daytime tests in a large, consecutive SAHS 
sample. 
6.2 Methods 
6.2.1 Patients and protocol 
The 150 patients involved in the study and the methods used have been described 
earlier (Sections 3.4, 3.5, 5.2). The daytime interrelationships examined are shown in 
Table 6.1. 
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Table 6.1; Table of the daytime interrelationships examined 
1. MSLT versus MWT 
2. MSLT and MWT versus self reports of daytime function:- 
Epworth sleepiness scale 
Stanford sleepiness scale 
Nottingham health profile (part 2) 
Hospital anxiety & depression scale 
SAHS symptom ratings 
SF -36 - physical components summary 
SF -36 - mental components summary 
SF -36 - vitality 
SF -36 - general health 
SF -36 - social function 
SF -36 - physical function 
SF -36 - role emotional 
SF -36 - role physical 
SF -36 - bodily pain 
SF -36 - mental health 
SF -36 - health transition 
Eysenck personality scale - neuroticism 
Eysenck personality scale - psychoticism 
Eysenck personality scale - lie scale 
Eysenck personality scale - extraversion 





Paced auditory serial addition task (PASAT) 2 sec 
Paced auditory serial addition task (PASAT) 4 sec 
Trail making A 
Trail making B 
% Steer Clear cow hits 
Simple unprepared reaction time - mean 
Simple unprepared reaction time - false response 
Simple unprepared reaction time - no. of gaps 
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6.2.2 Statistics 
Many of the daytime variables were non -normally distributed, therefore non - 
parametric correlational statistics were used throughout for consistency. Relationships 
between daytime function measures were evaluated by Spearman rank correlation 
coefficients. Age significantly correlated with the MWT (p =0.27, p= 0.001), and 
eleven self reports of daytime function (all p >0.15 p <0.05). In addition, age and 
awake oxygen saturation significantly correlated with nine cognitive function 
measures (all p >0.15, p <0.05). Therefore all correlations performed were partial, 
controlling for age and awake oxygen saturation. Multiple regression analysis on 
ranked variables was used to identify independent predictors when an outcome 
measure significantly correlated with more than one putative determinant variable. As 
previously described (Section 5.2.4), age and awake oxygen saturation were forced 
into the multiple regression analysis prior to stepwise regression of the significant 
correlates. All tests were 2- tailed and a probability value of less than 0.05 was 
accepted as statistically significant. All data were analysed using SPSS for Windows 
6.1. The statistically significant results in this chapter are represented in the tables in 
bold type for clarity. 
6.3 Results 
6.3.1 MSLT versus MWT 
There was a statistically significant relationship between the MSLT and the MWT 
(p =0.43, p <0.0001) (Figure 6.1). Using the method described by Sangal et al (1992a), 
the group median of the mean MSLT and MWT values are shown on the scatterplot 
of Figure 6.1. The graph is divided into four quadrants with areas of concordance and 
discordance between the two tests. Patients who were concordant for MSLT and 
MWT scores are represented in the lower left square (sleepy on both the MSLT and 
MWT), and the upper right square (not sleepy on either the MSLT and MWT). 
Discordance between the MSLT and MWT is demonstrated by points in the upper left 
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portion of the graph (sleepy on MWT, but not on MSLT), and by points in the lower 
right portion of the graph (sleepy on the MSLT, but not on the MWT). 
Figure 6.1; A scatterplot of the mean sleep latencies of the MWT versus the 
MSLT in 150 SANS patients. The vertical line represents the group median 
MWT mean sleep latency (30.9 mins), and the horizontal line represents the 
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Figure 6.1 shows that a large number of patients had ceiling effects on the MWT. 40 
patients did not sleep on all four daytime naps (27 %) and on a total of 267/600 MWT 
naps (45 %), no R & K sleep was seen. This contrasts with results from the MSLT, on 
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which only 1 patient did not sleep on all four naps, and no R & K sleep was seen on a 
total of 69/600 MSLT naps (12 %). 
If the correlation between the MSLT and MWT was recalculated without the 40 
patients who demonstrated ceiling effects on the MWT, the strength of the correlation 
increased to p =0.54, p <0.0001. Therefore to some extent, the ceiling effect on the 
MWT may be depressing the `true' correlation coefficient. 
The mean ( ±SD) sleep onset latency on the MSLT was 9.7(5) mins, with a range of 
2.5 minutes to the maximum of 20 minutes. The mean sleep onset latency on the 
MWT was 27(12) minutes, with a range of 2.6 to the maximum of 40 minutes. 
6.3.2 Objective sleepiness versus self reports of daytime function 
The MWT significantly correlated with a range of self reporting questionnaires (Table 
6.2). The MWT significantly correlated with ESS measured sleepiness in the expected 
direction (Figure 6.2). The MWT was also significantly associated with measures of 
quality of life and well- being, with the sleepier the MWT score, the poorer the level of 
functional status. However, the MSLT, only correlated significantly, but weakly, with 
the ESS (Figure 6.3, Table 6.2). 
Eight self rating scores significantly correlated with the MWT. For these self rating 
scores, a stepwise multiple regression analysis was performed on ranked data. The 
explained variance revealed by the analysis represents that after forcing in age and 
awake oxygen saturation levels (i.e. regardless of the order of entering age and wake 
oxygen saturation). In the multiple regression analysis of MWT, the best predictors of 
the MWT mean latency were the ESS and the SF -36 health transition dimension 
(together explaining 29% of the variance in MWT). 
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Table 6.2; Spearman rank correlation matrix of relationships between objective 
sleepiness and self ratings of daytime function. All correlations are controlled for 
age and awake oxygen saturation. 
MSLT MWT 
Epworth sleepiness scale -0.23 ** -0.48 * ** 
Stanford sleepiness scale 0.11 -0.01 
Nottingham health profile (2) -0.10 -0.31 * ** 
HAD - anxiety 0.09 -0.07 
HAD - depression -0.03 -0.22* 
SAHS symptom ratings -0.04 -0.22* 
SF -36 - physical components summary 0.02 0.23 ** 
SF -36 - mental components summary 0.06 0.16 
SF -36 - vitality 0.07 0.14 
SF -36 - general health 0.02 0.12 
SF -36 - social function 0.07 0.28 ** 
SF -36 - physical function -0.01 0.20* 
SF -36 - role emotional 0.09 0.12 
SF -36 - role physical 0.01 0.13 
SF -36 - bodily pain -0.03 0.14 
SF -36 - mental health -0.05 0.11 
SF -36 - health transition -0.08 -0.28 ** 
Eysenck personality scale - neuroticism 0.10 -0.11 
Eysenck personality scale - psychoticism -0.01 -0.04 
Eysenck personality scale - lie factor -0.05 -0.12 
Eysenck personality scale - extraversion 0.02 0.05 
MSLT= multiple sleep latency test; MWT= maintenance of wakefulness test; HAD= hospital anxiety 
and depression scale; *p <0.05; * *p <0.01; * * *p <0.001 
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6.3.3 Objective sleepiness versus cognitive function measures 
The MWT significantly correlated with block design, IQ measures, PASAT (4 secs), 
reaction time (Figure 6.4) and Steer Clear cow hits (Table 6.3). All significant 
relationships were in the expected direction, i.e. the sleepier the MWT score, the 
greater the performance impairment. No such significant relationships were found 
between the MSLT and measures of cognitive function (Table 6.3; Figure 6.5). 
Table 6.3; Spearman rank correlation matrix of relationships between objective 
sleepiness and measures of cognitive function. All correlations are controlled for 
age and awake oxygen saturation. 
MSLT MWT 
Block design -0.01 0.20* 
Digit symbol -0.13 0.12 
Performance IQ -0.10 0.22 ** 
IQ decrement 0.02 -0.22 ** 
PASAT (2 seconds presentation) -0.10 0.06 
PASAT (4 seconds presentation) -0.003 0.17* 
Trail making A 0.02 -0.01 
Trail making B 0.14 -0.16 
% Steer Clear cow hits -0.13 -0.30 * ** 
SURT - mean reaction time -0.15 -0.32 * ** 
SURT - false responses 0.04 -0.05 
SURT - frequency of gaps >1 sec 0.03 -0.15 
MSLT = multiple sleep latency test; MWT= maintenance of wakefulness test; PASAT =paced auditory 
serial addition task; SURT= simple unprepared reaction time; 
*p <0.05; * *p <0.01; * * *p <0.001 
Six cognitive function tests significantly correlated with MWT. For these cognitive 
function tests, a stepwise multiple regression analysis was performed on ranked data. 
The variance explained by the analysis represents the percentage variance after forcing 
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in age and awake oxygen saturation levels. In the multiple regression analysis of 
MWT, the best predictors of the MWT mean latency were mean reaction time and the 
performance IQ (together explaining 17% of variance in MWT). 
Figure 6.4; Scatterplot of the MSLT versus mean reaction time 
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6.4 Discussion 
6.4.1 Relationships between the MSLT and MWT 
A significant relationship was found between the MSLT and the MWT, with similar 
values to those reported by Sangal et al (1992a) in their population of 258 patients 
with excessive daytime sleepiness. Also in agreement with Sangal et al (1992a), 
discordance was found between the MSLT and MWT (Figure 6.1). The current study 
confirms that the MSLT and MWT are likely to be measuring different physiological 
abilities, otherwise two tests measuring the same outcome variable of EEG defined 
sleep onset, would be expected to have a higher rho value. 
The MSLT and MWT differ in their test instructions of ̀ to try and sleep' and `try and 
stay awake', respectively. This change in instruction lengthened the latency on the 
MWT, again supporting the idea that the tests measure different abilities. This study 
population reported a large ceiling effect with the MWT (27 %) which was in close 
agreement with that of Sangal et al (1992a) (29 %). This ceiling effect suggests that 
the MWT is susceptible to high levels of motivation. A post -hoc correlation between 
MSLT and MWT scores in the 110 patients who did not demonstrate ceiling effects 
on the MWT resulted in a stronger MSLT/MWT interrelationship. This leads on to 
the question of whether lengthening of the MWT would have improved the 
relationship. However, running an MWT for longer than 40 minutes would be too 
labour intensive and monotonous for patients to undertake. 
There are a number of speculative reasons for the discordance found between the 
MSLT and MWT. Patients that fell asleep quickly on both the MSLT and MWT may 
either represent individuals who are pathologically sleepy, or individuals with a low 
motivation level on the MWT. Patients that fell asleep on the MSLT and stayed 
awake on the MWT may represent patients who are not pathologically sleepy, but 
have high sleepability when instructed to fall asleep (Harrison & Home 1996b). 
Equally, these patients may be pathologically sleepy, but have high motivation to 
follow instructions, by staying awake on the MWT as instructed. There are many 
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explanations as to why some patients are sleepy and others not as measured by these 
objective tests. One further comment is that patients were asked if they felt they had 
slept at all after the termination of each MSLT/MWT (without feedback). Frequently 
patients would deny sleeping, when EEG evidence opposed this. It is possible that 
some patients think they are successfully staying awake on the MWT, when in fact 
they have fallen asleep, long enough to score sleep onset. 
The current study demonstrates in a population of 150 sleep apnoeics, that the MSLT 
and the MWT do not correlate highly with one another when considering they are 
both measuring sleep onset latency. 
6.4.2 Relationships between objective sleepiness and self reports of daytime 
function 
The MSLT significantly related to the Epworth sleepiness scale. This confirms 
previous study findings (Johns 1991 & 1994, Briones et al 1996, Chervin et al 1997) 
in a larger number of sleep apnoeics. In addition, the current sample does not include 
patients with other disorders of excessive sleepiness (Johns 1991 & 1993, Chervin et 
al 1997), or normal subjects (Briones et al 1996), thus the relationship presented 
reflects sleepiness in SANS patients alone. The current rho value was smaller than 
those from the previous studies (Johns 1991 & 1994, Briones et al 1996, Chervin et al 
1997). This was the only significant relationship found between the MSLT and the 21 
self reports of daytime function. 
The weak relationships between these two measures of sleepiness may exist because 
the MSLT and ESS measure different aspects of daytime sleepiness (Briones et al 
1996, Chervin et al 1997). The MSLT is a state assessment and is thought to measure 
sleepiness on one occasion, in one situation, whereas the ESS is a trait assessment and 
measures recent sleepiness over the past month, in a number of different situations. 
In this study, stronger significant relationships were found between the MWT and the 
ESS, compared to the MSLT. Perhaps closer relationships are found with the MWT 
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than the MSLT, because the ESS and MWT both measure the inability to stay awake, 
and not the ability to fall asleep. Both the MWT and the ESS are susceptible to similar 
levels of motivation, possibly making potential correlations stronger. 
This potentially closer relationship between the MWT and the ESS is reflected in a 
number of other daytime measures that correlated more closely with the MWT than 
the MSLT. The MWT related to measures of well- being, depression, social life, 
physical ability, health transition and SAHS symptoms. Briones et al (1996) compared 
the MSLT with the SF -36 and only found the MSLT to correlate significantly, but 
weakly, to SF -36 vitality. In the current study, no such relationships were found 
between the MSLT or MWT and SF -36 vitality. The vitality dimension asks the 
following 4 questions - `did you feel full of life? did you have a lot of energy? did you 
feel worn out? and did you feel tired ?' These questions reflect a lack of energy and 
tiredness rather than actual sleepiness, and this may explain the lack of relationship 
with the MSLT and MWT in the current study. 
The daytime variables that significantly correlated with the MWT estimated patients' 
symptoms, problems with work and home life, feelings of depression, factors 
affecting social activities, factors affecting physical ability and how health compares to 
one year ago. It may be that these variables are not necessarily the most severe 
decrements suffered by a patient, but that these are the ones that are easily recognised 
by the individual themselves. These significant variables are likely to be less 
subjective. For example, a physical functioning question such as `Does your health 
limit you, climbing one flight of stairs ?' is quite a straightforward question to assess. 
However, `Do you feel full of life' is going to vary more between individuals, 
depending on their perception of the question. Referring back to Chapter 5, it was the 
similar daytime self -reports that related to nocturnal SAHS variables (section 5.4.2), 
except that significant relationships were found between nocturnal variables and SF- 
36 vitality scores. 
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6.4.3 Relationships between objective sleepiness and cognitive function 
measures 
The MSLT did not significantly correlate with any tests of cognitive performance 
used in the current study. Similarly, Cheshire et al (1992) only found one significant 
relationship between MSLT and daytime tests, that being with IQ decrement (r =0.46, 
p <0.05). In contrast, the MWT significantly related to many measures of general 
cognitive functioning, sustained attention and reaction time. 
As discussed above, the MWT may show stronger correlations with performance 
measures than the MSLT, because both the MWT and cognitive tests are susceptible 
to motivation and are measuring outcomes whilst trying to stay awake. Individuals 
that upgrade their performance on the cognitive function tests may be more likely to 
try hard to stay awake on the MWT. 
In agreement with the study hypothesis, the MWT more closely relates to other 
measures of daytime function than the MSLT in the current SAHS population. It is 
possible that the MWT is the more appropriate test to perform in sleep apnoeics, or 
alternatively, the MWT is more similar to the other daytime function measures used 
here, therefore demonstrating stronger relationships. 
6.4.4 General discussion 
The MSLT is a widely used, well- validated test for measuring sleep tendency in 
patients with sleep disorders and for assessing the appearance of sleep onset REM 
periods for the diagnosis of narcolepsy. In addition, the MSLT aims to measure 
physiological sleep tendency by removing the majority of external environmental 
influences (Carskadon et al 1986), but this is not comparable with real life. The MWT 
on the other hand, measures the inability to stay awake and is influenced by greater 
motivational factors which may more closely relate to real life situations. Therefore 
the MWT may be the most appropriate test to use in SAHS patients, who tend to 
complain of their inability to stay awake rather than falling asleep too quickly when 
they try. The MWT may be more useful as a lab based test to quantify alertness ability 
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in SAHS patients, especially those who drive for a living or operate dangerous 
machinery (Poceta et al 1992). 
Correlations with larger rho values were found with daytime interrelationships than 
between nocturnal and daytime measures. This may be because the daytime 
interrelationships are between tests performed on the same day, whereas nocturnal 
versus daytime relationships are comparing tests performed at night and on another 
day, which may demonstrate greater variation. 
Even though correlations of a moderate size were found between the MWT and a 
whole range of daytime measures, relationships between both the MSLT and MWT 
and nocturnal SAHS measures were either weak or non -significant (Chapter 5). 
Alternative daytime function measures may improve relationships with nocturnal 
SAHS measures. 
One recently devised measure is the Oxford Sleep Resistance (OSLER) Test (Bennett 
et al 1997). This is a simple behavioural test in which subjects have to press a button 
in response to a light emitting diode (LED) which is illuminated for 1 second in 3. 
When the subject does not respond for 21 seconds, the test is terminated on the 
assumption that the individual has fallen asleep. This is based on cross -validation 
work with the MWT (Bennett et al 1997). In the OSLER test validation, 10 normals 
and 10 severe SAHS patients (median oxygen saturation dip rate = 33) completed 
both the MWT and the OSLER test in a crossover design, on two separate occasions. 
Results demonstrated that both the MWT and the OSLER test could discriminate the 
SAHS patients from the normal controls. In addition, the mean values of the OSLER 
test and the MWT were not significantly different in either the patient or normal 
groups. The OSLER scores in the SAHS group tended to be longer compared to the 
MWT for each individual test, but were only significantly longer on the third test of 
the day in the SANS group. These results imply that the OSLER test is slightly more 
stimulating than the MWT. However, this may not be to the OSLER test's 
disadvantage, as performing a simple task whilst trying to stay awake more closely 
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mimics real life. In addition, this non -EEG test will be terminated after 21 seconds 
even if an individual has failed to fall asleep in terms of R & K sleep, but may have in 
fact had a microsleep or a substantial lapse in concentration. Such phenomenon as 
these are still important, as they may occur at the wheel of a vehicle, for example. The 
validation work on this test does not suggest that the OSLER is likely to improve 
relationships with nocturnal SAHS measures, due to its similarity to the MWT. 
Although advantages of the OSLER test over the MWT are that it is less expensive, 
easier to perform than the MWT and requires less subjectivity. A large number study 
across the whole SAHS disease spectrum is required to further validate the OSLER 
test and examine correlations with nocturnal SAHS measures. 
Ideally the best method of monitoring daytime sleepiness is using portable EEG 
equipment which can be worn in the workplace or in a vehicle, for the detection of 
microsleeps (Harrison & Home 1996a). This is discussed further in Chapter 9. 
6.4.5 Conclusion 
The results presented suggest that the MWT rather than the MSLT may be a more 
useful SAHS patients due relationships that exist between it and other 
important measures of daytime dysfunction. The relationships found are at most, 
moderate in size, and alternative measures of daytime sleepiness and performance may 
improve potential relationships. 
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Chapter 7 
Patient Follow -up on Continuous Positive Airway Pressure (CPAP) 
Therapy 
7.1 Introduction 
Continuous positive airway pressure (CPAP) therapy (Sullivan et al 1981) is widely 
accepted as the treatment of choice for patients with SAHS, with evidence to suggest 
that CPAP improves daytime function (Engleman et al 1994a, 1998). This chapter 
describes follow -up data from the SAHS patients studied in Chapter 5, who were 
offered CPAP therapy. 
The first aim of this chapter was to identify potential predictors of objective CPAP 
use from a diverse range of baseline nocturnal and daytime function measures, in an 
attempt to determine which patients are likely to use CPAP effectively and therefore 
gain therapeutic benefit. 
The second aim of this chapter was to determine whether ESS scores consistently 
decreased after 12 months of CPAP therapy, and to examine the hypothesis that 
SAHS patients with high objective CPAP use demonstrate greater improvements in 
their level of subjective sleepiness. Additionally, the strength of baseline nocturnal 
predictors of improvements in ESS were examined. 
Previous studies have attempted to identify baseline SAHS determinants of CPAP 
use. Reeves -Hoche et al (1994) and Engleman et al (1994b) found neither baseline 
AHI or BMI to predict objective CPAP use. The influence of the baseline arousal 
frequency and measures of hypoxaemia were not examined in either of these studies 
as potential predictors of CPAP use. Conversely, other studies (Meurice et al 1994, 
Pieters et al 1996, Krieger et al 1996) have found significant predictors of CPAP use. 
Meurice et al (1994) found the baseline AHI, % SWS and % stage 1 sleep to predict 
objective CPAP use (all p >0.29, p <0.05). Krieger et al (1996) sought determinants of 
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long -term objective CPAP use (mean follow -up of 1,176 days) on a large sample of 
575 SAHS patients. Multiple regression analysis demonstrated that AHI and age 
independently contributed to the variance of CPAP use (< 10% of the variance), 
whereas baseline nap latency, subjective sleepiness and symptoms did not. Pieters et al 
(1996) found the nocturnal SANS variable of movement arousal frequency to weakly 
predict objective CPAP use (r =0.23, p <0.05), but found no such relationships with 
BMI, apnoea frequency, % SWS and the oxygen desaturation index. These studies 
have found either weak coefficients (explaining less than 7% of the variance in mean 
CPAP use), or a lack of significant relationships between baseline SAHS predictors 
and mean objective CPAP use. 
Significant improvements in ESS scores with CPAP therapy have previously been 
demonstrated (Johns 1992, Hardinge et al 1995, Smith & Shneerson 1995, Engleman 
et al 1996, 1998). The current study design improves on previous investigations by 
prospectively recruiting a large sample of consecutive patients, and recording 
objective CPAP use in all those recruited. 
7.2 Methods 
Patient recruitment and baseline SANS measurements are described in Chapters 3 and 
5. 
7.2.1 Patients 
Of the original 150 SANS patients (Chapter 5), 137 were offered CPAP therapy by 
the clinicians for long term home use. The 13 patients who were not offered CPAP 
were significantly younger, with milder SAHS disease (Table 7.1). Non -CPAP 
patients were not significantly different from CPAP patients in terms of either 
subjective or objective measures of daytime sleepiness. Non -CPAP and CPAP patient 
group means were compared using a Mann -Whitney U test (Table 7.1). 
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Table 7.1; A comparison of CPAP and non -CPAP patients 
Variable CPAP group 
median (range) 
n =137 




Age 50 (22 -71) 41 (33 -62) 0.006 
Arousal frequency 48 (8 -141) 31 (16 -54) 0.003 
Apnoea + hypopnoea index 42 (8 -144) 13 (7 -21) 0.000 
Epworth sleepiness scale 12 (0 -24) 12 (1 -17) 0.34 
Multiple sleep latency test 9 (3 -20) 12 (3 -18) 0.89 
Maintenance of wakefulness 
test 
31 (3 -40) 25 (13 -40) 0.71 
CPAP= Continuous positive airway pressure 
7.2.2 Protocol 
The 137 patients for whom long -term CPAP therapy was recommended returned to 
the sleep centre for a CPAP titration night. During this titration night, the lowest 
therapeutic CPAP pressure required to minimise respiratory events and arousals from 
sleep was established for each individual. Patients were then issued with a CPAP 
machine following the trial night, with the prescribed pressure set on an individual 
basis. All CPAP machines (Sullivan III or V, ResMed, San Diego, California) issued 
for subsequent home use contained time clocks. These time clocks display the total 
number of hours the CPAP unit has been run, allowing the objective mean machine 
`run time' per night to be calculated for a given time period. CPAP run time data from 
all 137 patients was included in the analysis, which was performed on an intention to 
treat basis. 
All CPAP patients were followed up with a phone call from a CPAP nurse at 2 weeks, 
and seen in the outpatient sleep clinic at 2 months and 1 year after commencing 
CPAP. If severe side effects occurred, a shorter interval between clinic visits was 
arranged. At clinic visits, CPAP use was noted, and CPAP machine and mask 
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problems or other adverse effects were discussed and rectified wherever possible by 
the nursing and medical sleep staff 
At 12 months after commencing CPAP therapy, all patients who were still in 
possession of a CPAP machine, regardless of CPAP use, were posted an Epworth 
sleepiness scale (ESS) for completion (3.4.1), enquiring about patient's recent dozing 
habits on CPAP therapy. 
7.2.3 Statistics 
The AESS ([Baseline ESS] - [on CPAP ESS]) was normally distributed and 
compared to zero using a 2- tailed paired t -test. All other statistical analyses used non - 
parametric tests for non -normally distributed data. Between patient group 
comparisons were tested using the Mann -Whitney U test. Relationships between 
nocturnal SAFTS measures and CPAP use and improvements in ESS (DESS) were 
evaluated by Spearman rank correlations. Correlations were partial, controlling for 
age and awake oxygen saturation (section 5.2.4). Multiple regression analysis on 
ranked variables was used to identify independent predictors when an outcome 
measure significantly correlated with more than one variable. Age and awake oxygen 
saturation were forced into the multiple regression analysis prior to stepwise 
regression of the significant correlates. A two -tailed probability value of less than 0.05 
was accepted as statistically significant. All data were analysed using SPSS for 
Windows 6.1. The statistically significant results in this chapter are presented in the 
tables in bold type for clarity. 
7.3 Results 
7.3.1 CPAP Use 
Mean ±SD CPAP run time in the 137 patients was 4.1 ±2.6 hours per night over the 12 
months study period. Forty -nine (36 %) patients used their CPAP machines for an 
average of less than 3 hours per night. 
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7.3.2 CPAP returnees 
During the 12 month follow up period, 24 CPAP machines (18 %) were returned to 
the sleep centre. A variety of reasons were given for returning CPAP units including: 
lack of benefit from CPAP (n =4); noise from the CPAP unit (n =4); bloating/flatulence 
(n =1); inability to cope with the CPAP pressure (n =3); CPAP mask problems (n =3); 
greater sleep disturbance on CPAP (n =1); referral for nasal surgery (n =1), patient 
death (n =1; of lung cancer); no reason given (n =6). 
The 24 CPAP returnees did not significantly differ from those patients still on CPAP 
therapy in terms of age, AHI, arousal frequency, ESS, MSLT or MWT. However, 
significant differences in CPAP use at 2 months were found. Patients continuing on 
CPAP (median and range): 5.1 (0.1 -9.0) hours per night; CPAP returnees: 0.6 (0 -8.4) 
hours per night, p <0.00001. 
7.3.3 Baseline SAHS predictors of CPAP use 
Relationships between baseline SAHS measures and mean CPAP use were examined 
to investigate whether predictors of CPAP use could be identified for the 137 patients 
issued with CPAP units. A few significant, but weak, correlations were found (Table 
7.2; Figure 7.1). No significant relationships were found between mean CPAP use and 
baseline arousal frequency (Figure 7.2) nor with any other measure of sleep 
continuity, objective sleepiness or cognitive function. 
Stepwise multiple regression analysis was then performed on the ranked baseline 
variables that significantly related to mean CPAP use. This analysis found the best 
predictors of mean CPAP use to be the AHI and the Stanford sleepiness scale 
(together explaining 26% of the variance in mean CPAP use). 
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Table 7.2; Spearman rank correlation matrix of the statistically significant 
relationships between baseline SANS measures and mean objective CPAP use. 
All correlations are controlled for age and awake oxygen saturation. 
Baseline SANS Variable Mean CPAP Use (hrs /night) 
Apnoea +hypopnoea index 0.19* 
2% desaturations 0.19* 
3% desaturations 0.20* 
4% desaturations 0.19* 
Body mass index (kg/m2) 0.23* 
Collar size (cm) 0.25* 
Waist circumference (cm) 0.24* 
Nottingham health profile (part 2) 0.20* 
Stanford sleepiness scale 0.19* 
SF -36 vitality -0.19* 
SAHS =Sleep apnoea/hypopnoea syndrome; CPAP= Continuous positive airway pressure; *p <0.05 
Figure 7.1; Scatterplot of the relationship between AHI and objective CPAP 
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Figure 7.2; Scatterplot of the relationship between arousals and objective 
CPAP run time (p =0.09, p =0.28) 
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7.3.4 Improvements in ESS with CPAP therapy 
ESS questionnaires were sent to the 113 patients still in possession of a CPAP 
machine at 12 months follow up. Ninety -two patients returned their ESS 
questionnaires (81% response rate). The non -responders were not significantly 
different in terms of age, disease severity or sleepiness (all p >0.19). However, the 
non -responders did have a significantly lower CPAP use at 12 months (median and 
range): responders 5.6 (0.7 -8.7) hours per night; non -responders 2.9 (0 -6.6) hours per 
night; p= 0.0001. 
For the 92 responders, the ESS (mean ±SD) significantly improved with CPAP 
therapy (Baseline ESS: 12 ±5, on -CPAP ESS: 5 ±4; p <0.0001), (Figure 7.3). 
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Figure 7.3; Bar chart representing baseline and on -CPAP mean (SD) ESS 
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7.3.5 Relationships between nocturnal SANS measures, mean CPAP use and 
improvements in ESS 
Improvements in the ESS score from baseline to on -CPAP (AESS) provide a useful, 
though subjective, outcome measure of the benefit of CPAP therapy. AESS was 
significantly related to measures of hypoxaemia, i.e. the greater the frequency of 
oxygen desaturations, the greater the improvements in ESS. However, AESS was not 
significantly associated with arousal frequency or AHI (Table 7.3). A significant 
relationship between AESS and mean CPAP use was also found (Table 7.3; Figure 
7.4), linking greater improvement in ESS score with higher CPAP use. 
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Table 7.3; Spearman rank correlation matrix of relationships between baseline 
PSG measures, mean objective CPAP use and AESS. All correlations are 
controlled for age and awake oxygen saturation. 
AEpworth sleepiness scale score 
Arousal frequency 0.13 
Apnoea +hypopnoea index 0.08 
2% desaturations 0.18 
3% desaturations 0.21* 
4% desaturations 0.22* 
Minimum saturation -0.28 ** 
Mean CPAP use 0.30 ** 
DESS= [Baseline mean ESS score - mean ESS score after 12 months on CPAP]; CPAP= Continuous 
positive airway pressure: *p <0.05; * *p <0.01 
Figure 7.4; Scatterplot of mean CPAP run time versus AESS (Baseline mean 
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* The points above the horizontal line represent improvements in ESS with CPAP therapy, those 
below the horizontal line represent worsening of ESS score with CPAP therapy. 
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Stepwise multiple regression analysis was then performed on the baseline PSG 
measures and mean CPAP use which significantly related to AESS. The analysis found 
the best independent predictors of AESS to be the mean CPAP use and the minimum 
oxygen saturation (together explaining 13% of the variance in AESS). 
7.4 Discussion 
7.4.1 Baseline SANS predictors of CPAP use 
There were only a few significant baseline predictors of CPAP use, including the AIII 
and oxygen desaturation measures. Each explained less than 7% of the total variance 
in CPAP use. These relationships are compatible with previous studies which found 
either weak predictors of objective CPAP use (Meurice et al 1994, Pieters et al 1996, 
Krieger et al 1996) or a lack of predictors of objective CPAP use ( Kribbs et al 1993, 
Reeves -Hoche et al 1994, Engleman et al 1994b). 
The current study improved on previous studies ( Kribbs et al 1993, Meurice et al 
1994, Engleman et al 1994b, Reeves -Hoche et al 1994, Pieters et al 1996) by using a 
larger sample size of 137 patients. In addition, the current study measured a more 
diverse range of possible baseline SANS predictors. These included nocturnal 
measures of sleep fragmentation and sleep continuity, and daytime measures of 
subjective and objective sleepiness, cognitive function and psychopathology. Previous 
studies (Kribbs et al 1993, Meurice et al 1994, Engleman et al 1994b, Reeves -Hoche 
et al 1994, Pieters et al 1996, Krieger et al 1996) only presented data on the 
predicting effects of the following: AHI, movement arousal frequency, minimum 
oxygen saturation, % stages 1 & 2 sleep and SWS, BMI, age, MSLT and years of 
education. Despite the wide range of possible predictors of CPAP run -time in the 
current study, in the correlational analysis few significant variables were identified. In 
the multiple regression analysis, the AHI and SSS scores were the best baseline 
predictors of mean CPAP use. 
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The weak relationships found between baseline SAHS measures and objective CPAP 
use are likely to be due to inter -patient variability (section 5.4.4). For example, some 
patients like, and others detest, the concept of sleeping with CPAP. In addition, some 
patients may require all night CPAP use to gain therapeutic benefit, whereas others 
may only require CPAP therapy for part of the night. Engleman et al (1994a) have 
demonstrated that improvements in daytime function are found with a low mean 
CPAP use of 3.4 hours per night. Therefore, if patients demonstrate variability in their 
CPAP use required to gain the same benefit, regardless of initial disease severity, 
baseline predictors of CPAP use are likely to be weak. 
7.4.2 Relationships with improvements in daytime function 
Examining baseline predictors of CPAP use has demonstrated that poor relationships 
exist, possibly due to patients' variation in perceived benefit for a given use. By 
examining improvements in baseline measures with CPAP, in particular symptoms 
perceived by the patient, the therapeutic effect of CPAP can be studied. 
Time was not available in this project to perform repeat daytime testing in all 137 
CPAP patients. However, as part of another study in the sleep centre, 62 of the 
current CPAP patient population were followed up with repeat daytime tests after 6 
months of CPAP therapy. Not all 137 CPAP patients were followed up, as this second 
study commenced part way through the current study. I performed the baseline 
daytime tests, and the second post -CPAP assessment was performed by two 
colleagues. These results are not presented in detail in this thesis, but do merit 
discussion. Significant treatment related improvements in sleep latency on the MWT 
were found, as was previously demonstrated by Sangal et al (1992b). Improvements 
were also observed in subjective sleepiness, well- being, quality of life and symptoms 
with CPAP. These results are in agreement with previous studies that have also 
demonstrated improvements in ESS (Johns 1992, Smith & Shneerson 1995, Hardinge 
et al 1995, Engleman et al 1998), SF -36 dimensions (Smith & Shneerson 1995, 
Jenkinson et al 1997), mood (Engleman et al 1994a) and SAHS symptoms (Engleman 
et al 1994a, 1998). Improvements in cognitive performance scores measuring 
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visuomotor coordination, information processing, attention and general cognition 
were also found after 6 months of CPAP therapy. Familiarisation with the cognitive 
tests was not performed and so improvements found here are likely to be influenced 
by learning effects (Engleman et al 1994a). 
Baseline sleep study variables were correlated with the change in daytime function 
measures (A =delta values) after 6 months on CPAP therapy. The arousal frequency 
only predicted one outcome measure, A reaction time gaps, and AHI only significantly 
correlated with A digit symbol. Hypoxaemia variables predicted a range of 
improvements in daytime function including MWT, SF -36 measures and trail making 
A. These results are in broad agreement with previous studies (Sangal et al 1992b, 
Engleman et al 1994a), in that CPAP therapy improves daytime function. This study 
suggests that these improvements in daytime function occur independently of baseline 
disease severity as measured by AHI and arousal frequency, and only a few 
improvements in daytime function significantly relate to baseline hypoxaemic 
variables. 
7.4.3 Improvements in ESS with CPAP 
This study has also demonstrated that ESS scores significantly decrease after 12 
months of CPAP therapy in a consecutive sample of 92 SANS patients. The mean 
ESS score on CPAP decreased to levels consistent with a middle -aged working 
community sample of normal subjects (Johns & Hocking 1997). This study confirms 
and extends the results of previous studies based on smaller samples of SAHS patients 
(Johns 1992, Smith & Shneerson 1995, Engleman et al 1998) and studies which did 
not measure objective CPAP run time in all patients (Johns 1992, Hardinge et al 1995, 
Engleman et al 1996). 
It is possible that this study and other uncontrolled studies (Johns 1992, Hardinge et 
al 1995, Smith & Shneerson 1995, Engleman et al 1996) found decreases in ESS 
scores with CPAP therapy as a result of placebo effects and cognitive dissonance -type 
effects. For example, administering a treatment of any type may 
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improve symptoms, both in terms of subjective benefit, and even when no benefit is 
found, the fact that there `ought to be a treatment benefit' may improve scores. In 
addition, pleasing the experimenter may also create subjective improvements in 
symptoms with therapy. Engleman et al (1998) performed a small number, 
randomised, single blind, placebo controlled crossover study, and found ESS scores 
to significantly decrease with CPAP therapy compared to a placebo tablet. However, 
as the current study was uncontrolled, it can only be speculated that the improvements 
found in ESS were due to the therapeutic effects of CPAP. 
The positive relationship between mean CPAP use and AESS, supports the hypothesis 
that the decrease in ESS with CPAP is due to the therapeutic effect of CPAP, i.e. the 
more an individual uses their CPAP machine, the greater the improvement in 
subjective sleepiness, or the greater the improvement in subjective sleepiness, the 
greater the CPAP use. 
Baseline nocturnal predictors of improvements in ESS were also examined in this 
study. AESS significantly, but weakly, correlated with measures of hypoxaemia alone. 
In contrast, a preliminary report by Bennett et al (1998) found significant relationships 
between AESS and AHI and measures of sleep fragmentation (frequencies of 
microarousals, movement arousals, autonomic arousals and changes in neural net 
EEG), all r> -0.38, p <0.05. The difference between the current results and those of 
Bennett et al (1998) are difficult to explain. There were differences in the 
demographics of the populations studied. Bennett et al (1998) examined relationships 
in 41 patients, including a greater proportion of mild patients and also normal subjects 
(median AHI =18, range 0 -123), whereas in the current study the demographics of the 
92 patients with AESS data had a median AHI of 44 and a range of 11 -144. It is 
possible that the normal subjects included in the analysis by Bennett et al (1998) 
increased the likelihood of significant correlations, by providing data points with low 
levels of sleepiness and sleep fragmentation. In the current study it is possible that 
relationships with AESS were only found with hypoxaemia, because measures of 
hypoxaemia are more robust than EEG scored indices of sleep fragmentation. 
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Significant relationships could be influenced by variability in signal and scoring 
reliability rather than a direct physiological effect (see 5.4.4). It is interesting to note 
that Bennett et al (1998) found the best predictors of AESS to be digitally -determined 
body movement events, and computer based neural network EEG analysis, together 
explaining 51% of the variance. Thus their use of different variables may contribute to 
the discrepancies with the current study - nevertheless, in their study AHI was 
significantly (r= -0.53, p <0.001) correlated with AESS, but there was no such 
significant relationship in the current study. 
In summary, the ESS is a useful assessor of response to CPAP therapy. However, one 
criticism of postal questionnaire studies is the potential selection bias that is created 
by the subset of non -responders. In this study, the non -responders were significantly 
poorer CPAP compliers, exactly the group of individuals a follow -up questionnaire is 
aiming to target. Hence, if a patient scores highly on their follow -up ESS ( >10), or 
fails to return their questionnaire, they are more likely to have a poor CPAP use and 
require an interim clinic appointment to discuss CPAP problems and be challenged 
about poor CPAP use. Administering the ESS on -CPAP therapy, as part of routine 
follow up, is simple and cheap to perform and would be easy to implement. The ESS 
is a subjective, retrospective measurement. However, it represents the perceived state 
of the patient, who will self -determine their CPAP use depending on their self - 
assessed therapeutic benefit. 
7.4.4 Conclusion 
In conclusion, this chapter has demonstrated that CPAP therapy reduces the ESS 
score to normal levels. However, prospectively determining who will use their CPAP 
machine and gain therapeutic benefit is difficult to predict. If finances allow, perhaps 
all patients with sleep disordered breathing should be offered a trial of CPAP. 
Ultimately, regardless of disease severity, the patient determines whether they will use 
their CPAP unit. This depends on personal, and to some extent, spouse benefit. 
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Chapter 8 
Is in -lab polysomnography required prior to measuring objective 
sleepiness? 
8.1 Introduction 
Guidelines for performing the multiple sleep latency test (MSLT) were produced in 
1986 by Carskadon and co- workers. They recommend that the MSLT is performed 
on a day following clinical polysomnography (PSG) to provide "accurate 
documentation of the preceding night's sleep ". This standard procedure has also been 
followed by Poceta et al (1992) using the maintenance of wakefulness test (MWT). 
Documentation of the preceding night's sleep can be measured using ambulatory PSG 
equipment in the patient's own home, or more commonly, in the sleep laboratory. 
The correlational study performed on 150 SANS patients (Chapter 5), did not follow 
these standard MSLT guidelines, as both the MSLT and MWT were performed after 
a normal night's sleep at home. There were three reasons for this; firstly, to measure 
the daytime sleepiness that occurs after a normal night's sleep at home, rather than 
after a PSG interfered night, secondly, to follow the same protocol as the previous 
small correlational study performed in the lab (Cheshire et al 1992), and thirdly to 
limit costs. The current study found a high mean MSLT nap latency of 9.7 minutes 
and our group previously reported a median MSLT sleep latency of 10 minutes 
(Cheshire et al 1992). These MSLT values are high compared to other studies in sleep 
apnoeics (Roth et al 1980, Guilleminault et al 1988b, Roehrs et al 1989) where full 
diagnostic polysomnography was recorded in the sleep lab on the night prior to the 
MSLT. 
The aim of the current study was to compare objective daytime sleepiness recorded 
after a night's sleep at home, with minimal neurophysiological sleep recording 
equipment, versus full diagnostic in- laboratory PSG. The hypothesis was that SANS 
patients are sleepier (as measured by the MSLT and MWT) after a PSG night in the 
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sleep centre, than after a night at home with less instrumentation. A secondary aim of 
the study was to compare sleep quality and sleep fragmentation when recorded at 
home versus in the sleep centre. 
No previous studies have compared objective daytime sleepiness after nights in the lab 
and at home in sleep apnoeics. One study (Edinger et al 1997a) has compared 
objective daytime sleepiness between 32 older insomniacs and 32 age and gender - 
matched normal controls after a night in the sleep lab or at home. All subjects 
underwent 3 consecutive nights of in -lab monitoring of sleep parameters, and 3 
consecutive nights of identical in -home monitoring in a crossover design. The MSLT 
was only performed on day 4 of the first study limb. The combined results of the 
insomniacs and normal subjects found no significant differences in sleepiness as 
measured by the MSLT after lab versus home recorded nights (Edinger et al 1997a). 
Sewitch & Kupfer (1985) compared neurophysiological sleep parameters measured in 
the sleep lab versus at home in a group of normal subjects, and found no significant 
differences in sleep parameters. Edinger et al (1997b) also measured lab and home 
based PSG in normal subjects and insomniacs, but did not compare nocturnal data 
between the two situations. Instead, this study focused on the differences in sleep 
parameters between normal controls and insomniacs within the two different 
recording locations. 
Studies have examined relationships between nocturnal SAHS variables measured 
using limited screening devices in the home and in -lab PSG in sleep apnoeics. Results 
demonstrate reproducible SANS severity indices at home in line with lab based PSG 
(Ancoli- Israel et al 1981, Redline et al 1991, White et al 1995, Whittle et al 1997b, 
Parra et al 1997). To my knowledge no such studies in sleep apnoeics have compared 




Consecutive clinic patients suspected of having SAHS, who were attending the sleep 
centre for diagnostic in -lab polysomnography were approached to participate in the 
study. The entry and exclusion criteria are listed in Table 8.1. 
Table 8.1; Recruitment Criteria 
Inclusion Criteria 
Living within Edinburgh city boundary 
Aged 18 -75 
Self -reported symptoms of either sleepiness (ESS>_8) or 2 other 
major symptoms of SAHS 
Exclusion Criteria 
Coexisting causes of daytime sleepiness (e.g. shift workers) 
Self -reported features of other sleep disorders 
Major psychiatric and neurological disorders 
Coexisting causes of hypoxaemia (e.g. COPD, nocturnal asthma) 
Twenty -one patients were eligible for the study and 13 (12 men) agreed to participate. 
The 8 declined because of work pressures (n =5) or family commitments (n =3). In 
addition, one patient failed to complete the study due to work commitments, leaving 
12 consecutive patients who completed the study (Table 8.2). 
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Table 8.2; Patient demographics (n =12) 
Measurement mean (SD) range 
Age (years) 50 (13) 28 - 74 
BMI (kg/m2) 30 (6) 24 - 44 
In -lab AHI (per hour slept) 34 (30) 7 - 97 
Epworth sleepiness scale 12 (6) 3 - 22 
Collar size (cm) 40 (3) 33 - 45 
Waist size (cm) 100 (16) 77 - 136 
BMI =Body mass index; AHI= Apnoea + hypopnoea index. 
All patients self -reported symptoms of either sleepiness (ESS>_8) or 2 other major 
symptoms of SAHS (Whyte et al 1989). These symptom ratings were taken from the 
in -house sleep /wake questionnaire (Appendix B). The percentages of SAHS 
symptoms reported by patients are described in Table 8.3. 
Table 8.3; Percentages of self -reported patient symptoms 
Self -reported symptoms* % patients reporting symptom 
Snoring 92% 
Daytime sleepiness (ESS>_8) 83% 
Unrefreshing sleep 58% 
Witnessed breathing pauses 58% 
Choking episodes 8% 
Nocturia 8% 




Patients were randomised using balanced blocks to commence with either the home or 
lab study limb in a crossover design (Figure 8.1). 
Figure 8.1; Study Design 
n = 12 
n=6 n=6 
2 Home nights 1 Lab night 
MSLT/MWT MSLT/MWT 
1 Lab night 2 Home nights 
MSLT /MWT MSLT /MWT 
In -home Study Limb 
Sleep was recorded using a portable polysomnographic recording system (P- series 2, 
Compumedics S, Australia; Figure 8.2). As the prime intention was to determine 
whether lab PSG, the night before MSLT/MWT, changed the MSLT /MWT result 
compared to a normal night's sleep at home, an acclimatisation night was included on 
the home limb. On this limb only neurophysiological sleep quality was recorded and 
not respiratory and other signals. The procedure for the acclimatisation and study 
nights was the same. 
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Figure 8.2; Portable polysomnographic recording system* 
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* Reprinted with permission of Compumedics S, Australia 
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I arrived at the patient's home at a prearranged time to attach the sleep monitoring 
equipment. This was 2 hours before the patient's usual bedtime, to allow 1 hour for 
the equipment to be attached, and 1 hour for the patient to relax and familiarise 
themselves with the equipment. Instructions to the patient regarding the avoidance of 
alcohol and caffeine on the evening of the studies had been previously discussed. All 
patients were wired up with scalp electrodes to record submental EMG, right and left 
outer canthus EOG - referenced to Fpz, bipolar EEG from sites Cz/Pz, and 
additionally from C3 /C4 as a back up EEG signal, and a reference electrode at A2 
(Cooper et al 1980). Following the lab protocol, EEG electrodes were secured using 
collodion, and all other electrodes were secured with adhesive tape. All electrodes 
were connected to a patient interface box (Pm), which clipped to the patient's pyjama 
waistband. The PIB was attached by a 2 metre analogue cable to the main portable 
unit (Figure 8.2). The main portable unit contained a 20MB memory card for data 
storage, and a 7.2V Nickel Metal Hydride battery to power the whole system, thus 
making it ambulatory. All neurophysiological channels were viewed to check technical 
signal quality on -line from the main portable unit. Impedances were measured and 
adjusted to less than 5 kOhms. 
Patients were instructed to go to bed at their usual time. Recording was commenced 
by myself before leaving the house. Patients were instructed to note down (from the 
clock on the main portable unit) their `lights -out' time in their sleep diary (Appendix 
C). Patients were then left unattended until the morning. I arrived back in the morning 
at a time prearranged to suit the patient. Patients completed their sleep diaries, noting 
down the time of their final awakening in the morning, and whether the sleep was 
representative of a normal night for them (Appendix C). All equipment was removed 
and returned to the lab. The same procedure was repeated the following (study) night 
and morning. On the second morning, patients attended the lab for their daytime 
assessments. All patients lived within 20 minutes of the sleep centre, and so could 
comfortably arrive in the sleep centre by 9.15 am. 
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In -Lab Study Limb 
Patients arrived at the sleep centre between 9.00 and 9.30 pm and were wired up for 
full diagnostic polysomnography as described in section 3.1. In addition to the scalp 
electrodes attached on the home limb, patients also had an oximeter, airflow monitor, 
abdominal and thoracic plethysomography bands, a position monitor, leg EMG 
electrodes and ECG leads attached. `Lights out' was standardised to between 10.45 
and 11.15 pm. In the morning patients were awakened at 7.00 am and all sensors 
removed except for the sleep monitoring electrodes. Patients remained in the lab for 
their daytime assessments. 
Daytime Assessments 
Objective daytime sleepiness was measured across the day by the MSLT (at 10.00, 
12.00, 14.00 & 16.00) and the MWT (at 11.00, 13.00, 15.00 & 17.00) as described in 
section 3.4.2. In addition, height, weight, collar size and waist size were measured, 
along with a background questionnaire to record medication, past medical history, 
tobacco and alcohol intake, occupation and educational status. 
8.2.3 Off line data analysis 
The overnight sleep data recorded from the portable home studies was downloaded 
from the memory card onto the Compumedics PC system for subsequent analysis. 
Home study data was analysed from `lights -out' to the final awakening , the times of 
which were subjectively recorded by the patient in their sleep diaries (Appendix C). 
Data acquired prior to `lights -out' were discarded. All polysomnography records and 
MSLT /MWT from lab and home limbs were scored according to the standard lab 
criteria described in Chapter 3. 
8.2.4 Statistics 
Sleep parameters and MSLT /MWT data were analysed using two -way analysis of 
variance (ANOVA) for repeated measures, with order of location as a between 
subject factor, and home versus lab location as a within subject factor. No order 
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effects were found between the home and lab limbs. A probability value of less than 
0.05 was accepted as statistically significant. Data were analysed using SPSS for 
Windows 6.1. The statistically significant results in this Chapter are presented in the 
tables in bold type for clarity. 
8.3 Results 
8.3.1 Home versus lab objective daytime sleepiness 
There were no significant differences in objective daytime sleepiness, as measured by 
both the MSLT and MWT, after a night in the sleep lab versus a night at home (Table 
8.4, Figures 8.3 & 8.4). There were also no significant differences between individual 
MSLT and MWT daytime naps measured after lab versus home limbs (Table 8.4). 




After home study 
mean (SD) 
After lab study 
mean (SD) 
p value 
10.00 MSLT (mins) 13.0 (5.1) 10.8 (5.2) 0.35 
12.00 MSLT (mins) 10.3 (6.1) 12.7 (6.7) 0.13 
14.00 MSLT (mins) 9.5 (5.9) 11.5 (5.9) 0.28 
16.00 MSLT (mins) 10.8 (6.6) 10.6 (5.0) 0.93 
11.00 MWT (mins) 31.5 (10.1) 29.8 (8.8) 0.64 
13.00 MWT (mins) 29.1 (13.4) 28.5 (11.9) 0.85 
15.00 MWT (mins) 29.2 (12.1) 26.4 (12.7) 0.23 
17.00 MWT (mins) 33.5 (10.6) 31.8 (11.5) 0.67 
Mean MSLT (mins) 10.9 (4.7) 11.4 (4.7) 0.31 
Mean MWT (mins) 30.8 (9.3) 29.1 (9.5) 0.26 
MSLT= Multiple sleep latency test; MWT= Maintenance of wakefulness test 
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Figure 8.3; Bland & Altman plot of relationships between in -lab and in -home 
mean MSLT scores 
6 
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Figure 8.4; Bland & Altman plot of relationships between in -lab and in -home 
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* The right -most data point represents 3 overlying points 
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8.3.2 Comparison of home versus lab recorded sleep variables 
Patients spent significantly less time in bed (TIB) at home than in the lab, yet did not 
differ in total sleep time (TST). Therefore, at home, patients had a significantly higher 
sleep efficiency (Table 8.5, Figure 8.5). Patients also had significantly fewer arousals 
from sleep at home compared to in the lab (Table 8.5, Figure 8.6). At home, 
significantly greater percentages of REM sleep and slow wave sleep (Figure 8.7), and 
a lower percentage time spent awake were found (Table 8.5). 
Table 8.5; Comparisons between home and in -lab nocturnal sleep variables 





Arousal frequency /hr slept 31 (14) 53 (26) 0.004 
TIB (mins) 448 (46) 481 (17) 0.04 
TST (mins) 365 (53) 345 (57) 0.21 
% sleep efficiency 82 (11) 72 (12) 0.007 
SOI, (mins) 17 (17) 16 (11) 0.77 
% wake 14 (9) 25 (12) 0.007 
% stage 1 sleep 6 (3) 5 (3) 0.37 
% stage 2 sleep 43 (7) 45 (10) 0.52 
% slow wave sleep 16 (6) 10 (5) 0.003 
% REM sleep 20 (7) 15 (6) 0.003 
TIB =Time in bed; TST =Total sleep time; SOL =Sleep onset latency; REM =Rapid eye movemen 
sleep; 
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Figure 8.5; Bland & Altman plot of relationships between in -lab and in -home 
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Figure 8.7; Bland & Altman plot of relationships between in -lab and in -home 
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This study presents preliminary findings that daytime sleepiness, as measured by the 
MSLT and MWT, is not significantly different following a night of PSG in the lab 
versus a night with limited instrumentation at home. These results are in agreement 
with a larger study (n =64) in insomniacs and normal controls (Edinger et al 1997a). 
The current findings also demonstrated that, on the home limb, a significantly better 
quality of sleep was found, in terms of a higher sleep efficiency, more SWS and REM 
sleep and less arousals from sleep. These results contrast with the study by Sewitch & 
Kupfer (1985) who found no significant differences in sleep variables when comparing 
home and lab recordings. However, Sewitch and Kupfer (1985) studied sleep patterns 
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in 24 normal healthy controls and performed acclimatisation nights on both the home 
and lab limbs. 
8.4.1 MSLT and MWT scores 
The results presented here suggest that the mean MSLT and MWT sleep onset 
latencies are the same despite the differences found in the prior night's sleep. The 
Bland & Altman plots (Figures 8.3 & 8.4) demonstrate individual differences in the 
MSLT and MWT mean scores for each patient, with some patients sleepier after a 
night at home, and others sleepier after a night in the lab, thus making the overall 
differences in location of prior night's sleep non -significant. This study does not 
support the hypothesis that patients are sleepier after a night in the lab compared to 
home, rather it suggests that location of prior night's sleep has no effect on objective 
daytime sleepiness. This suggests that the high mean MSLT value observed in 
Chapter 5 is not likely to result from performing the MSLT /MWT after a night's sleep 
at home. Perhaps the sleep disruption recorded on the home night, using the limited 
equipment, is far greater than the `normal' level of sleep disturbance on a night at 
home with no intervention whatsoever. The current study cannot answer this 
question. Ideally, a three -way crossover study would have been performed, with the 
MSLT and MWT recorded after (1) PSG night in the lab, (2) PSG night at home and 
(3) normal night's sleep at home, thus comparing the effect of the limited home 
equipment with no intervention in familiar surroundings. This protocol was not 
undertaken, as it was too demanding for the patient. The fact that mean MSLT and 
MWTs are not significantly different after lab or home nights does not prove that it is 
pointless monitoring sleep the night before MSLT /MWT. It remains possible that the 
occasional individual will deliberately restrict their nocturnal sleep if unmonitored at 
home in order to produce spurious evidence of excessive daytime sleepiness. It 
remains to be determined whether this is a common phenomenon. 
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8.4.2 Home versus lab sleep parameters 
A significantly better quality of sleep was found on the home limb compared to the lab 
limb, in terms of less sleep fragmentation and deeper sleep. In all but one patient, the 
arousal frequency was greater on the sleep lab night than the home night. Although 
numbers are small, it appears that there were greater discrepancies between home and 
lab arousal frequencies at the more severe end of the disease spectrum (Figure 8.6). 
The current data cannot identify the cause of better sleep quality at home, but various 
reasons can be speculated upon. 
Recording sleep in the home occurs in surroundings familiar to the patient, which 
could decrease anxiety. Patients can follow their normal bedtime routine, and 
choose the bedtime to suit them, depending on their level of sleepiness. This was 
reflected in the significantly shorter time spent in bed at home. Interestingly, 
despite this shorter time in bed, the same mean quantity of sleep was recorded as 
on the lab limb. Thus patients at home have a higher sleep efficiency. It is likely 
that at home, patients only retire to bed when they are feeling sleepy and arise 
when refreshed and are more efficient in utilising their time in bed. In the lab, 
`lights out' and wake up times are standardised so patients may wake up prior to 
the standardised wake up time, decreasing sleep efficiency. 
In the home, patients were given an acclimatisation night to provide familiarisation 
of the equipment. An acclimatisation night was not performed on the lab limb, as 
this is not standard lab practice, therefore the lab equipment may appear more 
obtrusive to the patient. 
In the home, the instrumentation was minimal, consisting of 10 scalp electrodes 
positioned away from the face and securely attached to the patient interface box, 
with one single connecting lead to the main patient unit (Figure 8.2). In the sleep 
lab, in addition to the electrodes, the following sensors are also attached: airflow 
monitor, pulse oximeter, 2 plethysomography bands, 2 leg EMG sensors, a 
position monitor and 2 ECG leads. These are all independently connected to the 
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patient headbox, so in effect there are leads coming from many sites on the body. 
This additional instrumentation is more likely to disturb an individual's sleep. The 
lab PSG equipment may also restrict the patient's body position in bed. It is 
anecdotally reported that patients in the sleep lab lie supine for a large proportion 
of the night. By lying supine, patients increase their likelihood of having breathing 
pauses, and thus sleep fragmentation. This alone may explain the increased sleep 
disruption in the lab compared to at home in a group of patients with SAHS. 
The presence of a video camera and an observing nurse /technician during the study 
night may increase patient anxiety and decrease sleep quality. 
One problem with performing unattended studies in the home is that patients may be 
anxious about the portable monitor breaking down, or the electrodes falling off 
During this study, all electrodes stayed in place. On one of the acclimatisation nights, 
all sleep study data was lost, and this was traced to the connecting cable becoming 
loose between the interface box and the main patient unit, when the patient retired to 
their bed. The acclimatisation night may help to reduce such anxieties. Night to night 
variability is also going to occur between lab and home study nights, in particular at 
the milder end of the disease spectrum (Wittig et al 1984), although this factor alone 
is going to affect both lab and home studies. 
In conclusion, the preliminary findings presented here suggest that the MSLT and 
MWT can either be performed after a night's sleep at home or following standard 
MSLT guidelines (Carskadon et al 1986). A larger sample size is being obtained to 
confirm these observations and improve the low statistical power currently present in 
this study. Results suggest that neurophysiological measurements recorded at home 
demonstrate significantly better sleep quality than in the lab. It has been suggested 
that neurophysiological recording of sleep is of little diagnostic benefit in the majority 
of patients suspected of SAHS, where limited respiratory monitoring is sufficient 
(Douglas et al 1992). Perhaps it would be possible to routinely use activity monitoring 
(Aubert- Tulkens et al 1987) to cheaply and non -invasively record patient's sleep 
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duration at home the night before an MSLT /MWT. However, for SANS patients with 
evidence of coexisting sleep disorders, and patients in research studies, such as that 
performed in Chapter 5, neurophysiological sleep monitoring is required (Douglas et 
al 1992). The question then arises as to whether this recording should take place in 
the lab, or in the home, and this may form the subject of future studies. 
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Chapter 9 
Conclusions and Future Work 
The correlational studies presented in this thesis found mainly weak or non -significant 
relationships between nocturnal SAHS variables and measures of daytime function. In 
the previous correlational studies discussed in Chapter 2, moderate or weak 
relationships were reported, in limited areas of daytime function. Results of previous 
studies are difficult to compare with the current study, due to differences in study 
size, design and outcomes assessed. Previous studies can be criticised for recruiting 
small numbers of patients (less than 30 in Roth et al 1980, Stepanski et al 1984, 
Findley et al 1986, Greenberg et al 1987, Bedard et al 1991b, Cheshire et al 1992, 
Borak et al 1996). Such sample sizes may fail to find positive relationships which do 
exist, or spuriously find relationships which do not. None of the previous large - 
number correlational studies included a wide range of nocturnal measures (Yesavage 
et al 1985, Millman et al 1989, Smith & Shneerson 1995) and /or daytime function 
measures (Yesavage et al 1985, Guilleminault et al 1988b, Roehrs et al 1989, Millman 
et al 1989, Poceta et al 1992, Smith & Shneerson 1995), thus making comparisons 
between studies difficult. Studies can also be criticised for using selected, severe 
SAHS patient samples (Roth et al 1980, Bedard et al 1991b) which are non- 
representative of the clinic population. In addition, only 3 previous studies controlled 
for age in their correlational analysis (Yesavage et a 1985, Cheshire et al 1992, Kim et 
al 1997). The current study improved on these previous studies by testing a wide 
ranging, large patient sample, in many areas of daytime function. 
The data presented in this thesis demonstrates a lack of strong nocturnal predictors of 
daytime function in a group of unselected SAHS patients. However, some statistically 
significant associations are reported in this thesis, and although they are at most 
moderate in size, they are derived from a diverse patient sample, using a wide range of 
daytime and nocturnal measures, suggesting the associations have been intensively 
sought. The reality may be that the daytime outcome variables assessed in this thesis 
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are predicted by multiple nocturnal variables, each accounting for only small amounts 
of the variance. Alternatively, the current measures used to detect features of SAHS 
are not sophisticated enough to quantify factors affecting daytime function in a 
heterogeneous patient sample. Experimental sleep fragmentation studies in normal 
subjects have demonstrated that repetitive microarousals from sleep lead to 
decrements in daytime function of a similar nature to those found in sleep apnoeics 
(Philip et al 1994, Roehrs et al 1994, Martin et al 1996 & 1997b). CPAP therapy 
reduces respiratory events and microarousals from sleep, and treatment related 
improvements in many areas of daytime function have been identified following CPAP 
(Lamphere et al 1989, Sangal et al 1992b, Engleman et al 1994a, 1998). Such 
evidence strongly suggests that there is a causal relationship between nocturnal SANS 
features and daytime function, but does not clarify which are the key nocturnal 
variables which determine daytime impairments. 
A correlational study, by design, is highly susceptible to inter -individual residual 
variation. As discussed in Chapter 5, it is possible that unknown or unmeasurable 
factors are affecting daytime function in SAHS. Further work is required to identify 
these inter -individual patient differences. For example, measurement of a patient's 
motivation and competitiveness and their perception of their ability to upgrade 
themselves on the test day could be undertaken. Detailed descriptions of the patient's 
daily routine and their occupation in terms of activity levels and sleepiness thresholds 
can be measured. In addition, the duration since disease onset, and the patient's 
perception of their level of adaptation to their disease could be estimated. However, 
such behavioural questions as these are difficult to quantify. 
The lack of significant correlations can alternatively be explained by the experimental 
measures used. Only conventional PSG variables were measured in this project, in an 
attempt to identify predictors of daytime dysfunction that could be implemented into 
standard lab procedures to determine who requires CPAP therapy. As no strong 
nocturnal predictors of daytime function were identified, perhaps more sophisticated 
measures and analytical techniques need to be implemented. Further analysis can be 
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performed on the nocturnal PSG data presented in Chapter 5, by identifying sleep 
stage specific events, interarousal durations and respiratory events with 30 -50% 
reductions in thoracoabdominal movement, for example. Such variables could be 
subsequently correlated with daytime function measures. With the current EEG data, 
it would also be possible to perform spectral analysis of the EEG to identify subtle 
changes in EEG frequency (Rees et al 1995, Drinnan et al 1996). Future studies could 
also incorporate more sophisticated nocturnal SAHS measures in a large correlational 
study with a broad battery of daytime tests. Detectors of subtle autonomic arousals 
such as the Finapress device (Davies et al 1993b, Rees et al 1995) and measures of 
pulse transit time (Pitson et al 1994, Bennett et al 1998) could be included. Pleural 
pressure swings measured with oesophageal balloons (Milic -Emili et al 1964, Issa & 
Sullivan 1984), and flow limitation using nasal cannulae (Hosselet et al 1998) could 
also be measured. However, many of these sophisticated detection techniques are 
more invasive than standard recording methods, and may interfere with sleep. 
As demonstrated in Chapter 8, results suggest that patients sleep better at home than 
in the lab. This could be due to less instrumentation used at home. Perhaps, home 
PSG monitoring rather than invasive techniques are required to identify predictors of 
daytime dysfunction. A future study could compare full portable PSG in the home and 
in the sleep lab in a crossover design to look solely at the effect of the unattended 
home environment versus the sleep lab. 
The lack of correlations presented could also be due to the daytime measures used. 
The MSLT and MWT EEG data in this thesis could be analysed further in future 
work. The raw EEG data is available to assess more subtle measures of sleep onset 
latency. Brief periods of sleep ( <15 seconds), so called `microsleeps' (Harrison & 
Home 1996a, Doghramji et al 1997), could be measured and correlated with 
nocturnal SANS measures. In addition, spectral analysis of the EEG from daytime 
tests could be performed to identify subtle changes in EEG frequency (Rees et al 
1995, Drinnan et al 1996). Such sensitive measures as these may identify EEG 
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changes in the patients who demonstrated ceiling effects on the MWT with the 
existing sleep latency criteria used in Chapter 5. 
The strongest nocturnal versus daytime relationships in this thesis were found with 
self -reported questionnaires, incorporating trait assessments. In these questionnaires 
patients were asked to rate their well -being and symptoms from recent past events in 
their real -life. Improvements in ESS were significantly associated with CPAP use 
(Chapter 7), indicating that patients who felt an improvement in their sleepiness tend 
to be those who used therapy the most. In addition, Chapter 6 found the MWT was 
better related to other daytime function measures than the MSLT. Although the MWT 
is a state assessment, its instruction `to try and stay awake' is more analogous to real - 
life, and is experienced by many patients every day. Future studies should record 
daytime function in these `real -life' situations. For example, the portable PSG monitor 
described in Chapter 8 (Compumedics S, Australia) could be worn for 24 hours. The 
daytime EEG could be scored for microsleeps, and complemented with patient reports 
of lapses in concentration and attention across their daily routine. Wearing any visible 
equipment such as portable EEG is likely to cause embarrassment and thus increase 
alertness. Therefore a sufficient familiarisation session would also be required. It is 
likely that further technological developments will occur and in an ideal world, such 
lightweight ambulatory EEG monitoring will consist of small sensors on the scalp 
which transmit EEG data by telemetry. 
Further understanding of cognitive decrements in SAHS can also be studied by newer 
technologies, such as computerised topographic brain mapping and cerebral blood 
flow imaging. Following on from the work of Martin et al (1996, 1997b), I am 
currently analysing data from a pilot study I performed examining the effect of sleep 
fragmentation on topographically mapped sensory evoked potentials in normal 
subjects. This study may identify areas of the brain where cognitive processing has 
been affected by sleep fragmentation. Such work could then lead to large scale studies 
on sleep apnoeics, possibly to identify why some patients with similar disease severity 
suffer cognitive decrements and others not, as demonstrated by the lack of strong 
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correlations in Chapter 5. Previous small sample studies on topographic mapping in 
sleep apnoeics (Walsieben et al 1993, Sangal & Sangal 1995) have found conflicting 
results, with Walsleben et al (1993) reporting delayed auditory P300 latencies in the 
right parietal area, whereas Sangal & Sangal (1995) reported delayed visual P300 
latencies in all brain areas except the right parietal region, thus further large scale 
studies are required. Recent preliminary work in monitoring cerebral blood flow using 
single photon emission computed tomography (SPECT) has identified deficits in 
blood flow to a variety of brain areas, including the inferior frontal lobe, the temporal 
lobe, and in 4 cases blood flow deficits were identified across the whole cortex and 
cerebellum (Tainturier et al 1998). Again this technique requires large sample studies 
in the future. Technological advances such as virtual reality will allow the 
development of more sophisticated driving simulators for future assessments of 
cognitive performance and daytime sleepiness. Ideally an EEG topographically 
mapped brain could be monitored during very realistic driving simulations, and then 
analysed by spectral EEG analysis. 
In conclusion, future studies need to use such new technologies to take the sleep 
experiments into the patient's real -life environment, including the workplace and the 
vehicle, two areas where patients complain of decreased functioning. Determining the 
causes of poor functioning in these areas are of great public health interest. 
Meanwhile, the results suggest that the measurement of apnoea/hypopnoea frequency 
and arousal frequency during clinical studies of breathing during sleep is less strongly 
predictive of daytime function decrements than had previously been thought, and that 
alternative, more strongly predictive, measures must be actively sought. 
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APPENDIX A 





Have you suffered from any of the following problems in the recent past? Please circle 
the appropriate value to show how frequently, if at all, these symptoms have been 
occurring. 
Heavy snoring 
NEVER LESS THAN 
ONE NIGHT 
PER MONTH 
Choking during the night 















Breathing pauses witnessed by partner 









Difficulty in staying asleep at night 

























THREE TO EVERY 
SIX NIGHTS NIGHT 
PER WEEK 
THREE TO EVERY 
SIX NIGHTS NIGHT 
PER WEEK 
THREE TO EVERY 
SIX NIGHTS NIGHT 
PER WEEK 
THREE TO EVERY 
SIX NIGHTS NIGHT 
PER WEEK 
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Unrefreshed / unsatisfied by sleep on awakening in the morning 









Napping during the daytime (9am -5pm) 









Napping in the evenings (after 5pm) 





















THREE TO EVERY 
SIX NIGHTS NIGHT 
PER WEEK 
THREE TO EVERY 
SIX NIGHTS NIGHT 
PER WEEK 
THREE TO EVERY 
SIX NIGHTS NIGHT 
PER WEEK 
Do you drive (please circle answer) YES NO 
If so, how many miles per year? 
Please circle answers to reflect your recent experience of driving 
Feeling sleepy whilst drivi 




Falling asleep whilst driving 
























THREE TO EVERY 
SIX NIGHTS NIGHT 
PER WEEK 
THREE TO EVERY 




Below is the in -house sleep /wake questionnaire given to all individuals referred to the 
sleep centre with a suspected sleep disorder. 
NAME: DATE 
SLEEP/WAKE QUESTIONNAIRE 
Please find enclosed two questionnaires, one for you (marked patient) and 
a shorter one (marked partner) for your partner if you have one. The aim 
of these simple questionnaires is to discover the extent of your problem. It 
would be very helpful if you could arrange to fill them in and hand them 
to the doctor seeing you in the hospital clinic or to the Sleep Centre, Ward 
48, Royal Infirmary of Edinburgh, at your next visit. 
The questionnaire for your partner must be filled in independently by 
him/her without consulting you. You may get help, however, from your 
partner in answering Questions 9, 11 and 20. 
For most questions several options are available, underline the answer 
which is most appropriate. 
The answers will form part of your medical records and remain 
confidential. 
Thank you for your co- operation. 
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PERSONAL INFORMATION: DATE: 
Name: Age: Date of Birth 
Address : Tel No: 
Height: Weight: 
Collar Size Marital Status: 
Age Sex 
Children: Number 
Occupation: current for years 
previous for years 
for years 
for years 
Are you a : smoker / non -smoker / ex- smoker (for years) 
What did / do you smoke: cigarettes yes /no Number per day 
cigars yes /no Number per day 
tobacco (own rolled) yes /no Oz. per week 
tobacco (pipe) yes /no Oz. per week 
Do you drink: tea yes /no cups per day 
coffee yes /no cups per day 
wine yes /no glasses per day 
beer yes /no pints per week 
spirits yes /no drinks per week 
sherry/port yes /no glasses per week 
Any alcohol immediately before going to bed: yes /no 
What medication, including sleeping pills are you taking at present? 










PAST MEDICAL HISTORY 
If you have had the following illnesses, please give details: 
Illness 
Asthma yes /no 
Bronchitis yes /no 
Emphysema yes /no 
Diabetes yes /no 
Heart attacks yes /no 
High blood pressure yes /no 
Ankle swelling yes /no 
Tonsillitis yes /no 
Ha) fever yes /no 
Broken nose yes /no 
Bed wetting yes /no 
Nose operations yes /no 
Throat operations yes /no 
Nerve problems yes /no 
* * * * * * * * * * * * * * * * * * * * * * * * * * * ** 
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1. When do you go to bed at night on average? 
2. When do you finally wake up in the morning on average? 
3. How long do you take to fall asleep at night? 
4. How often do you wake between going to bed and getting up in the morning? 
never / 1 -3 times / 3 -6 times / more than 6 times per night 
5. Do you do shift work? If so, please specify shifts and how long you are on each shift 
6. How many times have you wet the bed in the last year? 
never / occasionally / 2 -6 times / more than 6 times 
7. How often have you woken with a headache each week? 
never / 1 -2 times / 2 -5 times / more than 5 times 
8. How likely are you to doze off or fall asleep, in the following situations, in contrast to 
feeling just tired? This refers to your usual way of life in recent times. Even if you have not 
done some of these things recently, try to work out how they would have affected you. Use 





would never doze 
slight chance of dozing 
moderate chance of dozing 
high chance of dozing 
Situation 
Sitting and reading 
Watching TV 
Sitting, inactive in a public place (e.g. a theatre or a meeting) 
As a passenger in a car for an hour without a break 
Lying down to rest in the afternoon when circumstances permit 
Sitting and talking to someone 
Sitting quietly after a lunch without alcohol 
In a car, while stopped for a few minutes in traffic 
TOTAL 
Chance of Dozing 
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9. Do you snore during sleep? 
Yes /No 
If yes: 
a) How long have you snored loudly? 
Always since childhood / last 5 years / 3 years / 1 year 
b) Do you snore every night / most nights/ occasional nights 
c) Do you snore on your back only / on back and side / in all positions 
10. Do you have a regular bed -partner or room -mate? 
yes / no / previously but not currently 
11. Has your bed -partner /room -mate ever noticed that you stop breathing when asleep? 
yes / no 
12. Do you need to go to the toilet at night? 
never / occasionally / 1 -2 times / more than 2 times per night 
13. Do your ankles swell? If so, for how long 
yes / no months / years 
14. Have you ever had hallucinations when you have been falling off to sleep or waking 
up? 
yes / no 
15. Have you ever had episodes when you body or part of your body has become floppy 
in response to an emotional stimulus? 
yes / no 
16. Have you ever had episodes when you have woken up and been unable to move? 
yes / no 
If so, how often? 
once / less than 5 times / more than 5 times 
17. In the morning do you feel that your nights sleep was refreshing/satisfactory? 
always / 4 -6 nights per week / 1 -3 nights per week / never 
18. Have you or your partner noticed any change in your sex drive ? 
increased / unchanged / decreased / non -existent 
19. How many times have you woken choking or suffocating in the past month? 
never / 1 -2 times / 3 -6 times / more than 6 times 
20. How often is your bed -partner or room -mate, disturbed each week because of 
excessive arm and/or leg movements? 
never / 1 -5 times / 5 -10 times / more than 10 times / no bed partner 
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21. Are you ever forced to have a nap during the day? 
yes /no 
If so, how many naps (5 minutes) do you have per day? 
1 -2 / 2 -4 / 4 -6 / more than 6 
22. How many times have you fallen asleep against your will (for example, while eating, 
driving or in company) in the last year? 
never / 1 -2 / 2 -4 / more than 4 (give details below) 
23. For how long have you been sleepy during the day? 
3 months / 3 -6 months / 6 -12 months / over 12 months / over 10 years 
24. Do you drive? 
yes / no 
25. Have you ever had, or nearly had an accident because of falling asleep while driving? 
yes / no (give details below) 
26. Have you, your partner or family noticed any change in your personality? 
yes / no 
If so, specify : 
27. Has you weight changed in recent years? 
yes / no down / up 
If so, what is the change stones lbs 
When did your weight change occur : 




SLEEP WAKE QUESTIONNAIRE - PARTNER 
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PERSONAL INFORMATION: DATE: 
NAME: PATIENT'S NAME 
AGE: DATE OF BIRTH: 
1. Does your partner drink? 
tea yes /no cups per day 
coffee yes /no cups per day 
wine yes /no glasses per day 
beer yes /no pints per week 
spirits yes /no drinks per week 
sherry/port yes /no glasses per week 
Any alcohol immediately before going to bed: yes /no 
2. How likely does your partner doze off or fall asleep, in the following situations, in 
contrast to feeling just tired? This refers to your usual way of life in recent times. 
Even if you have not done some of these things recently, try to work out how they 
would have affected you. Use the following scale to choose the most appropriate 





would never doze 
slight chance of dozing 
moderate chance of dozing 
high chance of dozing 
Situation 
Sitting and reading 
Watching TV 
Sitting, inactive in a public place (e.g. a theatre or a meeting) 
As a passenger in a car for an hour without a break 
Lying down to rest in the afternoon when circumstances permit 
Sitting and talking to someone 
Sitting quietly after a lunch without alcohol 
In a car, while stopped for a few minutes in traffic 
TOTAL 
Chance of Dozing 
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3. Is your partner forced to have a nap during the day? 
yes / no 
If so, how many naps (5 minutes) does he /she have per day? 
1 -2 / 2 -4 / 4 -6 / more than 6 
4. How many times has your partner fallen asleep against his /her will (for example, 
while eating, driving or in company) in the last year? 
never / 1 -2 / 2 -4 / more than 4 (give details below) 
5. For how long has your partner been sleepy during the day? 
3 months / 3 -6 months / 6 -12 months / over 12 months / over 10 years 
6. Does your partner drive? 
yes / no 
7. Has your partner ever had, or nearly had an accident because of falling asleep while 
driving? 
yes / no (give details below) 
8. Has your partner or family noticed any change in his /her personality? 
yes / no 
If so, specify: 
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APPENDIX C 
Below is the sleep diary given to patients in the home versus lab study (Chapter 8) 
Sleep Diary 
Night: at home / in sleep lab (please delete as appropriate) 
Name: 
Date of Birth: 
Date of study: 
1. What time did you go to bed? 
2. What time do you think you fell asleep? 
3. How many times were you aware of waking up during the night? 
4. What time do you think you woke up in the morning? 
5. What time did you get out of bed in the morning? 
6. Was last nights sleep representative of a normal nights sleep for you? 
yes No (please tick yes or no) 
Comments 
7. How refreshed did you feel on awakening? (ring appropriate number) 
1 2 3 4 5 
unrefreshed refreshed 
8. Please write down any further comments about last nights sleep 
Thank you for your co- operation 
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APPENDIX D 
Articles, abstracts and presentations resulting from this thesis. 
Original Articles 
Kingshott RN, Sime PJ, Engleman HM, Douglas NJ. Self assessment of daytime 
sleepiness: patient versus partner. Thorax 1995; 50:994 -995. 
Kingshott RN, Engleman HM, Deary IJ, Douglas NJ. Does arousal frequency predict 
daytime function? Eur Respir J (In press). 
Abstracts and Presentations 
Assessment of daytime sleepiness in new sleep clinic patients and their partners using 
the Epworth Sleepiness Scale (ESS). Kingshott RN, Sime PJ, Engleman HM, 
Douglas NJ. Proceedings of the British Sleep Society. London; September 1995. 
Factors affecting daytime function in sleep apnea. Kingshott RN, Douglas NJ. Am J 
Respir Crit Care Med 1997; 155:A847. 
A comparison of the MSLT and the MWT in SAHS patients. Kingshott RN, Douglas 
NJ. Proceedings of the 5th international sleep and breathing symposium. Edinburgh, 
October 1997. 
Relationships between the MSLT and MWT and other measures of daytime function 
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Self assessment of daytime sleepiness: patient 
versus partner 
Ruth N Kingshott. Patricia J Sime, Heather M Engieman, Neil J Douglas 
Abstract 
Background - Patients with the sleep 
apnoea/hypopnoea syndrome (SANS) and 
their spouses often differ in their as- 
sessment of the patient's sleepiness. A 
study was therefore undertaken to in- 
vestigate whether either the patient's or 
partner's rating on the Epworth sleepiness 
scale (ESS) was better related to illness 
severity. 
Methods - Nocturnal variables (apnoeas - 
hypopnoeas/hour (AHI) and arousals/ 
hour) and patient and partner ESS scores 
were compared in 103 new patients at- 
tending the sleep clinic. 
Results - Mean patient and partner ESS 
scores were not different. In the whole 
population neither patient nor partner 
ESS variables correlated with AHI or 
arousal frequency. In the patients with 
SAHS (AHI 15), partner ESS correlated 
weakly with AHI, but patient ESS did not. 
Conclusions - This study suggests that 
neither patient nor partner ESS ratings 
are strong predictors of SAHS severity. 
Thorax 1995;50:994 --995 
Keywords: sleep apnoeahypopnoea syndrome. sleep- 
iness, partner. 
Excessive sleepiness is the most prevalent day- 
time symptom of the sleep apnoea/hypopnoea 
syndrome (SANS),' resulting in an increased 
risk of vehicle accidents! The multiple sleep 
latency test (MSLT)3 and its variant, the main- 
tenance of wakefulness test (MWT),4 are used 
as objective methods for measuring daytime 
sleepiness, but are labour intensive and ex- 
pensive to conduct. More simply, the Epworth 
sleepiness scale (ESS)," a self administered 
questionnaire, provides a subjective estimation 
of daytime sleepiness. There is frequently a 
discrepancy between the patient and their part- 
ner's ESS assessment. The. aim of this study 
was to determine if patient or partner's as- 




One hundred and three patients referred for 
assessment of suspected SANS were studied. 
Patients subsequently diagnosed with nar- 
colepsy, periodic limb movement disorder, psy- 
chological or psychiatric illness were excluded 
from the study. The patients consisted of 8 
men and 16 women of mean (SD) age 48 (13) 
years, with a mean apnoea'hypopnoea index 
(AHI) of 28 (22)íhour slept, and a mean arousal 
index (see below) of 25 (18) /hour slept. 
Overnight clinical polysomnography was re- 
corded in the Scottish National Sleep Labora- 
tory, with the nocturnal variables defined as 
follows: (1) An apnoea is the cessation of airflow 
for at least 10 seconds,' and a hypopnoea is a 
50% reduction in thoracoabdominal move- 
ment for at least 10 seconds.' (2) An arousal 
is an increase in electromyographic tone for at 
least 1.5 seconds associated with the return of 
alpha or theta rhythm.° 
Patients' sleepiness was independently rated 
by both patients and parmers using the ESS, 
which yields a total score corresponding to the 
chance of dozing in each of eight real life 
situations.' In addition, the minimum ESS 
(minESS) and the maximum ESS ; maxESS) 
values for each couple were analysed. 
DATA ANALYSIS 
Data were analysed using the SPSS -PC - 
(SPSS Inc, Chicago, USA). Patient and partner 
ESS scores were compared using two tailed 
Wilcoxon tests, and relationships between noc- 
turnal variables and ESS variables were eval- 
uated by Spearman rank correlations. 
Results 
Patient and partner mean ESS scores (table 1) 
were not significantly different. In the whole 
population (table 2) no significant correlations 
were seen between nocturnal variables and ESS 
scores (figure). In the SANS diagnosed sub- 
group (AHI 15), patient ESS did not cor- 
relate significantly with nocturnal variables, 
whilst partner ESS and minESS scores cor- 
related weakly but significantly with AHI (table 
2). One quarter of patients with severe SAHS 
(AHI 50, n = 16) scored below 10 on the 
ESS, in contrast to a previous study=' where 
all patients with severe SANS (n = 19) scored 
10 or more. 
Table I Comparisons of mean .,'SD) panent ..na partner 
ESS scores irr the rcitoie population .lnd to those _träg . iHl 
t,I": 
I'.:r:ent ocean ?arrner nen ^ ;awe 
ESS scan ESS scorn 
Whole sample 
tn = 103. 
AHI ?- 15 
,n = ori) 
:2 .5) 12 4, NS 
12 51'. :1 4/ NS 
ESS = Epworth sleepiness scale: AHI = apnoea- inpopnoea 
index :per hour slept :: NS = non -significant i' >0.1 
nel 1. 
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Whole sample (n = 103) 
AHI 0.02 -0.07 -0.13 0-10 
Arousal index 0.01 -0 -05 -0.06 0.03 
AHI 315ín =66) 
AHI 01; 0.27.. 0.11 032" 
9i' CI 003 to 0517 :95'.'e CI 0.08 to 0.56} 
Arousal index -0-001 0-07 0-04 0.04 
ESS = Epworth sieepiness scale: AHI = apnoea - htpopnoea indes )per hour slept;; 95% 
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Partner Epworth sleepiness score 
24 
R nF _orreianon of apnoea - mpopnoea :n:iex :.4111) 
and _pr,orii sleepiness scale scons in (i) parient and -B) 
panne. 
Discussion 
Anaiyses of the whole population indicate that 
patient and parmer ESS scores are similar, in 
keeping with a smaller recent study. iÓ However, 
the have extended that study by showing that. 
in the whole group, mere were no significant 
coreiations between ESS variables and noc- 
tumai variables for ratings of sleepiness by 
either the patient or partner. 
Ln he subgroup of SAHS diagnosed patients 
Ark 15) the patient's ESS rating was not 
significantly related to AHI. This contrasts with 
an earlier study:1 where correlations (r = 0.44, 
p «1.001) were found between patient ESS 
score and AHI in patients with SANS by the 
org:..ator of the ESS. We can see no obvious 
expian anons for ^e discrepancy. The partner'_ 
ESS rating was significantly correlated with 
AHI. but only weakly. The minimum ESS score 
ì couple was honer correlated :Yltn AHI 
eam he larger Jì :fie ,.vo scores. 
`V e believe that our failure to find sir iñcant 
correlations between ESS and SAHS seventy 
995 
'teas several causes which reflect Me problems 
with subjective ratings. As part of human na- 
ture, some patients maximise and others min- 
imise their symptoms. In addition, some 
patients with severe SAHS and severe objective 
sleepiness are so obrunded that they do not 
appreciate the severity of their symptoms. at 
least until after they are treated. 2 Our failure 
to find any better correlation using partners' 
estimates of ESS may be due to a combination 
of two factors: (1) partners 'only observe 
patients over a limited part of the day, and thus 
have difficulty in making an accurate estimate 
on all points of the scale, and ;2) the patients' 
complaints about sleepiness may influence the 
scoring by their spouses. 
Alternatively, the lack of correlation between 
ESS and polysomnography results could mean 
that polysomnography is not providing useful 
measurements of disease severity. This seems 
unlikely as daytime sleepiness measured by the 
MSLT3 correlates significantly with apnoea 
hypopnoea frequency and micro- arousal fre- 
quency but not with ESS score» Our data are 
supported by studies using other subjecn :e 
sleepiness assessments - for esampie. Dement 
er 1P' using the Stanford sleepiness scale found 
that subjective sleepiness correlated with sleep 
latency in normal subjects but not in patients 
with sleep apnoea. 
We conclude that the clinical predictive value 
of ESS scores is limited. with the results in- 
dicating that neither the patients scores nor 
those of their parmers are strong predictors of 
disease severity. Hence. Me ESS alone cannot 
be used to determine the mode of investigation 
or the likelihood of an individuai having SAES. 
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